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Abstract 
Bacterial toxins have evolved to an effective therapeutic option for cancer therapy and 
numerous studies demonstrated their antitumoral potential. The Clostridium perfringens 
enterotoxin (CPE), produced by the anaerobic Clostridium perfringes bacteria, is a pore-
forming (oncoleaking) toxin, which binds to its receptors claudin-3 and -4 (Cldn3 / 4) and 
exerts a selective, receptor-dependent cytotoxicity. The transmembrane tight junction 
proteins Cldn3 and Cldn4 are known CPE receptors and are highly upregulated in several 
human epithelial cancers such as breast, colon, ovarian and pancreatic cancer. 
 
This study aimed at the evaluation of the potential of oncoleaking gene therapy using a 
non-viral translation optimized CPE vector (optCPE) as a new suicide approach for the 
treatment of Cldn3  /  4 overexpressing pancreatic cancer in vitro and in vivo. We 
demonstrated the successful in vitro use of optCPE gene transfer in a panel of human 
pancreatic cancer (PC) cells and more importantly patient derived pancreatic cancer 
xenograft (PDX) derived cells. We showed significant reduction of cell viability in all 
Cldn3 / 4 overexpressing PC cells after optCPE transfection. Furthermore a positive 
correlation between CPE cytotoxicity and level of claudin expression was shown. We 
revealed accessibility of CPE receptors for toxin binding as determining for optCPE 
mediated cytotoxicity. Since investigation of optCPE induced cell death mechanism was of 
particular interest, detailed analyses of apoptotic and necrotic key players were 
performed. By this, caspase dependent- and independent apoptosis and necrosis 
activation after gene transfer was demonstrated, which was dependent on amount of 
expressed optCPE and accessibility of Cldn. More importantly, this study demonstrated 
the applicability and antitumoral efficacy of optCPE gene therapy by the non-viral 
intratumoral jet-injection gene transfer in vivo in different luciferase-expressing CDX and 
PDX pancreatic cancer models. The animal experiments demonstrated the selective CPE 
mediated tumor growth inhibition, associated with reduced tumor viability and effective 
induction of tumor necrosis. This further corroborated the advantages of this novel 
oncoleaking strategy. 
 
With this gain of knowledge about our new oncoleaking concept of suicidal gene therapy 
and its mechanism of action, novel combinations with conventional therapies are possible 
to further improve therapeutic efficacy and to overcome resistance in pancreas carcinoma. 
Moreover this CPE gene therapy will be of value for improved local control of the disease, 
particularly for unresectable or therapy refractory liver metastasis of pancreatic cancer. 
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Zusammenfassung 
Bakterielle Toxine, wie Diphtherie Toxin A, Streptolysion O oder Clostridium 
perfringens enterotoxin stellen eine wirkungsvolle und effektive Alternative zur 
Therapie von Tumorerkrankungen dar, deren antitumorales Potential in einer Vielzahl 
an in vitro und in vivo Studien gezeigt werden konnte. Durch die Etablierung solcher 
Toxin-basierten Therapien wurden neue Therapieoptionen, wie z.B. eine schnelle und 
effektive Zelllyse durch Porenbildung, eröffnet. Das vom Clostridium perfringens Typ A 
produzierte Clostridium perfringens enterotoxin (CPE) gehört zu der Gruppe der 
porenbildenden Toxine und weist eine rezeptorspezifische zytotoxische Wirkung auf, 
welche über die Membranrezeptoren Cldn3 und Cldn4 entfaltet wird. Diese Claudine 
liegen vor allem in Epithelialkarzinomen wie dem Brust-, Prostata-, Kolon- oder 
Eierstock, sowie dem Pankreaskarzinom stark hochreguliert vor.  
 
Ziel dieser Arbeit war die Anwendung des neuen selektiven und effizienten 
„Onkoleaking“ Suizid-Gentherapie Konzepts für die Behandlung von Cldn3 / 4 
überexprimierender Pankreaskarzinome (PK) unter Verwendung eines nicht-viralen 
translations-optimierten CPE exprimierenden Vektors (optCPE). Weiterhin sollte in 
dieser Arbeit der genaue molekulare Mechanismus der CPE-vermittelten Zytotoxizität 
in vitro und auch in vivo analysiert werden. 
 
Für die in vitro Analysen wurden verschiedene humane PK Zelllinien, Patienten 
abgeleitete Xenotransplantate (PDX) und deren abgeleiteten Zellen bezüglich ihrer 
Cldn3 / 4 Expression und Sensitivität sowohl gegenüber rekombinantem CPE (rekCPE) 
als auch nach optCPE Gentransfer untersucht. Im Zuge dessen konnte eine positive 
Korrelation zwischen der Effizienz CPE vermittelter Zytotoxizität und der Höhe der 
Cldn3 / 4 Überexpression gezeigt werden. Darüber hinaus wurde die Verfügbarkeit und 
Zugänglichkeit der CPE Rezeptoren für die Toxinbindung als kritischer Faktor für die 
durch Porenbildung induzierte Zytotoxizität beschrieben. Da bislang nur wenig über 
den durch optCPE induzierten Wirkmechanismus bekannt ist, war in der vorliegenden 
Arbeit eine detaillierte Analyse verschiedener apoptotischer und nekrotischer 
Signalwege und deren Schlüsselmoleküle vom besonderen Interesse. Dadurch 
konnten sowohl Caspase –abhängige als auch -unabhängige Signalwege des 
programmierten Zelltodes, aber auch Nekrose nach optCPE Gentranfer aufgezeigt 
werden. Diese Signalwege wurden in Anhängigkeit von der Menge des exprimierten 
optCPE und der Verfügbarkeit und Zugänglichkeit der Claudine aktiviert. Von noch 
größerer Wichtigkeit war jedoch die Anwendbarkeit und Nachweis der antitumoralen 
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Wirksamkeit der optCPE-basierten Suizid-Gentherapie mit Hilfe des nicht-viralen 
intratumoralen Jet-Injektion Gentransfers in verschiedenen Luziferase-exprimierenden 
CDX und PDX Modellen des Pankreaskarzinoms. Alle diese in vivo Studien zeigten 
eine selektive optCPE vermittelte Verminderung der Tumorvitalität in Verbindung mit 
Nekrose, die in fast allen Fällen mit einer Reduktion des Tumorvolumens einher ging. 
Die tierexperimentellen Studien belegen damit die Effektivität der CPE-basierten 
Gentherapie im Pankreaskarzinom. 
 
Mit diesen neu gewonnenen Erkenntnissen zum „Onkoleaking“ Konzept der CPE 
Suizid-Gentherapie und deren Wirkungsmechanismen sind Kombinationen mit 
konventionellen Therapien möglich. Sie können deren therapeutische Wirksamkeit 
verbessern und möglicherweise Therapieresistenzen im Pankreaskarzinom 
überwinden. Darüber hinaus ist diese CPE-basierte Gentherapie für eine verbesserte 
lokale Kontrolle der Tumorerkrankung vom großen Wert besonders in Hinblick auf die 
Behandlung nicht resektierbarer Tumore, von Rezidiven oder Metastasen des 
Pankreaskarzinoms.  
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1. Introduction 
1.1 Pancreatic cancer: Epidemiology 
1.1.1 Incidence and mortality 
Pancreatic cancer (PC) is one of the leading causes of cancer death in developed 
countries and one of the most lethal malignant neoplasms across the world [1, 2]. This 
malignancy is associated with very poor prognosis, which is reflected by the close 
parallel of mortality and incidence rate. With a 5-year survival rate of less than 5  % and 
a median survival of less than 6 months, diagnosis of PC demonstrates one of the 
most dismal prognoses [3]. According to the American Cancer Society, there have 
been an estimated 53,670 new cases of PC in 2017 with 43,090 deaths in the United 
States [4]. Moreover, PC is the fourth leading cause of cancer death in both sexes in 
the United States and it is expected to become the 2nd with 2030 [5]. In Germany it is 
ranked as the seventh leading cause of cancer associated death [6]. Worldwide, this 
disease accounts more than 200,000 deaths every year and its number is still 
increasing [5].  
 
 
1.1.2 Risk factors and hereditary causes for pancreatic cancer 
The etiology of PC remains poorly defined, although a number of risk factors have 
been identified by epidemiological and genetic studies. PC is a disease associated with 
age – mean age at onset of 71 years for men and 75 years for women. The incidence 
also differs between sexes; it is 50 % higher in men than in women [7]. The majority 
(> 80 %) of pancreatic carcinomas are due to sporadically occurring mutations. About 
10 % of cases have a genetic disregard, which increases an individual´s risk to develop 
the disease [8]. A number of hereditary cancer syndromes are known to be associated 
with an increased risk of PC, mainly Peutz-Jeghers syndrome (relative risk (RR) 132), 
melanoma pancreatic-cancer syndrome relative or familial atypical multiple mole 
melanoma  - pancreatic cancer (RR 13-147), hereditary breast-ovarian cancer (RR 3.5-
10) and also in lesser extent Lynch syndrome (RR 8.6) and familial adenomatous 
polyposis (RR 2-3) [9–11]. Inherited germline mutations in particular genes, such as 
Breast cancer 1/2 (BRCA1/2), ataxia-telangiectasia mutated serine/ threonine kinase 
(ATM), Serine/threonine kinase 11 (STK11), protease, serine 1/2 (PRSS1/PRSS2), 
serine protease inhibitor Kazal-type 1 (SPINK1), partner and localizer of BRCA2 
(PALB2) and DNA mismatch repair genes (e.g. MutL homolog 1 (MLH1), MutS protein 
homolog2 (MSH2), MutS homolog 6 (MSH6) and mismatch repair endonuclease PMS2 
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are associated with increasing risk for PC [10,12,13]. However, the genetic background 
for most familial PC remains unknown. Aside from family history, other factors are 
cigarette smoking [14–16], followed by obesity, which is associated with a 20-40 % 
higher rate of death from PC [17–19]. Furthermore, meta-analyses have shown 
associations between diabetes mellitus type 1 and 2 [20–24], chronic pancreatitis 
[3; 25], Helicobacter pylori infection [26–28] and dietary habits (red meat, 
fruit/vegetables and alcohol intake) and increased risk to develop PC [29–33]. 
 
 
1.2 Tumorgenesis and progression of pancreatic cancer 
1.2.1 Anatomy and Histopathology  
The pancreas is a large glandular organ, which is located transversely on the posterior 
abdominal wall behind the stomach and across the lumbar spine. The pancreas 
comprises four parts; the head, lying in the duodenal C-loop in front of the inferior vena 
cava and the left renal vein; the constricted neck, which lies in front of the superior 
mesenteric vein, splenic vein and portal vein junction and is the arbitrary junction 
between the head and body; and the body and tail of the pancreas that run obliquely 
upward to the left in front of the aorta and the left kidney.  
 
PC arises either from the exocrine or endocrine parenchyma of the glands (Figure 1.1). 
However, more than 95 % occur within the exocrine part and originate from ductal 
epithelium, acinar cells or connective tissue. Pancreatic ductal adenocarcinoma 
(PDAC) is by far the most common pancreatic neoplasm as it accounts for 
approximately 85  % of all pancreatic cancer cases. It is an invasive mucin-producing 
gland-forming neoplasm with an intensive stromal desmoplastic reaction [34]. The 
majority of PDACs arises in the head region of the pancreas and reveals a glandular 
pattern that varies in degree of differentiation, which can be distinguished by several 
histological features; random arrangement of glands, nuclear pleomorphism, 
incomplete glandular lumina, luminal necrosis, perineural invasion and lymphovascular 
invasion. Comparable to other tumor entities PDAC is staged using the tumor, nodes 
and metastasis (TNM) classification, where tumor size and precise burden as well as 
arterial and venous local involvement are addressed (see Table 1) [35]. 
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Table 1: TNM classification and stage grouping of pancreatic cancer 
Primary tumor (T) 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Tumor limited to the pancreas < 2 cm in greatest dimension 
T2 Tumor limited to the pancreas > 2 cm in greatest dimension 
T3 Tumor extends beyond the pancreas, without involvement of the coeliac axis or the 
superior mesenteric artery 
T4 Tumor involves the coeliac axis or the superior mesenteric artery         
(unresectable tumor) 
Regional lymph nodes (N)  
NX Regional lymph nodes cannot be assessed  
N0 No regional lymph nodes  
N1 Lymph node metastasis 
Distant metastasis (M)  
M0 No distant metastasis 
M1 Distant metastasis 
Stage grouping  
0 Tis, N0, M0 
I A T1, N0, M0 
I B T2, N0, M0 
II A T3, N0, M0 
II B  T1, N1, M0 
T2, N1, M0 
T3, N1, M0 
III T4, any N, M1 
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1.2.2 Malignant transformation of pancreatic epithelial cells and step-wise 
progression  
PDAC arises from non-invasive precursor lesions, where three different types have 
been identified: pancreatic intraepithelial neoplasia (PanIN), mucinous cystic neoplasm 
(MCN) and intraductal papillary mucinous neoplasm (IPMN). Most PDAC arise from 
PanIN that are microscopic (< 5 mm) mucinous-papillary lesions within the intralobular 
ducts of the exocrine pancreas, leading to an invasive carcinoma through an adenoma-
carcinoma sequence [36]. Additionally, they are graded into three stages on the basis 
of morphological and cytological characteristics. Normal pancreatic ductal cells can be 
identified by single cuboidal layer of cells, whereas PanIN-1a/b (low grade dysplasia) is 
characterized by mucinous differentiation and elongation of the ductal cells with slight 
nuclear atypia. PanIN-2 lesions (intermediate grade) show loss of mucinous epithelium 
and nuclear pleomorphism and crowding. On the other hand PanIN-3 (high grade) 
reveals pseudopapillary formation, high degree of nuclear atypia, intraluminal debris 
and frequent mitotic figures [37, 38] (Figure 1.1).  
 
 
 
 
 
Figure 1.1: Histological grades of pancreatic intraepithelial neoplasia (PanINs). PanINs represent progressive 
stages of neoplastic growth and each step in the progression from normal epithelium to low-grade PanIN on to high-
grade PanIN is distinguished by histological features. Modified after Chang DK et al. [39] and Makohon-Moore & 
Iacobuzio-Donahue [38]. 
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By contrast, MCN and IPMN are macroscopically visible cystic neoplasms. MCNs are 
large mucin-producing epithelial cystic lesions usually found in the body and tail of the 
pancreas, whereas IPMNs arise in the main pancreatic duct or one of its branches [37]. 
Both MCNs and IPMNs are also categorized into low-grade, intermediate-grade and 
high-grade dysplasia depending on the degree of dysplasia in the lining epithelium.  
 
In the past, the knowledge about genetic alterations underlying tumorigenesis in the 
pancreas has been expanded and many genetic mutations have been associated with 
PDAC, which can be distinguished by five categories:  
 
1) Mutational activation of oncogenes, predominantly V-KI-ras2 Kirsten rat 
sarcoma viral oncogene homolog (KRAS), which is present in more than 90 % 
of pancreatic cancers. 
2) Inactivation of tumor suppressor genes such as cyclin-dependent kinase 
inhibitor 2A (CDKN2A), detectable as early as in PanIN-2 lesions, or tumor 
antigen p53 (TP53) and the SMAD family member 4 (SMAD4) present in 
PanIN-3 lesions. 
3) Inactivation of genome maintenance genes, such as human mutL homolog1 
(hMLH1) and mutS Homolog 2 (MSH2) that control DNA damage repair and 
lead to microsatellite instability (MSI). 
4) Infrequent mutations of e.g. histone actetyltransferase p300 (EP300), SWI/SNF 
related, matrix associated, actin dependent regulator of chromatin (SMARCA4), 
Cadherin1 (CDH1), EPH receptor A3 (EPHA3), F-box and WD repeat domain 
containing 7 (FBXW7) or roundabout guidance receptor 2 (ROBO2).  
5) Genetic variations responsible for susceptibility pancreatic cancer, such as 
specific loci regions 17q25.1, 7p13, 3q29 or single nucleotide polymorphisms 
(SNPs) rs2853677 and rs401681 [40–43]. 
 
Similar progression models are proposed for the other two precursors MCN and IPMN 
of PC, although the genetic features are less well characterized [42, 44]. 
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1.3 Diagnosis and therapy of pancreatic cancer 
1.3.1  Clinical presentation, signs and symptoms 
Unfortunately, PC is usually diagnosed at an advanced stage as it develops without 
well-defined early signs or symptoms. Approximately 50 % of PC patients will present 
with jaundice, which is more frequent in patients with tumors located in the pancreatic 
head, where they cause obstruction of the adjacent biliary system. Other common 
symptoms are weight loss, nausea and vomiting. The initial presentation of PC varies 
according to tumor location [45, 46]. A recent case-control study identified back pain, 
lethargy and new-onset diabetes as unique features of pancreatic cancer. Further, 
Keane et al. observed five symptoms that occur more than 6 months before diagnosis: 
back and shoulder pain, lethargy, changes in bowel habit and dysphagia [47]. Another 
recent systemic review revealed nine symptoms of advances PC, of which abdominal 
pain (78 - 82 %) and diabetes (97 %) were most frequent [48].  
 
Due to the lack of specific symptoms at the early stage of disease patients are usually 
diagnosed in later stages. Moreover, there is no known biomarker specific to 
pancreatic cancer, but carbohydrate antigen 19 - 9 (CA19-9) has shown clinical value 
for therapeutic monitoring and surveillance of disease recurrence [49]. Even though 
CA19-9 does not have the sensitivity or the specificity to detect PC, but if elevated it is 
useful in following patients with a known disease. CA19-9 has a significant value as a 
prognostic factor and can be used as marker to measure disease burden [50, 51]. 
 
 
1.3.2 Treatment options 
Treatment and clinical management of pancreatic cancer are determined by the clinical 
stage of the disease and includes surgery, chemotherapy, radiation therapy, chemo-
radiation therapy, targeted therapy and palliative care. Unfortunately, current treatment 
options for pancreatic cancer are not satisfying. Although advances in molecular and 
targeted therapies have improved the patient survival of many different types of cancer, 
the outcome for PC has not improved much over the past 30 years. Since 1997 
gemcitabine mono-therapy has been the standard of care, which showed distinctive 
pharmacological properties and a broad spectrum of antitumoral activity [52].  
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Nevertheless, for patients with locally advanced or metastatic disease gemcitabine has 
no or very little effects on median overall survival [53]. Due to this reason many studies 
have been performed with combined gemcitabine and other chemotherapeutic drugs 
with the intention to improve the median survival, but results are still dismal. 
Gemcitabine in combination with 5-fluorouracil (5-FU) or platinum drugs, such as 
cisplatin or carboplatin, did not show a significant increase of overall survival [54–56]. 
In 2011, major improvements were demonstrated with the 5-FU-based triplet 
chemotherapy FOLFIRINOX (oxaliplatin, irinotecan, 5-FU and leucovorin) as it 
increased the median overall survival to 11.1 months compared to 6.8 months in the 
gemcitabine treated group [57]. But adverse events were seen, including grade 3 and 4 
neutropenia, limiting the use for patients with good performance status [2, 57]. 
However, this has been by far the most meaningful improvement in metastatic 
pancreatic cancer [2, 58-60]. Another combination of gemcitabine with nab-paclitaxel, 
albumin-bound paclitaxel particles, resulted in an improved overall survival (OS 8.5 vs. 
6.7 months), progression free survival and response rate compared to gemcitabine 
monotherapy [61]. In September 2013, the American food and drug administration 
(FDA) approved gemcitabine in combination with nab-paclitaxel for first-line treatment 
of metastatic pancreatic cancer. Disappointingly, strong side effects such as peripheral 
neuropathy and myelosuppression were also significantly increased [62, 63].  
 
Surgical resection is the only potentially curative treatment of pancreatic cancer and 
can lead to significantly longer survival compared to other treatment options. 
Assessment of the primary tumor and involvement of the local vessels are decisive for 
resectability [64–66]. Pancreatic cancer without distant metastasis can be categorized 
as resectable, borderline resectable and locally advanced  /  unresectable according to 
the degree of contact between tumor and vessels. The location and size of the tumors 
defines the type of surgery (pancreaticoduodenectomy, pancreatosplenectomy or 
laparoscopy). However, only 20  % of patients are resectable at the time of diagnosis. 
Unfortunately, the majority of patients have locally invasive disease and micro-
metastases at time of surgery, causing high recurrence and low 5-year survival rates of 
only 8  -  20  % [67, 68]. Due to the poor outcomes associated with surgery alone, many 
efforts regarding adjuvant therapy with 5-FU or gemcitabine-based chemo-radiation 
have been made to improve 5-year survival rates [69, 70]. 
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Pancreatic cancer is a disease that remains strongly resistant to most conventional 
therapies such as chemotherapy or radiation. The missing success can be partly 
associated with the underlying heterogeneity of pancreatic cancer. Therefore, the 
identification of molecular changes / pathomechanisms and development of new 
strategies to target the tumor are desperately needed.   
 
 
1.4 Cancer gene therapy 
Chemotherapy, radiotherapy and surgery still remain cornerstones of cancer treatment. 
In several cancer entities neo-adjuvant and adjuvant treatment is applicable and 
complete surgery prolongs survival. However, adverse effects and poor outcome in 
pancreatic cancer led to investigation of novel strategies, e.g. cancer gene therapy 
[71–74]. 
 
Initially, gene therapy was developed to treat genetic diseases. With expanding 
knowledge of cancer biology and tumor-host interactions these attempts became 
quickly adapted to cancer treatment. To date approximately two-third of all gene 
therapy trials worldwide are aimed at treatment of various types of cancer. This has 
become an inherent part of basic and clinical research [75–78]. Cancer gene therapy 
represents a promising strategy, where selective tumor cell killing, tumor growth 
inhibition or immune stimulation can be achieved by introducing foreign nucleic acids to 
tumor cells. This can be approached from different directions (Figure 1.2): 
 
a) Immune stimulation by using immune cells to either enhance antitumoral 
response or to boost the immune system of the patient to kill cancer cells  
[79–84] 
b) Insertion of a normal gene into cancer cells to replace a mutated or altered 
gene [85, 86] 
c) Gene suppression by intervention of gene transcription and translation by short 
interfering RNA (siRNA), micro RNA (mRNA) or antisense-oligonucleotides 
(AS-ODNs) [87–90] 
d) Selective tumor cell killing by suicidal mechanism [91, 92] 
e) Additive gene insertion to induce apoptosis [93, 94] 
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Figure 1.2: Major strategies in cancer gene therapy. The different approaches in gene therapy either aim at 
stimulation of the immune response against the tumor, or tumor killing as well as intervention of target gene expression 
via gene correction or gene suppression to reduce tumor growth or tumor resistance. APC: antigen presenting cell, 
ODNs: oligodeoxynucleotides, siRNA: short interfereing RNA, miRNA: microRNA. Modified after Amer [95] and 
published in Pahle and Walther [96]. 
 
 
1.4.1 Gene transfer methods and vectors used for gene therapy 
The diverse set of therapeutic options for gene therapy provides promising alternatives 
for cancer treatment. Despite the different methods and types, the delivery of the 
potential therapeutic gene is crucial for a successful treatment as the optimal vector 
and delivery systems depend on the targeted cell, duration of expression and the size 
of the genetic material incorporated in the vector [96, 97]. During the last decades, a 
broad variety of viral and non-viral vectors have been developed and modified 
[97-100]. The most commonly used viral vectors in gene therapy are adenoviruses, 
adeno-associated viruses, lenti- and retroviruses, which vary regarding cell tropism, 
mechanism of gene transduction and insertion, expression profiles, transgene capacity, 
immunogenicity and duration of transgene expression [100, 102–104]. Viral vectors 
have shown their potential as efficient gene transfer tools, but major limitations, such 
as rapid clearance after systemic injection, insertional mutagenesis and their 
immunogenic and inflammatory potential have given rise to the urgent need of non-viral 
alternatives. 
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The simplest form of a non-viral system is naked plasmid DNA, representing an 
important platform for gene delivery, as they are safe in application, stable in storage, 
easy to manipulate and comparatively moderate in expenses for production [96, 105]. 
However, gene transfer efficiency of non-viral vectors, either as naked DNA / RNA or 
as complex / encapsulated vector, is low [106]. Thus, non-viral systems have reached a 
new stage of development represented by novel vector types, including minicircle, 
dumbbell-shaped minimalistic vectors or sleeping beauty, improved transfer 
technologies such as nanoparticles / lipofection and physical technologies, such as 
electroporation, particle bombardment, jet-injection etc. (Figure 1.3). All these recent 
developments allow non-viral vectors to efficiently express genes while exhibiting low 
toxicity and immunogenicity at significantly improved levels of gene transfer [107–113]. 
Insufficient selectivity and transfer efficiency are still limiting factors for a successful 
gene therapy, which demand improvements in vector delivery, transgene transcription 
or translation. Another main obstacle is the specific vector targeting. If cancer in 
advanced stages becomes a metastatic disease, systemic gene delivery is still 
challenging [114].  
 
Figure 1.3: Representation of different chemical and physical delivery technologies of non-viral vectors. 
Chemical (e.g. liposomes or polyplexes) or physical (electroporation or ultrasound) technologies are used for improved 
delivery of non-viral vectors to tumor tissue. Modified after Ramamoorth and Narvekar [97] and published in Pahle and 
Walther [96]. 
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In this context antitumoral immune stimulation via RNA or DNA vaccination and 
immunogene therapy are the most promising approaches to combat cancer metastasis 
[115–119]. Another attractive strategy is the local gene therapy to control the disease, 
as sustained gene expression only occurs within a limited area at the injected tumor 
site. In fact, approximately 20  % of all clinical cancer gene therapy trials are performed 
as local viral or non-viral approaches [120].  
 
 
1.4.2 Strategies used for gene therapy  
Apart from the development of transfer technologies, an appropriate therapeutic gene 
is decisive. The choice of the respective and most suited gene is often determined by 
the mode of action of the specific gene therapeutic strategy, e.g. gene correction, 
suicide gene or gene suppression and gene silencing. These strategies are explained 
in detail in the following paragraphs.  
 
 
1.4.2.1 Gene correction 
The initial goal of gene therapy was to provide gene correction of defective genes. This 
was adapted to the treatment of malignant diseases in order to replace mutated and 
altered genes of oncogenic potential with the aim to inhibit the malignant phenotype of 
cancer cells [121]. Unfortunately, this strategy had only limited impact on cancer gene 
therapy but still has potential if combined with conventional therapies, such as chemo- 
or radiotherapy. In contrast, strategies aiming on the restoration of tumor suppressor 
gene expression, such as tumor suppressor candidate 2 (TUSC2) or TP53, harbor 
potential, as it has been shown in several in vitro and in vivo studies, as well as viral 
and non-viral gene therapy clinical trials [85, 86, 122–125]. These strategies can be 
conducted by e.g. repeated systemic delivery of liposomally encapsulated plasmid-
DNA. In the recent study of Lu et al. the tumor suppressor gene TUSC2, which is 
frequently inactivated in lung cancer development, was applied to cancer patients with 
recurrent and / or metastatic lung cancer by intravenous injection. The authors 
demonstrated transgene expression in primary and metastatic lung tumors associated 
with alteration of TUSC2 mediated apoptotic pathways. Furthermore, five out of 23 
patients achieved stable disease for 2.6 to 10.8 months and two patients showed 
reductions in tumor size, revealing the safe administration and antitumoral effect of 
TUSC2 restoration gene therapy [85]. 
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Another first-in-man Phase I clinical trial, restoring the human tumor suppressor gene 
TP53 using a nanocomplex demonstrated tumor selective p53 expression in primary 
and metastatic biopsies. Minimal side effects were observed and majority of patients 
demonstrated stable disease. These results showed well tolerated, systemically 
delivered p53, which exhibits anticancer activity and also supplies evidence of targeted 
delivery to metastatic lesions [86].  
 
 
1.4.2.2 Gene suppression and gene silencing 
Gene suppression therapies aim at the intervention of gene transcription and 
translation and are of growing importance. AS-ODNs and siRNAs represent targeted 
nucleic acid-based pharmaceuticals. Both possess high potential for cancer treatment 
as tumor growth inhibition, improved patients sensitivity towards chemo- and 
radiotherapy and tumor progression and metastasis formation has been observed in 
vitro and in vivo [87, 88, 90, 126–131].  
 
Since their discovery, numerous miRNA have been identified with important impact on 
tumor development, progression and metastasis formation, tumor suppression or 
therapeutic response, revealing that they might also be attractive targets as well as 
therapeutics for gene therapeutic approaches to treat cancer. Therefore, miRNA 
cancer therapy is currently experiencing accelerated growth [89, 132, 133].   
 
Another novel therapeutic strategy for gene suppression is the use of ODNs decoy, 
which is based on the competitive inhibition of transcription factors by double-stranded 
ODNs composed of transcription factor recognition sequences. They compete for 
transcription factor binding to transcriptionally inhibit the targeted gene expression. For 
example, the ODN decoy strategy has been used to generate antitumoral effects by 
transcriptional targeting of signal transducer and activator of transcription 3 (STAT3), a 
well-known oncogenic transcription factor in several types of cancer [134–136]. The 
intratumoral administration of cyclic STAT3 decoy ODNs abrogated target gene 
expression in patients with head and neck cancer and led to tumor growth inhibition in 
xenograft models after systemic administration [137–139]. This demonstrates the great 
potential of such decoy therapies.  
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1.4.2.3 Cancer immunogene therapy 
Cancer immunotherapy aims to stimulate a host antitumor response, resulting in tumor 
growth inhibition and improved clinical outcomes of patients. During last years, many 
different classes of agents, which aim at enhancing immune responses against tumor, 
have been developed. These include cytokines, immune checkpoint inhibitors, adaptive 
T-cell therapy and numerous vaccine strategies [117, 140, 141]. Some of these new 
immunotherapies, especially immune checkpoint inhibitors, such as nivolumab in non-
small cell lung cancer [142] and ipilimumab in metastatic melanoma [143], have shown 
impressive survival benefits in phase III trials, which led to FDA approval as new 
modality for cancer treatment.  
 
Based on the fact that cancer is a systemic disease with potential metastasis formation, 
immunogenic therapy represents an attractive approach to systemically treat cancer. In 
this context, vaccination strategies became attractive to combat cancer by systemic 
activation of the anticancer immune response. By definition nucleic acid vaccines 
contain antigens encoded either by DNA or RNA. DNA vaccines, which are usually 
naked DNA vectors expressing tumor-associated antigens (TAAs), are administered to 
the host and internalized by the host cell, where it is transcribed and further translated 
into the respective TAA. The resulting TAA peptides are presented on the surface of 
host antigen-presenting cells, stimulating an antitumoral immune response [118]. In this 
regard, gene therapy is employed to express specific TAAs, such as human epidermal 
growth factor receptor 2 (Her2/neu) [144, 145], melanoma antigen recognized by T 
cells 1 (MART1) [146], prostate specific antigen (PSA)  [146–148] or carcinoembyronic 
antigen (CEA) [150–153] and have been already translated into clinical trials.  
 
In parallel to DNA vaccine development, RNA vaccines, mainly mRNA, were 
established. These RNA vaccines comprise messenger RNA (mRNA) that encodes the 
antigen of interest. Once applied and internalized by host cells, mRNA transcripts are 
translated directly into the TAA peptide to mediate immune response [119]. RNA 
vaccines have demonstrated their high potential for cancer immunotherapy as they 
retain the same characteristics as DNA vaccines but also enable delivery of large 
amounts of patient-specific antigens from small tumor samples, induce humoral and 
cellular immune responses, provide co-stimulatory signals, have no oncogenic potential 
and are well-tolerated [117,154-157]. 
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1.4.2.4 Suicide gene therapy 
Suicide gene therapy was particularly developed for the treatment of cancer. This has 
been a major breakthrough in gene therapy because safety and effectiveness are 
successfully addressed. The suicide-inducing transgene transfer into cancer cells has 
been extensively investigated in several types of cancer, including colon [158–160], 
breast  [161], prostate [162], and lung cancer [150, 163] or glioma [164–166] and has 
further been established as anti-vascular endothelial treatment [167, 168] and immune 
stimulator [169, 170]. 
 
The basic concept of suicide gene therapy or so-called gene-directed enzyme-
producing therapy (GDEPT) is the introduction of viral or bacterial genes into tumor 
cells, which convert non-toxic prodrugs into its toxic metabolites, subsequently killing 
tumor cells. Suicide gene therapy consists of different systems. The two most 
prominent members are: the bacterial or viral cytosine deaminase (CD), which converts 
the pro-drug 5-fluorocytosine (5-FC) to 5-FU and most widely, the Herpes simplex virus 
thymidine kinase (HSV-tk) that converts ganciclovir (GCV) to ganciclovir mono-
phosphate, which is further modified to a triphosphate by the cancer cell expressing 
HSV-tk enzyme. Both, CD- and HSV-tk expressing vectors have entered clinical 
phases I and II [92, 160, 162, 171]. A supportive element in using these suicidal 
systems is the bystander effect. Here neighboring or by-standing cancer cells that were 
not transduced or transfected with the suicide gene are eliminated along with 
transduced or transfected cells, leading to an improvement of efficiency (Figure 1.4a). 
However, there are certain factors affecting the efficiency of suicide gene therapy. In 
this regard, the percentage of gene  /  enzyme of interest expressing cells, the extent of 
contacts between cells and their ability to transfer small toxic molecules were found to 
be the most crucial conditions [172]. The idea of one targeted cancer cell is able to kill 
more cells has been a revolutionary concept for suicide gene therapy, but has also 
been challenging to translate this into effective and safe therapy in patients. 
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Figure 1.4: Targeted killing of cancer cells by using suicide gene therapy. (a) This approach involves the transfer 
of a therapeutic gene encoding a prodrug-activating enzyme into tumor cells followed by specific prodrug treatment.  
Expression of the therapeutic gene – the prodrug-converting enzyme – enables conversion of an inactive non-toxic 
prodrug into an active cytotoxic drug. The metabolites can pass to neighboring cells causing cell death through the 
bystander effect. (b) Direct cell killing can be achieved if the inserted gene is expressed to produce a toxin-induced 
cytotoxicity or proapototic protein. As the transfected cell undergoes cell death, expressed toxin / protein can affect 
neighboring non-transfected cells via bystander effect. Modified after Frank McCormick [173] and published in Pahle 
and Walther [174]. 
 
 
Recent developments with respect to the aforementioned suicide genes aimed at 
optimization via mutated variants or fusion proteins of suicidal genes, allowing either a 
more efficient conversion of the metabolite or modification / improvement of substrate 
specificity [92]. This enzyme-prodrug system demonstrates strong tumor cell killing, 
however there are two major drawbacks: the above-mentioned bystander effect, which 
can cause unwanted side effects on normal tissues and the reduced effectiveness in 
slow-dividing cancer cells. Alternatively, new suicide concepts based on apoptotic 
genes, such as TP53, Bcl2 associated x (BAX) or Fas ligand (FASL), have entered the 
field of suicide gene therapy. Thus, the term has meanwhile expanded toward the 
delivery of genes that are either directly toxic or pro-apoptotic [93, 175, 176] 
(Figure 4b). However, they also revealed limitations because cancer cells develop 
resistance to apoptosis induction [177, 178]. To overcome the obstacles of resistance 
and proliferation dependence of classical suicidal systems, novel therapeutics, such as 
bacterial or plant toxins, became of interest to combat cancer.  
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1.5 Bacterial toxins for suicidal gene therapy 
Alternatively to the classical suicide gene therapy concept, use of bacterial toxins came 
into focus. Bacterial toxins are toxic substances that are produced and released by 
bacteria to target host cells and can be categorized according their mode of action:  
 
1) Pore-forming or membrane damaging toxins  
(e.g. Clostdridium perfringens enterotoxin, listeriolysin O, streptolysin O) 
2) Inhibition of protein synthesis  
(e.g. diphtheria toxin, Pseudomonas exotoxin A, Shiga toxin) 
3) Activation of second messenger pathways  
(e.g. Clostridium botulinum C2/3 toxin, cholera toxin, pertussis toxin) 
4) Activation of immune response  
(e.g. pyrogenic exotoxin, Staphylococcus aureus enterotoxin) 
5) Proteases  
(e.g. Bacillus anthracis lethal factor, Clostridium botulinum neurotoxin A-G) 
 
Depending on their mode of action, toxins are able to eliminate cancer cells and alter 
cellular mechanism controlling proliferation, apoptosis and differentiation, which are 
deregulated during carcinogenesis. Regarding this point, a continuously growing 
number of experimental in vitro and in vivo studies using the variety of bacterial toxins 
for cancer treatment, demonstrate the capability of bacterial toxins for effective cancer 
cell killing [179–181]. Within the last years, the processing and manipulation of toxic 
bacterial proteins, such as diphtheria toxin, streptolysin O or Clostridium perfringens 
enterotoxin as well as their encoding genes was facilitated, which resulted in the 
establishment of ‘toxin-based therapy’ for treating cancer [182–184]. With this 
approach novel features such as rapid and effective pore-forming cell lysis were 
introduced, describing a new therapeutic approach of oncoleaking strategies.  
 
 
1.5.1 Diphtheria toxin-based suicide gene therapy 
A prominent bacterial toxin that has been extensively studied in therapeutic 
approaches is the diphtheria toxin (DT). This 62  kDa exotoxin is secreted by 
pathogenic strains of Corynebacterium diphtheria and binds to the heparin-binding 
epidermal growth factor precursor (HB-EGF) on the cell surface [185]. DT consists of 
535  amino acids and belongs to the group of AB toxins.  
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It can be cleaved into two major fragments, DT-A and DT-B, whereof DT-B mediates 
the cell entry by binding to surface receptors and subsequent translocation into 
cytoplasma by undergoing endocytosis (Figure 1.5). On the other hand, DT-A is 
responsible for the cytotoxic enzymatic activity and inactivates the ADP-ribosylation of 
the elongation factor 2 (EF2) resulting in inhibition of protein syntheses and cell death 
[186, 187] (Figure 5). A single DTA molecule is sufficient to kill a cell, but without DT-B 
it is not able to enter a neighboring cell. The features of high potency, locally restricted 
toxic effect, no anti-DT immunity (since it is endogenously expressed within the tumor) 
and the absence of cellular resistance underline the high potential of DT-A as gene 
therapeutic agent. However, to avoid unintended side effects on normal cells, this 
potent toxin requires efficient and reliable selective targeting. Several attempts have 
been done to target the DT-A toxicity, e.g. by modifying the promoter [188] or replacing 
the wild type DT-A sequence with attenuated mutant variants [189], with dissatisfying 
outcome.  
 
 
Figure 1.5: Mechanism of diphtheria toxin. (1) Secreted toxin consists of three functional domains:  the N-terminal 
catalytic domain (DT-A), the translocation domain (T) that is bridged by a disulfide bond to receptor-binding domain (R). 
(2) DT binds to its receptor (Heparin-binding epidermal growth factor precursor). (3) Furin protease cleaves the 
polypeptide chain between C and T domain. (4) Toxin-receptor complex is internalized into clathrin-coated pit. (5) Inside 
the early endosome, furin protease cleaves toxin molecule and T domains undergo conformational change, insert into 
endosome membrane and form channel, resulting in translocation of catalytic domain into cytoplasm, followed by 
reduction of disulfide bond. (6) DTA inactivates eukaryotic translation elongation factor 2 (eEF2) by ADP-ribosylation, 
leading to inhibition of translation and cell death. Modified after Shapira & Behnhar [184] and published in Pahle and 
Walther [174]. 
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To minimize damage on healthy tissue a specific targeting mechanism is essentially 
required. In the last decades, researchers focused on identifying tissue- and tumor-
specific promoter elements that are critically important for more effective application of 
gene therapy [190–192]. With expanding knowledge transcriptional targeting was 
established - an approach based on positioning a therapeutic gene under the 
transcriptional regulation of a promoter, which is preferentially activated in targeted 
tumor tissue [192–194]. To date, numerous tissue-specific promoters, e.g. imprinted 
maternally expressed transcript (H19), mesothelin (MSLN) or mucin 1 (MUC1), have 
been cloned, characterized and applied for controlled DT-A expression in different 
types of cancer, such as ovarian cancer [195, 196], PC [197–199], colon 
adenocarcinoma [200] or lung cancer [201].  
 
 
1.5.2 Streptolysin O-mediated oncolytic suicide gene therapy 
Apart from the strategy of protein translation intervention, the approach of cell lysis 
mediated through pore-forming toxins is also of attractiveness to eradicate tumor cells, 
particularly with regard to additional immunostimulation. If a tumor cell is lysed it could 
deliberate tumor specific antigens, which could in turn contribute to the activation of 
patient´s immune response against the tumor. Streptolysin O (SLO) represents one of 
such pore-forming toxins. It is a 62  kDa toxin, secreted by Streptococcus bacteria and 
belongs to the family of cholesterol-dependent cytolysins [202]. SLO is comprised of 
four domains D1-D4, of which D3 and D4 are the most important ones, since D3 
provides transmembrane spanning regions and D4 interacts directly with cholesterol of 
cell membranes. After binding, SLO monomers oligomerize to form homotypic 
aggregates, which insert into the membrane to form a large pore leading to lysis of the 
cell [203, 204] (Figure 1.6). 
 
 
Figure 1.6: Mechanism of cytolytic action of strptolysin O (SLO). SLO binds specifically to membrane cholesterol 
and oligomerizes to a ring structure that contains 45 ‒ 50 units, which then inserts into membrane to create a large pore. 
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This leads to loss of in- and efflux balance across the cell membrane, inducing cytolysis. Modified after Dal Peraro & 
van der Goot [205] and published in Pahle and Walther [174]. 
Most bacterial toxins, such as DT or Pseudomonas exotoxin A, act inside the targeted 
cells, conversely pore forming toxins are known to act at the cell membrane. This has 
been shown by many studies using recombinant proteins [206–213]. Nevertheless, 
Yang et al. used a conventional plasmid expression vector carrying the cDNA of the 
SLO gene in a liposome-mediated transfection system and demonstrated cell 
membrane permeabilization and disintegration after SLO gene transfer [214]. Further in 
vitro and in vivo experiments confirmed the cytotoxic activity by SLO as cell viability 
was significantly reduced in several human cancer cell lines after gene transfer and 
demonstrated the successful use of SLO gene as anticancer agent [204]. However, 
cholesterol is certainly present in cell membranes of normal cells, which highlights the 
major drawback of this approach, since unwanted side effects could occur. Therefore, 
modifications such as attachment of tumor-specific promoter upstream the SLO gene 
as described in DT-based therapy or use of nanoparticles, which bind to specific tumor 
cell surface proteins, are required. 
 
 
1.5.3 Clostridium perfringes enterotoxin-based oncoleaking suicide gene 
therapy 
Another very promising pore-forming bacterial toxin for suicide gene therapy is the 
Clostridium perfringens enterotoxin (CPE), which is produced by the anaerobic gram-
positive bacterium Clostridium perfringens and mainly associated with food poisoning 
[215, 216]. This 35 kDa protein comprises 319 amino acids with a unique primary 
sequence. CPE is a two-domain protein consisting of a C-terminal receptor-binding 
domain (residues 184-319) that recognizes and binds to certain members of the 
claudin (Cldn) family and an N-terminal region, which is involved in oligomerization and 
pore formation [217–221]. The C-terminal fragment of CPE, known as cCPE, is a nine-
strand β-sandwich revealing high-affinity binding to its receptors, but has no capability 
to initiate or form pores. This is exclusively initiated by the N-terminal residues 80-160, 
also known as TM1 region, consisting of hydrophilic and hydrophobic amino acids that 
resemble β-loops, which mediate membrane insertion followed by pore formation 
[183,  222–225] (Figure 1.7a).  
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Figure 1.7: Structure of CPE monomer (left) and C-CPE bound to claudin (right). (a) Two domain structure of CPE 
monomer, comprising the C-terminal binding domain (cCPE, yellow-red) and the N-terminal oligomerization and 
membrane insertion domain. (b) Binding of cCPE to claudin (Cldn) receptor that consists of four transmembrane 
domains, two extracellular loops (ECL) and a short C-terminal tail (not shown). Here, cCPE interacts with both ECLs 
whereof second ECL distinguishes Cldn capable of binding CPE. Modiffied after Freedmann [225].  
 
 
The Cldn family comprises at least 27 proteins that are essential for tight junction 
formation located at apical cell – cell contact regions in epithelial and endothelial cells. 
They play an important role in controlling paracellular transport as well as maintenance 
of cell polarity [226]. The classical Cldn consist of a short cytoplasmic N-terminal 
domain, four transmembrane domains, two extracellular loops (ECL1 and 2) and a 
cytoplasmatic C-terminal tail [227]. Even though all claudins reveal the aforementioned 
features, certain members are not functional receptors of CPE, e.g. claudin-1, -2, -5 
and -10. Fujita et al. showed that the ECL-2 region is critical for the binding of CPE, 
which was further confirmed by Winkler et al. as they identified a pentapeptide 
sequence within the ECL-2 region that is important for CPE binding [219]. Additional 
studies revealed the interaction of both ECL regions with CPE, the necessity of 
interaction between ECL-1 and toxin and demonstrated that only receptor claudins 
possess a specific ECL-2 region [228–230] (Figure 1.7b). 
 
The mechanism of CPE action is initiated by the binding to its receptors, in particular, 
claudin-3, -4, -6, -8 and -14 [225, 230–233]. This binding triggers the formation of a 
90 kDa ‘small complex’, containing CPE and both receptor and non-receptor claudins 
[234, 235] (Figure 1.8). Unable to mediate cytotoxicity, ‘small complexes’ have to 
interact with other ‘small complexes’, which then oligomerize to a prepore on the 
membrane surface, leading to a 450 kDa ‘large complex’ – named CH1 complex 
[223, 236].  
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Figure 1.8: Mechanism of oncolytic action of CPE. CPE binds to its receptors, preferably claudin-3 and/or -4 at 
membrane of intestinal epithelium. The small CPE/claudin complexes and oligomerize to form a large hexameric 
complex – CH1 that increases permeability of cell membrane. CH-1 complexes incorporate occludins, resulting in an 
even larger CH-2 complex, which disrupts epithelial tight junctions and breakdown of colloid-osmotic equilibrium of 
affected cells. In consequence cells undergo cell death by cytolysis. Modified after Smedley et al. [237] and published in 
Pahle and Walther [174]. 
 
 
The CPE hexamer and claudin containing CH1 complex subsequently forms a pore 
into the membrane, which in turn leads to membrane permeability alterations and 
increased influx of calcium (Ca2+), resulting in cell death [225, 238]. With extended 
time, morphological damages lead to exposure of the basolateral cell surface, allowing 
additional binding of the toxin to form an even larger complex of approximately 600 kDa 
(CH2), which further consists of claudins as well as occludins [239]. Up until now it is 
known that high concentration of CPE causes formation of many pores, which leads to 
massive Ca2+ influx and consequently to necrotic cell death, whereas low CPE 
concentration results in low numbers of pores, rather causing apoptosis [225, 240]. 
 
Numerous publications have revealed that certain types of cancer, especially epithelial 
cancers, such as colon, breast, prostate, ovarian and pancreatic cancer possess a high 
expression level of claudin-3 and / or -4 compared to normal tissue [235, 241–247]. 
Regarding this fact and the cytotoxic potential of CPE, considerable effort has been 
made to develop a CPE-based approach for cancer therapy and to exploit its potential 
clinical benefit in targeting Cldn3 / 4 overexpressing tumors has been broadly 
evaluated. A variety of studies demonstrated the delivery of recombinant CPE in vitro, 
as well as a cytotoxic effect on high Cldn3 / 4 expressing pancreatic [248], breast [249] 
and ovarian carcinoma [250] cells, which was associated with tumor reduction or 
elimination. Since the binding of CPE is highly specific to Cldn, CPE is attributed with 
great potential for the targeted treatment of Cldn3 / 4 overexpressing tumors. The 
application of recombinant CPE revealed many therapeutic advantages.  
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Up to now, no endogenous inhibitors are known for CPE, which could interfere with its 
cytotoxic action. Furthermore, CPE develops a receptor-specific, dose-dependent, fast 
and efficient therapeutic effect and reveals a selective mechanism of action and 
provides only low potential for resistance development. This allows the use of CPE in 
therapy-resistant tumors. However, some disadvantages have to be considered as 
well. CPE might cause strong side effects due to its toxicity to normal Cldn3 / 4 
expressing tissue, as it has been described after i.p. injection of recombinant CPE in 
immune suppressed mice [249]. Further, it has been demonstrated that the use of 
recombinant CPE proteins requires repeated application to achieve significant 
therapeutic effects [249, 251].  
 
To overcome these obstacles, a gene therapeutic approach using a CPE-expressing 
vector could prolong toxin availability, improve intratumoral dispersion and 
subsequently amplify the cytotoxic effect. Based on this idea, Walther et al. established 
a eukaryotic translation optimized CPE vector, which combines both target specificity 
and efficient cytotoxicity [252]. The intracellular expression and accumulation of CPE 
after gene transfer led to efficient killing of Cldn3 / 4 expressing tumor cells in vitro and 
significant reduction in tumor growth in vivo, demonstrating its great value for the 
targeted tumor gene therapy. This study further revealed first enlightenment of the 
possible mechanism of oncolytic action mediated through expressed CPE, as induced 
necrosis was recorded. Up to this point little is known about the induction of cell death 
mechanism after CPE gene transfer. Knowledge about this will be crucial for the 
improvement of the oncolytic effect and will allow possible combination therapies with 
conventional therapies, such as chemotherapeutics. Moreover this would be decisive 
for a safe clinical use.  
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1.6 Aims of study 
The intensive research of the last two decades provides strong evidence that bacterial 
toxins have evolved to an effective therapeutic option for cancer therapy. Particularly 
recombinant CPE has demonstrated remarkable and specific cytotoxicity for Cldn3 / 4 
overexpressing epithelial tumors. However, little is known about the gene therapeutic 
use or the mechanism of action after gene transfer of this particular toxin as only one 
study has been conducted in colon cancer. Thus, we hypothesized, that CPE is a 
valuable option for therapy refractory tumors such as pancreas carcinoma. 
 
Therefore, the aim of this thesis was to evaluate the feasibility and potential of the 
oncoleaking gene therapy using CPE as a new suicide approach for the treatment of 
Cldn3  /  4 overexpressing pancreatic cancer. As prerequisite for more detailed 
analyses, this study aimed first at the characterization of a suitable panel of human 
pancreatic cancer cell lines and patient derived xenograft (PDX) models, in which CPE 
mediated cytotoxicity is investigated. Furthermore, sensitivity of individual cell lines 
towards recombinant CPE is tested and correlation between antitumoral CPE effect 
and respective Cldn3  /  4 expression and distribution pattern in pancreatic cancer cells 
are examined. More importantly, the successful CPE expression and biological 
effectiveness after gene transfer is investigated in pancreatic cancer cell lines. In this 
regard, CPE mediated mechanism of action, by which different cell death pathways are 
potentially induced, is elucidated in more detail at cellular and molecular level. As 
important translational aspect, the applicability and efficiency of CPE gene therapy is 
evaluated by the non-viral intratumoral jet-injection gene transfer in vivo. For this, 
different human pancreatic cancer cell line xenografts (CDX) and PDX models are 
established to investigate the CPE mediated inhibition of tumor growth and reduced 
tumor viability by non-invasive in vivo bioluminescence imaging and by molecular 
analyses of treated tumors.  
 
The improved knowledge based on the present study about this new oncoleaking 
concept of suicidal gene therapy and its mechanism of action will also allow the design 
of novel combinations with conventional therapies to further improve therapeutic 
efficacy and to overcome resistance in pancreas carcinoma. Moreover this CPE gene 
therapy will be of value for improved local control of the disease particularly for 
unresectable tumors or therapy refractory liver metastasis of pancreatic cancer. 
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2. Material and Methods 
2.1 Cell cultivation, patient derived xenograft (PDX) models and transfection  
2.1.1 Human cancer cell lines 
All human cancer cancer cell lines used in this study were either purchased from 
American Type Culture Collection (ATCC, Manassas, VA, USA) or German Collection 
of Microorganisms and Cell culture (Leibnitz Institute DSMZ, Braunschweig, Germany). 
The immortalized normal human pancreatic duct epithelial cell line HPDE-H6c7 was 
kindly provided by the laboratory of Ming-Sound Tsao, University Health Network, 
Canada. All used cell lines are summarized in table 2.1 with detailed description from 
ATCC or DSMZ database. Cells were maintained either in RPMI-1640 or DMEM 
medium (Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 10 % fetal 
bovine serum (FBS) Superior (Biochrom AG, Berlin, Germany), in a humidified 95 % air 
and 5 % CO2 incubator at 37 °C. Phosphate buffered saline (PBS) and Trypsin/EDTA 
solution for passaging of cells was obtained from Thermo Fisher Scientific. Cell culture 
plastic ware was obtained from TPP (Trasadingen, Switzerland), BD Biosciences 
(Heidelberg, Germany) or Greiner BioOne (Kremsmünster, Austria). All cell lines were 
regularly tested for mycoplasma contamination using MycoTM Mycoplasma Detection kit 
(Lonza, Basel, Switzerland).  
 
 
2.1.2 Virus production and generation of stably eGFP-Luc expressing cell lines 
1.5 × 107 HEK cells were plated for transfection. After 24 h cells were transfected using 
2.85 ml serum-free medium, mixed with 90 μg of polyethylenimine (PEI) and kept at 
room temperature for 5 min. 30 μg of eGFP-Luc lentiviral plasmids with packing vectors 
(20 μg psPax2, 10 μ pMD2. G) were mixed and incubated at room temperature for 
20 min and added to the respective plates. After 48 h of incubation, the supernatant 
was collected and filtered (0.45 μm filter). The filtered supernatant was loaded on a 
20 % sucrose cushion and centrifuged at 4 °C for 4 h at 28,000 rpm. The viral particles 
were dissolved in 500 μl sterile PBS and stored at -80 °C. Capan-1, HUP-T3, 
MIA PaCa-2 and PA-TU-8902 cells were transduced in 6-well plates with a multiplicity 
of infection (MOI) less than 10 for each respective well.  
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After 24 h of incubation, virus-containing medium was replaced with the regular 
medium and the GFP expressing cells were sorted using FACS. After sorting, the 
luciferase expression of the stably transduced cells was analyzed by measuring 
relative luminescence using the Steady-Glo® Luciferase Assay System (Promega). 
The eGFP-Luc stably expressing cells were used for animal experiments and 
bioluminescence imaging, respectively. 
 
 
Table 2.1 Summary of used human cancer cell lines  
Cell line 
(ATCC/DSMZ number) 
Medium Characteristics 
 
Pancreatic cancer cells:  
 
  
      AsPC-1  
     (CRL-1682) 
RPMI + 10 % FBS adherent, pancreas adenocarcinoma, 
derived from metastatic site ascites  
 
      BxPC-3 
     (CRL-1787) 
RPMI + 10 % FBS adherent, pancreas adenocarcinoma 
 
 
      Capan-1  
     (HTB-79) 
RPMI + 10 % FBS adherent, pancreas adenocarcinoma, 
derived from metastatic site liver  
      HUP-T3  
     (ACC 259) 
DMEM + 10 % FBS adherent, pancreas carcinoma, derived 
from metastatic site ascites  
 
      MIA PaCa-2  
     (CRL-1420) 
DMEM + 10 % FBS adherent, epithelial, pancreas carcinoma 
 
 
      PA-TU-8902  
     (ACC 179) 
DMEM + 10% FBS adherent, pancreas/duct adenocarcinoma 
 
   
Melanoma and colorectal 
carcinoma cells: 
  
      SK-MEL-5  
     (HTB-70) 
RPMI + 10 % FBS adherent, skin, derived from metastatic 
axillary node, malignant 
 
      HT-29  
     (HTB-38) 
DMEM + 10 % FBS adherent, colon, colorectal 
adenocarcinoma 
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2.1.3 Pancreatic cancer patient derived xenograft (PDX) models 
For in vivo expression and therapy studies, 18 pancreatic cancer PDX models, 
established and kindly provided by EPO Berlin Buch GmbH, were included (Table 2.2). 
Tumor staging, grading and typing was performed according to UICC and WHO 
guidelines. Tumor tissue of patients was collected after surgery (F0), shortly stored in 
RPMI media supplemented with 10 % FBS and antibiotics, diced into 15 - 20 mm3 
pieces and implanted into subcutaneous pocket on one side of the lower back into 
immunodeficient mice (F1). After successful engraftment, tumors were passaged (F2) 
and expanded in large cohorts for experiments (F3) (Figure 2.1).  
 
 
2.1.4 PDX derived cell lines
Before in vivo gene transfer experiments were conducted, PDX models were tested for 
CPE sensitivity in vitro. Therefore, PDX models (Table 2.2) were used to generate 
single cell suspensions for PDX derived cell lines, which were then cultivated with 
RPMI supplemented with 20 % FBS. For this purpose, PDX pancreas tumors were 
dissociated using the Tumor Dissociation Kit (Miltenyi Biotec, Gladbach, Germany) and 
the gentleMACS™ Dissociator (Miltenyi Biotec) according to manufacturer’s 
specification. For additional bioluminescence in vivo experiments, cells derived from 
the PDX Panc9996, Panc11344 and Panc12536 were transduced with the eGFP-Luc 
lentiviral plasmids as described in paragraph 2.1.2. 
 
 
 
 
Figure 2.1 Establishment of patient derived xenograft models (PDX) of pacreatic cancer. Tumors from cancer 
patients (F0) are fragmented and subcutaneously transplanted into immunodeficient mice (F1) for engraftment. Once 
grown, the tumors are transplanted into secondary recipients (F2) for tumor expansion. The expanded tumors can then 
be cryopreserved or transplanted into F3 mice for further in vivo studies. Modified after Tentler et al. [253].  
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Table 2.2 Characteristics and staging of pancreatic cancer PDX models 
Panc PDX Histology TNM Gender Age 
Panc 9553 Ductal adenocarcinoma pT3N1 (1/10) female 67 
Panc 9699 Ductal adenocarcinoma  
pT3N1 
(7/25)L1V1Pn1G3 
male 70 
Panc 9759 Ductal adenocarcinoma  
pT3N1 (1/19) 
R1G3L1V0 Pn1 
male 61 
Panc 9996 Ductal adenocarcinoma  pT3N1 (3/17) female 60 
Panc 10713 Ductal adenocarcinoma  pT4N1 (2/12) male 64 
Panc 10953 Ductal adenocarcinoma  pT3pN1 (2/25) female 61 
Panc 10991 Ductal adenocarcinoma  pT3pN1 /2/23) female 72 
Panc 11056 Ductal adenocarcinoma  pT3pN1 (1/19) male 77 
Panc 11074 Ductal adenocarcinoma  pT3pN0 /0/12) female 76 
Panc 11159 Ductal adenocarcinoma  T3N1 (5/25) male 76 
Panc 11344 Ductal adenocarcinoma  T3N1 (1/23) male 69 
Panc 11495 Ductal adenocarcinoma  T3N1 (3/23) female 51 
Panc 12529 
Ductal adenocarcinoma 
(metastasis from liver) 
Stage IV female 53 
Panc 12531 
Ductal adenocarcinoma 
(metastasis from liver) 
Stage IV male 54 
Panc 12532 
Ductal adenocarcinoma 
(metastasis from liver) 
Stage IV female 72 
Panc 12534 
Ductal adenocarcinoma 
(metastasis from liver) 
G3, T3, N1, M1 female 71 
Panc 12535 
Ductal adenocarcinoma 
(metastasis from lung) 
Stage IV, T3, N0, M1 male 46 
Panc 12536 
Ductal adenocarcinoma 
(metastasis from liver) 
Stage IV male 69 
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2.1.5 Transfection conditions of expression plasmid 
To optimize the gene transfer conditions for the CPE-expressing plasmid vectors, 
different transfection reagents were used for the human pancreatic cell lines to ensure 
comparable conditions for all cancer cell lines. In order to determine the optimal 
transfection reagents, the transfection efficiencies (Table 2.3) of all cell lines were 
determined by transfecting the green fluorescent protein-expressing plasmid pEGFP-
N1 (Clontech, Mountain View, CA, USA). Number of green fluorescent protein-
expressing cells was quantified by FACScalibur (Becton Dickinson, San Jose, CA, 
USA) 24 h after transfection in three independent experiments and given as % green 
fluorescent protein-positive cells.  
 
 
Table 2.3 Best transfection conditions of the respective human cancer cell line 
Cell line Transfection reagent Transfection efficiency 
AsPC-1 FuGene X- treme     (Roche) 48.4 % 
BxPC-3 TransIT® - 2020       (Mirus) 10.2 % 
Capan-1 Metafectene Pro®      (Biontex) 50.6 % 
HUP- T3 Metafectene Pro®      (Biontex) 16.9 % 
MIA PaCa-2 Metafectene®          (Biontex) 65.2 % 
PA-TU-8902 TransIT® - 2020       (Mirus) 28.5 % 
SK-MEL-5 FuGene X- treme     (Roche) 48.6 % 
HT-29 Metafectene Pro®    (Biontex) 38.2  % 
 
 
2.1.6 Transfection of expression plasmids  
For transfection experiments the pCpG-mcsG2 empty vector control (VC) plasmid 
(Invivogen, San Diego, CA, USA) or the translation optimized pCpG-optCPE (optCPE) 
plasmid (Walther et al.) were used. Additionally a mutated optCPE construct (mutCPE) 
unable to bind Cldn3 / 4 was included for selectivity testing in vivo, which was kindly 
provided by PD Dr. Jörg Piontek (Charitè, Berlin). 
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Transient transfections were carried out in 6-well plates. For this 3 x 105 – 5 x 105 cells 
per well were plated and 24 h after seeding transfected with VC or optCPE plasmid 
DNA and respective transfection reagent listed in table 2.4, according to 
manufacturer’s specification. After 12 - 72 h of incubation cells were washed with PBS 
and further processed for RNA or protein isolation. 
 
 
Table 2.4 Summary of transfection procedure for respective cancer cell line 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.7 Transfection of siRNA 
Specific knockdown of claudin-3 (Cldn3) and claudin-4 (Cldn4) was performed with 
pools of three different pre-designed iBONi short interfering RNAs (siRNA) for each 
gene and the corresponding iBONi siRNA (see Table 2.5) Negative Control-N1, 
purchased from RIBOXX (Radebeul, Germany). For siRNA knockdown experiments, 
3 x 105 cells were seeded in 6-well plates and 24 h later transfected with 50 nM siRNA 
targeting the respective gene or with the corresponding negative control using 7 µl 
Lipofectamine® RNAiMAX Reagent (Thermo Fisher Scientific) was performed. 48 h or 
72 h post transfection cells were washed with PBS and further processed for RNA and 
protein isolation. 
  
Human cancer cell line Transfection reagent DNA 
AsPC-1   4.0 µL FuGene X-treme 2.0 µg 
BxPC-3   7.5 µL TransIT® - 2020 2.5 µg 
Capan-1   6.0 µL Metafectene Pro® 1.5 µg 
HUP-T3 12.0 µL Metafectene Pro® 1.0 µg 
MIA PaCa-2   6.0 µL Metafectene ® 1.5 µg 
PA-TU-8902   7.5 µL TransIT®- 2020 2.5 µg 
SK-MEL-5   4.0 µL FuGene X-treme 2.0 µg 
HT-29 12.0 µL Metafectene Pro® 1.0 µg 
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Table 2.5 Sequences of used siRNA for targeting human claudin-3 and -4 
 CLDN3 CLDN4 
si1 guide         (5 - 3´) UGCGACGUGAUGUUUGCCCCCC 
passenger (5 - 3´) GGGGGGCAACAUCAUCACGUCGCA 
guide         (5 - 3´) CGCACAGACAAGCCUUACCCCCC 
passenger (5 - 3´) GGGGGGUAAGGCUUGUCUGUGCG 
si2 guide         (5 - 3´) UGAGGUUUCACAGUCCAUGCCCCC 
passenger (5 - 3´) GGGGGCAUGGACUGUGAAACCUCA 
guide         (5 - 3´) AUGGUCUUGGCCUUGGAGGCCC 
passenger (5 - 3´) GGGCCUUCCAAGGCCAAGACCAU 
si3 guide         (5 - 3´) AGUAGACGACCUUGGUCCCCC 
passenger (5 - 3´) GGGGGACCAAGGUCGUCUACU 
guide         (5 - 3´) ACAGAAACCACAAAGAAGGCCCCC 
passenger (5 - 3´) GGGGGCCUUCUUUGUGGUUUCUGU 
 
 
2.2 Gene and protein expression analyses 
2.2.1 RNA isolation and quantification 
RNA was isolated from cell lines and PDX tumor cryo samples using GeneMatrix 
Universal RNA Purification Kit EURx (Roboklon, Berlin, Germany), including DNA 
digestion step according to manufacturer’s instructions. All RNA samples were eluted 
with nuclease-free water, quantified using NanoDrop 1000 Spectrophotometer (Thermo 
Fisher Scientific) and stored at -80 °C. 
 
 
2.2.2 Reverse Transcription (RT) of RNA 
For reverse transcription 50 ng total RNA was used with random hexamers in a 
reaction mix containing 5 mM MgCl2, 1 × RT buffer, 250 μM pooled dNTPs, 1 U RNase 
inhibitor and 1 U M-MuLV reverse transcriptase (Thermo Fisher Scientific). The 
reaction was performed at 23 °C for 15 min, 42 °C for 45 min, 95 °C for 5 min, and 
subsequent cooling at 4 °C. The cDNA samples were stored at -20 °C or immediately 
1 : 5 diluted with nuclease-free water for qRT-PCR reaction (see Section 2.2.4). 
 
 
2.2.3 Quantitative real-time PCR (qRTPCR) 
The qRT-PCR was performed with the LightCycler 480 (Roche Life Science, Penzberg, 
Germany) using the GoTaq® qPCR Master Mix (Promega, WI, USA). All used primer 
sets were designed using the listed references shown in Table 2.6. Oligonucleotides 
were synthesized and HPLC purified by BioTeZ Berlin Buch GmbH.  
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Quantification of expression was achieved by BRYT Green®, a fluorescent DNA-
binding dye with minimal PCR inhibition for maximum PCR efficiency and greater 
fluorescence enhancement compared to SYBR Green I. For cDNA amplification, 
specific primer sets, listed in table 2.6, in a total volume of 10 μl in 96-well plates were 
used with the following PCR conditions: 95 °C for 2 min, followed by 45 cycles of 95 °C 
for 7 s, 60 °C for 10 s, and 72 °C for 5 s. In addition, the melting curve was measured 
with a continuous temperature increase from 65 °C to 95 °C with a rate of 0.1 °C/s to 
check for unspecific amplification products or primer dimers. The respective controls 
and amount of housekeeping gene (RNA polymerase II; RPII or Glucose-6-phosphate-
dehydrogenase; G6PDH) were used for calculation of relative gene expression. 
 
 
Table 2.6 Primers used for quantitative real-time PCR 
Gene Primer Sequence 5´- 3´ 
Claudin-3 CLDN3 fwd CTG CTC TGC TGC TCG TGT CC 
 CLDN3 rev TTA GAC GTA GTC CTT GCG GTC GTA 
Claudin-4 CLDN4 fwd CCT CTC CCA GAC CCA TAT AA 
 CLDN4 rev CAC CGT GAG TCA GGA GAT AA 
RPII  RPII fwd 
RPII rev 
GCA CCA CGT CCA ATG ACA T  
GTG CGG CTG CTT CCA TAA  
G6PDH G6PDH fwd 
G6PDH rev 
GAA GAT GGT GAT GGG ATT TC 
GAA GGT GAA GGT CGG AGT 
 
 
2.2.4 Protein isolation and quantification  
For protein extraction cells, tissue cryosections or enriched purified exosomes were 
washed with PBS and lysed with RIPA buffer (50 mM Tris-HCl,pH 7.5; 150 mM NaCl, 
1 % Nonidet P-40, supplemented with complete protease inhibitor tablets; Roche Life 
Science) for 1 h on ice and centrifuged at 14,000 rpm for 30 min at 4 °C.  
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For protein quantification Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific) 
with the respective standard curve based on serial dilutions of bovine serum albumin 
(BSA) solution was used. The samples and standards were diluted 1:10 with PBS for 
absorption measurements at 560 nm using the Infinite M200 Pro Reader (TECAN) and 
protein concentrations were calculated with the Magellan 7 Software. For isolation of 
cellular protein fraction (whole lysate, membrane, cytoplasmic and nuclear), the Cell 
Fractionation Kit (Cell Signaling, MA, USA) was used according to manufacturer’s 
instructions and further processed as mentioned above.  
 
 
2.2.5 Western blot analysis  
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunoblotting was used to analyze protein expression. Protein extracts were diluted 
with PBS to obtain 15 μg of total protein in 1 x NuPAGE® loading buffer (Thermo Fisher 
Scientific) and 10 % DTT (Roth, Karlsruhe, Germany). The protein samples were 
denatured at 95 °C for 10 min. The pre-stained Spectra™ Multicolor Broad Range 
Protein Ladder (Thermo Fsiher Scientific) and protein samples were loaded onto pre-
casted PROTEAN® TGXTM 10 % or 4 - 20 % Bis-Tris Gels (BioRad, CA, USA). Protein 
electrophoresis was done in 1 x Tris/Glycine/SDS Running Buffer (BioRad) at 120 V for 
90 min within the Mini-PROTEAN® Cell System (BioRad). Trans-Blot® Turbo™ RTA 
Midi PVDF Transfer Kit (Bio-Rad) was used for semi-dry electrotransfer blotting of 
proteins onto 0.2 μM PVDF membranes at 2.5 V and 2 A for 10 min in the Trans-Blot® 
Turbo™ Transfer System (Bio-Rad). The membrane was washed with TBST (50 mM 
Tris-HCl, 150 mM NaCl, 0.05 % Tween 20, pH 7.5) and blocked for 1 h at room 
temperature with blocking buffer (5 % milk powder in TBST). Respective membrane 
parts were incubated with primary antibody overnight at 4 °C (see Table 2.7). 
Afterwards membranes were washed with TBST followed by incubation with HRP-
conjugated secondary antibody for 1 h at room temperature (see Table 2.7). After 
washing several times with TBST, proteins were visualized by incubation with Western 
Bright ECL horseradish peroxidase (HRP) substrate (Advansta) and subsequent 
exposure to CL-Xposure Films (Pierce). Immunoblotting for β-actin served as protein 
loading control. 
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Table 2.7 Antibodies used for Western blot analysis, their dilution and origin 
Target Dilution Antibody 
Primary antibodies   
   β – actin 1:25,000 Mouse monoclonal IgG (Pierce) 
   CD63 1:1000 Rabbit polyclonal IgG (System Bioscience, CA, USA) 
   Claudin-3 1:3000 Rabbit polyclonal IgG (Acris, Herford, Germany) 
   Claudin-4 1:3000 Rabbit polyclonal IgG (Acris) 
   CPE 1:4000 Rabbit polyclonal IgG (BioRad) 
   HSP70 1:1000 Rabbit polyclonal IgG (System Bioscience) 
   Lamin B1 1:4000 Rabbit monoclonal IgG (CST, Danvers, MA, USA) 
   β – tubulin 1:2000 Mouse monoclonal IgM (BD Bio Sciences) 
Secondary antibodies   
   Anti-rabbit IgG-HRP 1:10,000 HRP- conjugated antibody (Promega) 
   Anti-mouse IgG-HRP 1:25,000 HRP- conjugated antibody (Pierce) 
   Anti-mouse IgM-HRP 1:10,000 HRP-conjugated antibody (Sigma, WI, USA) 
 
 
2.2.6 Immunocytoochemistry of human pancreatic cancer cells 
For immunohistochemistry 2 × 105 cells were seeded into 4-well chamber slide and 
after 24 h washed with PBS, fixed 15 min in 4 % paraformaldehyde (PFA, Pierce 
Thermo Fisher Scientific) in PBS, permeabilized 10 min with 0.5 % Triton-X in PBS and 
blocked 1 h with 1 % IgG-free albumin (Sigma Aldrich, Taufkirchen, Germany) and 
0.05 % Tween 20 in PBS at room temperature (RT). As primary antibody, rabbit anti-
human Cldn3 or rabbit anti-human Cldn4 antibody (1:100, Acris) was added for 2 h at 
RT. Cells were washed with TBST and incubated with HRP-conjugated goat anti-rabbit 
IgG antibody (1:500, Promega) for 1 h at RT. Then, cells were washed in PBS and 
incubated 1-5 min with diamino-benzidine (DAB, DAKO, Hamburg, Germany) at RT 
and washed in ddH2O for 5 min. Cells were counterstained for 30  - 60 s with hemalum 
(Roth), rinsed in tap water, covered with glycergel (DAKO) and evaluated in a light 
microscope (Zeiss, Jena, Germany). 
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2.2.7 Immunocytochemistry of PDX tumor tissue 
To detect Cldn3 / 4 expression or expressed CPE after gene transfer of the PDX tumor 
samples via immunohistochemistry, 3-5 μm paraffin embedded tumor sections were 
deparaffinized, fixed with 4 % PFA for 15 min at RT, quenched 20 min with 0.1 M 
glycin, incubated 10 min with 3 % H2O2, washed with PBS, permeabilized by 0.2 % 
Triton X-100 in PBS for 10 min, RT and blocked 1 h with 1 % IgG-free albumin and 
0.05 % Tween 20 in PBS at RT. Following steps of staining are according to 
aforementioned procedure (see Paragraph 2.2.7).  
 
 
Table 2.8 Antibodies used for immunofluorescence, their dilution and origin 
Target Dilution Antibody 
Primary antibodies   
   Claudin-3 1:100 rabbit polyclonal IgG (Abcam, Cambridge, UK) 
   Claudin-4     1:50 goat polyclonal IgG (Santa Cruz, TX, USA) 
   CPE 1:100 rabbit polyclonal IgG (BioRad) 
Secondary antibodies   
   Goat anti-rabbit Alexa 488 1:200 Alexa Fluor® 488 dye-conjugated antibody  
(Thermo Fisher) 
   Goat anti-rabbit Alexa 555 1:200 Alexa Fluor® 488 dye-conjugated antibody  
(Thermo Fisher) 
   Goat anti-rabbit Alexa 647 1:200 Alexa Fluor®647 dye-conjugated antibody  
(Thermo Fisher) 
   Donkey anti-goat Alexa 555 1:200 Alexa Fluor® 555-conjugated antibody  
(Thermo Fisher) 
   Donkey anti-goat 647 1:200 Alexa Fluor®647-conjugated antibody  
(Thermo Fisher) 
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2.2.8 Immunofluorescence staining for distribution and co-localization study 
To evaluate distribution of respective Cldns and co-localization of expressed CPE, 
immunofluorescence analyses were done. For this 2 × 105 cells were seeded onto 
cover slips (Steiner GmbH, Siegen Eiserfeld, Germany). After 24 h cells were 
transfected with VC or optCPE plasmid DNA as described in paragraph 2.1.6. At 
different time points cells were washed with PBS, fixed 15 min in 4 % PFA in PBS, 
quenched 20 min with 0.1 M glycin in PBS and blocked 1 h with 1 % serum-free 
albumin and 0.05 % Tween 20 in PBS at RT. The respective primary antibody, listed in 
table 2.8, was added for 2 h at RT. Cells were washed with TBST and incubated with 
secondary antibody (see Table 2.8) for 1 h at RT. Nuclei were stained with DAPI 
(Sigma-Aldrich) and counterstaining of cytoplasm was done by using Alexa 555-
phalloidin (Thermo Fisher Scientific). Cells were evaluated in a confocal fluorescence 
microscope (Zeiss).  
 
 
2.2.9 CPE specific ELISA 
To quantify liberated CPE in supernatants of transfected cells, the Ridascreen 
Clostridium perfringens Enterotoxin ELISA (R-Biopharm, Darmstadt, Germany) was 
performed. For this, 4 x 105 cells were seeded into 6-well plates and transfected with 
VC or optCPE plasmid DNA. Supernatants were used for the detection as 
recommended by the manufacturer.  
 
For analyzing potential shedding of CPE into the blood of animals, which received gene 
transfer, blood was collected and CPE was quantified in serum samples. For all 
ELISAs recombinant CPE was used to generate the standard curve at serial dilutions 
of 0.4 - 25 ng ml-1 CPE. Measurements were done in duplicates at 450 nm in the plate-
reader (Tecan). Values were calculated according to the standard curve and expressed 
as ng ml-1 CPE. 
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2.3 Analyses of CPE mediated cytotoxicity and cell death  
2.3.1 MTT cytotoxicity assay 
MTT assay was performed to test cytotoxicity of recombinant CPE or after optCPE 
transfection and biological activity of released CPE from transfected cells. For 
sensitivity testing of the cell lines towards recombinant CPE 6 x 103 – 4 x 104 cells were 
seeded into 96-well plates and 24 h later recombinant toxin was added at different 
concentrations (0, 50, 100, 150 ng ml-1) and incubated for additional 24  - 72 h. In 
transfection experiments with CPE-expressing plasmids, 1 × 104 transfected cells were 
seeded in 96-well plates and MTT assay was carried out after respective incubation 
times (24 - 72 h). To determine the biological activity of liberated CPE in supernatants 
of transfected cells, supernatants were collected 24 - 72 h after transfection. In parallel, 
6 x 103 non-transfected cells were seeded into 96-well plates and 24 h after seeding 
100 μl of respective supernatant was added and incubated for additional 72 h. For all 
cytotoxicity assays MTT (3-(4,5-dimethylthiazyol-2yl)-2,5-diphenyltetrazolium bromide 
(5 mg ml-1, Sigma) was added after 24  - 72 h of CPE incubation and absorbance was 
measured in triplicates at 560 nm in a plate-reader. The evaluation of cytotoxicity was 
performed relative to the respective control. The measured absorbance values of the 
treated samples were related to control value and expressed as a percentage of vital 
cells. 
 
 
2.3.2 Apoptosis assay: Annexin-V / Propidium Iodide (PI) staining and FACS 
analyses 
To elucidate CPE mediated mechanisms of cell death, Annexin-V / PI stainig (Annexin 
V-FITC Apoptosis Detection Kit, Abcam) was performed and analyzed by FACS. 
Staining with Annexin-V and PI allows identification of different types of cell death, such 
as early apoptosis, late apoptosis and necrosis. Annexin-V has a strong calcium-
dependent affinity for phoshatidylserine (PS) and therefore can be used for early 
apoptosis detection. PI is a DNA-binding dye that can only enter cells when cell 
membranes are ruptured, which is a characteristic of late apoptotic and necrotic cells, 
respectively. For the assay, 1 x 105  cells were seeded into 12-well plate and 24 h later 
transfected with either VC or optCPE expressing vector. At different time points 
(6 - 72 h after transfection) cell culture supernatants were removed, cells were washed 
and centrifuged, followed by incubation with Annexin-V-FITC and PI-PE according to 
manufacturer’s specification.  
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For differentiation and quantification of vital, early-apoptotic and necrotic cells, FACS 
analysis was performed in VC and optCPE transfected cells. The Annexin-V and PI 
positive cells were quantified using the FACScalibur (Becton Dickinson) and data was 
represented as percentage positive cells.  
 
 
2.3.3 Caspase assay 
Caspase - Glo®-3/7, -8 and -9 assays (Promega) were used to investigate the specific 
Caspase-dependent cell death mechanism of CPE-treated tumor cells. For this, 1 x 105 
cells were seeded into 12-well plate and 24 h later transfected with either VC or 
optCPE plasmid DNA. At different time points (6 - 72 h after transfection) supernatants 
were removed, cells were washed and incubated with Caspase - Glo® reagent as 
recommended by manufacturer. After incubation luminescence was measured at 
450 nm using a plate-reader luminometer (Tecan). Caspase activity was expressed as 
measured luminescence n-fold to VC. 
 
 
2.3.4 Calpain-1/2 assay 
Calpains belong to the family of calcium-dependent, non-lysosomal cysteine proteases 
and have been implicated in apoptotic cell death and appear to be an essential 
component of necrosis [254]. Therefore, Calpain-1/2 activity was analyzed in optCPE-
treated cells to further elucidate the CPE-mediated cell death mechanism. For this, 
1 x 105 cells were seeded into 12-well plate and after 24 h transfected with either VC or 
optCPE plasmid DNA. At different time points (6 - 72 h after transfection) cell culture 
supernatants were removed, cells were washed and Calpain-Glo® Protease Assay 
(Promega) was applied as specified by manufacturer. The incubation with pro-
luminescent substrate and reagent results in calpain-1/2 cleavage of substrate and 
luminescence signal, which was measured at 450 nm using a plate-reader luminometer 
(Tecan). The measured Calpain-Glo Assay signal was proportional to calpain-1/2 
activity. Data was expressed as activated calpain-1/2 relative to µg protein. 
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2.3.5 Lactate dehydrogenase (LDH) release assay 
The colorimetric Thermo ScientificTM PierceTM LDH Cytotoxicity Assay Kit was used to 
determine released LDH of optCPE-transfected cells to the medium. This cytoplasmic 
enzyme is only released if plasma membrane is damaged, indicating cytotoxicity and 
necrosis. For this assay, 1 x 105 cells were seeded into 12-well plate and after 24 h 
transfected with either co. or optCPE expressing vector. At different time points 
(6 - 72 h after transfection) cell culture supernatants were collected and incubated with 
LDH reaction mixture according to manufacturer’s recommendation. After incubation 
stop solution was added and the colorimetric LDH absorbance was measured at 
490 nm and 680 nm using plate-reader (Tecan). LDH activity was determined by 
subtracting 680 nm absorbance from 490 nm absorbance values. Data was expressed 
as released LDH n-fold to VC. 
 
 
2.3.6 IncuCyte ® real time live cell analysis 
To verify and demonstrate CPE-mediated cell death in real time, the IncuCyte® Live 
cell Analysis System from Essen BioScience was used, which captured and analyzed 
images of optCPE treated cells over time. Here, different approaches were done to 
analyze optCPE mediated cytotoxicity using IncuCyte®CytoRed reagent, detection of 
Ca2+ influx using calcium indicator Fluo-4 (Thermo Fisher Scientific), Caspase-3/7 
activity using IncuCyte® Caspase-3/7 reagent (Essen BioScience) or exposed PS in 
apoptotic/necrotic cells using IncuCyte® Annexin-V reagent (Essen BioScience). For 
analyses, 1 x 105 cells were seeded into 12-well plate and 24 h later transfected with 
either VC or optCPE plasmid DNA, respectively. 6 h post-transfection, cells were 
treated with specific reagent according to manufacturer´s recommendation and plates 
were transferred into the IncuCyte®. Specific protocols were set using IncuCyte® 
software and pictures were automatically taken at defined time points. Analysis of 
pictures was also performed with IncuCyte® software. 
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2.3.7 Human apoptosis array 
The Proteome Profiler TM Array Human Apoptosis Array kit (R&D Systems, Minneapolis, 
MN, USA) was used to analyze the expression profiles of apoptosis-related proteins to 
understand their role in CPE-mediated cell death. This array is a rapid and sensitive 
tool to simultaneously detect the relative expression levels of 35 apoptosis-related 
proteins, which have been spotted in duplicate on nitrocellulose membranes. 
Therefore, 3 x 106 cells were seeded into 10 cm dishes and 24 h later transfected with 
VC or optCPE plasmid DNA. Transfected cells were frequently evaluated under the 
light microscope. As first signs of cell death were seen cells were rinsed with PBS and 
solubilized in lysis buffer, and incubated on ice for 30 min. Afterwards cells were 
centrifuged at 14,000 x g for 5 min and sample protein concentrations were quantified 
using Pierce® BCA Protein Assay Kit. Cell lysates were diluted and incubated 
overnight with human apoptosis array as recommended by manufacturer. To remove 
unbound proteins array was washed and then incubated with cocktail of biotinylated 
detection antibodies, followed by Streptavidin-HRP incubation. After another washing 
step, chemiluminescent detection reagent was applied, which visualized each captured 
spot corresponding to the amount of bound protein.  
 
 
2.4 Non-viral in vivo gene transfer and bioluminescence imaging 
2.4.1 Pancreatic cancer cell line derived xenograft (CDX) models 
In cooperation with EPO GmbH, subcutaneous (s.c.) and orthotopic pancreatic cancer 
models were established by using 6-week-old NMRI: nu/nu (Janvier labs) mice or 
NOD/Shi-scid/IL-2Rγnull (NOG) mice. In all CDX models (see Table 2.1), stable eGFP-
Luc expressing pancreatic cancer cell lines (see Paragraph 2.1.2, Capan-1/eGFP-Luc, 
HUP-T3/eGFP-Luc, MIA PaCa-2/eGFP-Luc, PA-TU-8902/ eGFP-Luc and PDX-
derived-cells/eGFP-Luc) were used. For s.c. tumors, 1 x 107 stably eGFP-Luc 
expressing cells were injected into left flank of each animal. When tumors were 
palpable, body weight, tumor volume and bioluminescence was measured twice a 
week.  
 
For orthotopic transplantation, mice were anesthetized with 35 mg kg-1 Etomidate® and 
skin and peritoneum were laterally incised to exteriorize the pancreas. 5 x 105 eGFP-
Luc-expressing cells were injected directly into pancreas with a 27-gauge needle. 
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The pancreas was carefully placed back, the peritoneum was closed with Surgicryl® 
absorbable suture and skin was clamped twice. After approximately two weeks 
bioluminescence of each animal was measured to monitor tumor growth.  
 
 
2.4.2 Patient derived pancreatic cancer xenograft (PDX) models 
In addition to CDX also PDX models were established (see Table 2.2) in cooperation 
with EPO GmbH. Similar to aforementioned procedure, pieces of app. 3 × 3 mm in size 
of pancreatic cancer PDX tissue were transplanted s.c. into left flank of mice. 
Established s.c. tumors were monitored twice a week by measuring tumor volume and 
body weight.  
 
 
2.4.3 in vivo bioluminescence imaging 
For non-invasive bioluminescence imaging mice were anesthetized twice a week with 
Isofluran (Baxter, San Juan, Puerto Rico) and received intraperitoneally 150 mg kg-1 
D-luciferin (Biosynth, Staad, Switzerland) dissolved in PBS. Imaging was performed 
with the NightOWL LB 981 system (Berthold Technologies, Bad Wildbad, Germany) 
with exposure times of 1 s and 60 s. ImageJ software version 1.50i was used for 
quantification and color-coding of the signal intensity. Overlay pictures were created 
with Adobe Photoshop CS5.1 software  
 
 
2.4.4  Non-viral in vivo gene transfer  
When s.c. tumors reached a mean volume of 0.3 cm3, animals were randomized into 
respective treatment groups: 1) PBS as internal control, 2) empty vector control (VC) 
and 3) optCPE. In the first in vivo experiment optCPE selectivity was tested. Therefore 
an additional treatment group was included as mutCPE. Intratumoral non-viral gene 
transfer was performed in anesthetized animals by intratumoral jet-injection [255]. For 
this, 50 μg plasmid DNA of respective vector construct was applied once by 5 injections 
(jet injector, EMS Medical Systems SA, Nyon, Switzerland) of 10 μl injection volume 
(1 μg μl-1DNA in PBS). Tumor volumes (TV) were measured at indicated time points 
and calculated using the formula:  
 
TV = (width2 x length)/2.  
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Animals with eGFP-Luc expressing tumors were also monitored via bioluminescence 
imaging twice a week to detect tumor viability. As toxicity parameters body weight, 
clinical signs and behavior were recorded for all mice twice a week. Furthermore, 
plasma samples were taken from respective animals at different time points to monitor 
potential CPE shedding into blood stream. Animals were sacrificed and tumors were 
harvested, shock frozen with liquid nitrogen and stored at -80 °C for further analyses. 
Moreover, gene transfer was performed in orthotopically grown pancreas tumors. 
When tumors reached sufficiently strong bioluminescence signals, animals were 
randomized into 2 groups (VC and optCPE plasmid DNA). Animals were anesthetized 
with Isofluran and skin and peritoneum were laterally incised to exteriorize the 
pancreas and the carcinoma. 50 µg of respective plasmid DNA was directly injected 
into tumor using a 27-gauge needle. After intratumoral needle injection, pancreas was 
placed back, the peritoneum was closed with Surgicryl® absorbable suture and skin 
was clamped twice. Two to three days after gene transfer bioluminescence was 
measured to detect optCPE-mediated antitumoral effect.  
 
 
2.4.5 Analysis of pancreatic cancer tissues after in vivo gene transfer 
To determine optCPE mediated antitumoral effect, shock frozen tumor tissues were 
fixed with Tissue-Tek Medium (Satura Tek) and dissected with the cryostat into cyro-
sections each of 5 µm thickness, which were transferred onto cover slides. These 
samples were differently processed following for further analysis as described below. 
 
 
2.4.5.1 Hematoxylin & Eosin (HE) staining 
To gain overview of histopathological features and structural changes in treated 
pancreas tumors, tissue sections were stained with HE. Therefore, tissues were fixed 
with isopropanol for 30 s and incubated with hemalum (Roth) for 2 min, resulting in blue 
stained nuclei, followed by washing step with running tap water for 5 min and 
counterstaining with eosin (Roth) for 1 min, leading to pink stained cytoplasm. 
Afterwards slides were dehydrated through 95 % alcohol incubations (twice, 5 min 
each), 2 soaks in xylene (Sigma-Aldrich) for 5 min each and then covered with 
mounting medium. Tissue was evaluated in light microscope (Zeiss).  
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2.4.5.2 Ki67 staining 
Ki67 is a nuclear protein that is present at low levels in quiescent cells and at high 
levels in proliferating cells. Thus, Ki67 activity is a specific marker for cell proliferation 
and viability. Here, it was used to analyze whether optCPE gene transfer also affected 
proliferation. Therefore, tissue sections were fixed with 4 % PFA for 10 min at RT and 
washed with PBS. The endogenous peroxidase was blocked with 3 % H2O2 for 5 min at 
RT, followed by another washing step. Sections were blocked with 20 % goat serum for 
45 min and incubated with the primary antibody mouse anti-Ki67 / MIB1 (hu) [Klon 
K67P-unkonj.] (Dianova, diluted 1:100 in AB-Diluent von Dako) in humidified chamber 
for 60 min at RT. After sections were washed, secondary antibody HRP-conjungated 
anti-mouse IgG (Jackson, diluted 1:400 in PBS) was added for 30 min at RT in 
humidified chamber and washed again in PBS. Then sections were incubated with 
DAB-chromogen substrate (DAKO) for 1 - 5 min, until appearance of brown staining, 
washed with ddH2O and counterstained with hemalum, washed with running tap water 
for 5 min and covered with mounting medium (DAKO). Ki67 staining was captured with 
light microscope and blue and brown stained spots were counted with ImageJ 
software, the percentage of Ki67 was calculated and expressed as mean percentage of 
Ki67 positive cells.  
 
 
2.4.5.3 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)  
assay 
Appearance of DNA fragments is a characteristic hallmark of apoptosis and can be 
stained and visualized by using TumorTACS™ In Situ Apoptosis Detection Kit 
(Trevigen). During apoptosis chromosomal DNA is cleaved by endonucleases to 
generate DNA fragments with free 3´-hydroxyl residues. In situ, the 3' ends of cleaved 
DNA fragments provide a substrate for terminal deoxynucleotidyl transferase (TdT) that 
adds nucleotides at the site of DNA breaks. The incorporation of biotinylated 
nucleotides allows chromosomal DNA fragmentation to be visualized by binding 
streptavidin-horseradish peroxidase followed by reaction with DAB to generate a dark 
brown precipitate and counterstaining with methyl green. Assay was performed as 
recommended by manufacturer. TUNEL staining was captured with light microscope 
and green and brown stained events were counted with ImageJ software, the 
percentage of TUNEL was calculated and expressed as mean counted value of TUNEL 
positive cells. 
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2.5 Statistical analyses 
All calculations and statistical analyses were performed using GraphPad PRISM 
version 7.0. The comparison of two different groups was done by Student’s t-test or 
nonparametric Mann-Whitney U-test. Comparison of three or more different treated 
groups was performed by One way or Two way analysis of variance (ANOVA) and 
Turkey´s post multiple comparison test. All significance tests were two sided, and P-
values less than 0.05 were defined as statistically significant. 
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3. RESULTS 
Our group has introduced the translation-optimized optCPE expressing vector as gene 
therapeutic tool to potentially combat cancer. The novel suicide gene therapeutic 
approach demonstrated that CPE gene transfer could be employed for targeted gene 
therapy of claudin-3 and -4 (Cldn3 / 4) overexpressing tumors, as rapid and efficient 
tumor cell killing was achieved in vitro and in vivo. In the present study, this potent 
approach was applied to pancreatic cancer to demonstrate an alternative and novel 
treatment for patients suffering with this dismal disease. In particular, the specific 
mechanisms of action of the CPE mediated cytotoxicity were investigated in vitro and 
in vivo to improve the oncolytic effect (oncoleaking) and define a gene therapeutic 
strategy, which could be combined with conventional therapies, such as chemotherapy.  
 
3.1 Human pancreatic cancer cells endogenously overexpress the CPE 
receptors Cldn3 / 4 and show sensitivity towards recombinant CPE 
Prerequisite for the study was the determination of the endogenous expression of the 
CPE receptors Cldn3 / 4 in a panel of human pancreatic cancer (PC) cell lines, as the 
CPE mediated cytotoxicity is linked to their presence. Therefore, receptor availability 
was analyzed at mRNA and protein level, which was further confirmed by 
immunohistochemistry (IHC). Moreover it was of importance to determine the cellular 
distribution and assembly of these Cldns to analyze the accessibility and binding of 
CPE. After expression analyses, sensitivity towards recombinant CPE (recCPE) of 
chosen cancer cell lines was tested. The overview of the analyzed cell line panel is 
provided in the Material and Methods section (see Paragraph 2.1.1, Table 2.1). 
 
 
3.1.1 Diverse Cldn3 / 4 expression in human PC cell lines 
To evaluate the mRNA expression of both specific CPE receptors, quantitative real-
time PCR (qRT-PCR) was performed (Figure 3.1a). The human colorectal cancer cell 
line HT-29 was included as positive control into this characterization study, as it has 
been described as high Cldn3 and Cldn4 expressing cell line [256]. This was confirmed 
as these cells revealed the highest Cldn3 expression among all tested cell lines and 
further showed high expression levels of Cldn4. The human PC cell lines Capan-1, 
PA -TU-8902 and AsPc-1 demonstrated high Cldn3 and Cldn4 mRNA levels, whereas 
moderate levels of Cldn3 and Cldn4 were detected in MIA PaCa-2 and HUP-T3 cells. 
BxPC-3 cells revealed low Cldn3 expression and moderate Cldn4 expression 
compared to HT-29 cells. However, in our internal negative control, the human 
melanoma cell line SK-MEL-5, no Cldn3 expression or Cldn4 expression was detected.  
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Figure 3.1: Expression and distribution analysis of claudin-3 (Cldn3) and claudin-4 (Cldn4) in human pancreatic 
cancer cell line panel. (a) Quantitative real time PCR (qRT-PCR) and Western blot analyses for Cldn3 (left) and Cldn4 
(right), demonstrating high Cldn3 / 4 expression in Capan-1, PA-TU-8902 and AsPc-1. The human colorectal cancer cell 
line HT-29 was defined as positive control based on a previous study [256]. HUP-T3 cells showed moderate expression 
of both Cldns. MIA PaCa-2 and BxPC-3 were characterized by moderate Cldn4 and low Cldn3 expression. The human 
melanoma cell line SK-MEL-5 was defined as negative control based on previous studies [252, 256] and did not show 
any Cldn3 / 4 expression. Data are represented as means  +  S.D. (n = 3) (b) Representative immunohisto-chemistry of 
Cldn3 (left) and Cldn4 (right) in respective pancreatic cancer cell lines, demonstrating different distribution of Cldn3 / 4 
(brown). (c) Western blot analysis of cell fractions from selected pancreatic cancer cells using Cldn3 / 4, and Lamin B1, 
showing whole cell lysates  (L), cytoplasmic  (C), membrane  (M) and nuclear  (N) localization, whereas Lamin B1 served 
as nuclear fraction control. (d) Representative immunofluorescence images of respective pancreatic cancer cells, 
confirming diverse Cldn3 (yellow)  and Cldn 4 (red) expression in various cell compartments. Scale bar is 25  µm. DAPI 
and actin staining was used to define nuclear and cytoplasmatic fraction, respectively.  
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The Western blot analysis confirmed the qRT-PCR expression pattern, as strong Cldn3 
and Cldn4 protein levels were detected in Capan-1, PA-TU-8902 and AsPc-1. Also the 
protein expression of BxPC-3 and HUP-T3 correlated with their low and moderate 
mRNA expression, respectively. Interestingly, the pancreatic cancer cell line 
MIA PaCa-2 demonstrated moderate Cldn4 expression as seen at mRNA level, but did 
not confirm the moderate Cldn3 mRNA expression as no protein was detected.  
 
 
3.1.2 Different distribution and assembly of Cldn3 / 4 in human PC cell lines 
Next, immunohistochemistry (IHC) was performed to analyze the distribution of the 
tight-junction proteins Cldn3 and Cldn4 in the pancreatic cancer cell line panel 
(Figure 3.1 b). The detected expression pattern of Cldn3 / 4 did not follow a certain 
pattern. In detail, Capan-1 showed strong membranous Cldn3 expression, particularly 
within cell-cell contact region, whereas Cldn4 was highly expressed in the cytoplasm 
and nuclei. PA-TU-8902 cells also showed strong Cldn3 / 4 expression in the 
cytoplasm, which in some cells accumulated in vesicle like pattern. Similar 
accumulation of the Cldns was seen in BxPC-3 and HUP-T3 cells, respectively. 
Further, in HUP-T3 strong Cldn4 expression was detected in the nuclei whereas 
MIA  PaCa-2 showed low Cldn3 expression in the cytoplasm and moderate Cldn4 
expression in the cytoplasm and on the cell membrane. Even though strong Cldn3 and 
Cldn4 expression was shown on protein and mRNA level, IHC of AsPc-1 revealed 
moderate Cldn3 expression in the cytoplasm and moderate Cldn4 expression on the 
plasma membrane. 
 
To gain more insight into distribution and assembly of Cldn3 and Cldn4, cell fractioning 
Western blot analysis (Figure 3.1 c) and immunofluorescence (IF) experiments were 
performed (Figure 3.1 d). Here, the Capan-1 and HUP-T3 cell line demonstrated strong 
Cldn4 expression in all cell fractions / compartments (whole lysate, cytoplasm, 
membrane and nuclear), which was also confirmed by IF. By contrast, Capan-1 cells 
revealed low Cldn3 expression in cytoplasm and membrane fraction but strong 
expression within the nuclei. Low Clnd3 expression was also detected in the cytoplasm 
of HUP-T3 cells, whereas moderate Cldn3 expression was detected in membrane and 
nuclei fraction. The Cldn distribution patterns of Capan-1 and HUP-T3 particularly for 
Cldn4 could facilitate strong CPE binding, as toxin receptors are accessible. The 
Cldn3 / 4 distribution of MIA PaCa-2 differed from aforementioned cell lines, as Cldn3 
was only expressed in the cytoplasm and Cldn4 only in membranous fraction, which 
again provides receptor accessibility of the toxin.  
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Also Pa-TU-8902 cells showed a different distribution as Cldn3 was moderately 
expressed in the cytoplasm and very low expressed on the membrane, but Cldn4 was 
strongly expressed on the membrane and in the nuclei. This data could conduce to a 
successful gene therapeutic approach, as accessibility and availability of CPE are 
fundamental for its efficacy.  
 
 
3.1.3 Selective dose dependent cytotoxicity of recCPE in Cldn3 / 4 expressing 
human pancreatic cancer cells  
In the next step sensitivity of Cldn3 / 4 expressing pancreatic cancer cell lines towards 
recombinant CPE (recCPE) protein was addressed. Therefore, different recCPE 
concentrations (0 -  250 ng ml-1) were applied to respective cells and mediated 
cytotoxicity was measured 72 h after treatment, using MTT cytotoxicity assay 
(Figure 3.2a). The high Cldn3 / 4 expressing Capan-1 and AsPC-1 cells revealed a 
significant (p = 0.0001) dose dependent recCPE mediated cytotoxicity, which was 
already seen at low concentration of recCPE (50 ng ml-1) but most pronouned at a 
concentration of 250 ng ml-1 recCPE. In both cell lines viability was significantly 
reduced to 11 % or 12 %, respectively compared to untreated control. HUP-T3 cells, 
expressing Cldn3 / 4 in a moderate manner, also demonstrated a significant dose 
dependent sensitivity towards recCPE treatment (p = 0.0001), as only 7.5 % of cells 
remained vital after treatment at highest concentration, which is comparable with 
sensitivity of positive control cell line HT-29 (4  % viability). In both cell lines, HUP T3 
and HT-29, the toxin reached maximum cytotoxic effect at concentration of 100 ng ml-1 
recCPE (viability  <  10 %), reflecting its high tumor cell killing capacity. Despite high 
Cldn3 / 4 expression level, PA-TU-8902 cells showed comparatively low sensitivity 
towards recCPE, as highest concentration led to 60 % viability (p = 0.0019). By 
contrast, even in Cldn3 / 4 low expressing BxPC-3 and MIA PaCa-2 cells higher 
cytotoxicity was measured. Here, cell viability was significantly reduced to 40  % or  
32 % compared to control, respectively (p  = 0.0001). The IHC and also IF (Figure 3.1b, 
d) revealed strong Cldn4 expression in the nuclei of PA-TU-8902 cells, which is not 
accessible by recCPE, whereas Cldn4 was mainly expressed in the membrane of 
MIA PaCa-2 cells, proving high accessibility for the toxin that consequently results in 
cell death. By contrast negative cell line SK-MEL-5 was insensitive towards the toxin, 
supporting that CPE cytotoxicity is restricted to expressing cells. These findings point 
to the fact, that expression level and more importantly distribution of Cldn3  / 4 are key 
determinants in cytotoxicity, which could explain why high Cldn3  /  4 expressing PA-
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TU-8902 cells are not as sensitive as low or moderate Cldn3  / 4 expressing MIA PaCa-
2 or BxPC-3 cells. 
 
Figure 3.2: Sensitivity and selectivity testing of human pancreatic cancer cell lines. (a) Cell sensitivity upon 
recombinant CPE protein (recCPE) was determined 72 h post treatment using MTT assay and compared to 
untreated/solvent treated controls. Strong cytotoxic effects were seen in all pancreatic cancer cell lines and the positive 
control cell line HT-29, whereas negative control cell line SK-MEL-5 remained unaffected. MTT data are represented as 
means + S.D. (n = 6) and expressed as mean percentage of untreated control. Level of significance was calculated by 
One way-Anova and Turkey´s multiple comparison post-test. (b) Rescue experiment was performed to demonstrate 
CPE dependency on Cldn3 / 4 availability. Representative pancreatic cancer cell lines MIA PaCa-2 and PA-TU-8902 
were transfected with a pool of specific small interfering RNA (siRNA) or respective control (siCtrl), leading to efficient 
knockdown of Cldn3 / 4 on protein level, demonstrated in representative Western blot (upper panel). Silenced cells were 
ttreated with recCPE at indicated concentrations and MTT assay was performed 72 h later, revealing significantly less 
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responsiveness in both cell lines, MIA PaCa-2 (left) and PA-TU-8902 (right). Data are represented as means + S.D. 
(n = 2) and expressed as mean percentage of siCldn3  /  4 treated cells. Level of significance was calculated by 
One way-Anova and Turkey´s multiple comparison post-test, ns: not significant; *p < 0.05; ** p < 0.01; ***p < 0.001; 
****p = 0.0001. 
To better investigate the importance and dependency of Cldn3 / 4 availability for the 
targeted CPE mediated cytotoxicity RNAi strategies were used. Therefore, MIA  PaCa-
2 and PA-TU-8902 cells were transfected with a pool of siCldn3 (si2 and si3) and 
siCldn4 (si1 and si2) or siCtrl followed by CPE treatment. The knockdown of Cldn3 / 4 
led to efficient reduction of protein expression in both cell lines 48 h after transfection 
(Figure 3.2b, upper panel). Cldn3 / 4 silenced cells were treated with recCPE at 
different concentrations (0 - 250 ng ml-1) and cytotoxic effect was measured 72 h after 
treatment (Figure 3.2b, lower panel). Here, cell viability of MIA PaCa-2 treated with 
siCtrl was significantly reduced at all concentrations, compared to Cldn3 / 4 silenced 
cells. Unfortunately, untreated control showed already less viability or proliferation than 
silenced cells, which might be due to changed proliferation activity after gene silencing. 
Nevertheless, siCtrl treated MIA PaCa-2 only revealed 8.5  % viability after treatment 
with 250 ng ml-1 recCPE (p < 0.0001), whereas Cldn3  / 4 silenced cells remained 
unaffected. Also in silenced PA-TU-8902 cells, cytotoxic effect of recCPE was rescued 
as siCtrl treated cells showed sensitivity towards toxin at concentrations of 
150 - 250 ng ml-1, leading to only 22 - 15 % viability respectively, compared to 100  % in 
siCldn3 / 4 treated cells. These findings demonstrate the selectivity and dependency on 
receptor availability of recCPE mediated cytotoxicity, which is crucial for specific and 
effective tumor cell killing.  
 
 
3.2 Cldn3 / 4 expression analysis of pancreatic cancer patient derived xenograft 
(PDX) models  
To extend the approach beyond established cell line in vitro models and for the 
translational aspect, a heterogeneous panel of human pancreatic cancer patient 
derived xenograft (PDX) (summarized in Table 2.2; Material and Methods 
Section 2.1.3) was characterized regarding histopathological features and Cldn3 / 4 
expression. Of eighteen established pancreatic cancer PDX models, twelve originated 
from ductal adenocarcinoma and the remaining six resulted from liver metastases of 
pancreas carcinoma. Both, primary and xenograft tissue were analyzed by HE staining, 
whereupon pancreatic cancer PDX tissues were found to exhibit similar histologic 
phenotype, such as haphazard growth pattern, atypical glands, desmoplasia, or 
nuclear pleomorphism to primary tumor tissue of which they were derived of 
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(Figure 3.3 a, upper two panels). Therefore, pancreatic cancer PDX models represent a 
useful platform to test CPE mode of action, including CPE gene therapy in vivo. 
 
 
Figure 3.3: Heterogenous panel of pancreatic cancer patient derived xenograft (PDX) models. (a) Analysis of 
histopathological features of primary and xenograft tissue demonstrated similar histologic phenotype, in representative 
models (upper two rows). Representative images of Cldn3   /   4 expression (brown staining) in PDX tumors Panc9699, 
Panc9996, Panc10991, Panc11074 and Panc11495 correlating with protein expression. (b) Western blot analysis of all 
18 analyzed PDX models revealed expression of Cldn3 and/or Cldn4, whereof high expression of both was seen in 5 
models, only one tumor showed low expression of both receptors. β-actin was used as internal loading control.  
 
Western blot analysis of all eighteen analyzed PDX models showed expression of 
Cldn3 and/or Cldn4 (Figure 3.3 b), whereof high expression of both receptors was 
detected in five models: Panc9553, Panc9699, Panc9759, Panc9996 and Panc11159. 
This was further confirmed by immunohistochemistry, highlighting the specific 
membranous expression in pancreatic cancer cells within the PDX tissue (Figure 3.3 a, 
lower two panels). Only one tumor (Panc12534) revealed low expression of both, 
Cldn3 and Cldn4. Panc12529 and Panc12531 revealed low Cldn3 but high Cldn4 
expression. By contrast high Cldn3 and low Cldn4 expression was determined in 
Panc11495 and Panc12535, which was further validated by IHC staining. All other 
models showed high/moderate expression of one these claudins, suggesting that these 
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pancreatic cancer PDX models represent a useful platform for in vivo CPE gene 
therapeutic approaches. 
 
 
3.3 in vitro CPE expression and selective cytotoxicity after CPE gene transfer 
in PC cells 
In the last preceding paragraph a correlation of Clnd3  /  4 expression, their distribution 
and CPE mediated cytotoxicity in respective human cancer cell lines was shown. Cell 
lines with Cldn3  /  4 mainly expressed on cell membrane revealed higher sensitivity 
toward recCPE treatment than cells, whose claudins were expressed cytoplasmic or 
nuclear. By using gene transfer, expressed CPE will not only prolong cytotoxic effect, it 
might also be able to bind those claudins, which are “unavailable” for externally applied 
recCPE and therefore can drastically improve its cytotoxic efficiency.  
 
 
3.3.1 Analysis of optCPE expression after in vitro gene transfer   
Prerequisite for the gene therapeutic approach was an efficient expression of the 
translational optimized pCpG-optCPE expressing vector (optCPE), which was analyzed 
and evaluated by confocal microscopy (Figure 3.4a). The three representative cell lines 
– Capan-1, HUP-T3 and PA-TU-8902 – revealed high optCPE expression 12 h  after 
transfection. The CPE protein was differently distributed among transfected cells. In 
Capan-1 and HUP-T3 vesicle like accumulation of optCPE within the cytoplasm and on 
plasma membrane was seen, whereof HUP-T3 revealed higher optCPE presence in 
cell-cell contact region compared to Capan-1, which showed more CPE appearance on 
poles/buds of cells. On the other hand, PA-TU-8902 demonstrated strong membranous 
localization of optCPE also in cell-cell contact region and strong accumulation within 
cytoplasm. This distribution pattern of optCPE suggests a binding of optCPE and its 
receptors in for the externally added recombinant toxin “inaccessible” regions, which 
might result in more efficient cell killing compared to approaches using recCPE. 
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Figure 3.4: optCPE expression and selective cytotoxicity after CPE gene transfer in vitro. (a) Representative 
immunofluorescence images showing expressed optCPE (green) 12 h after transfection in the pancreatic cancer (PC) 
cell lines Capan-1, HUP-T3 and PA-TU-8902. Cells were counterstained with Phalloidin (red) and nuclei were visualized 
with DAPI (blue). These images revealed strong toxin expression, differently distributed among transfected cells 
e.g.vesicle like accumulation within cytoplasm, strong appearance on cell membrane in cell-cell contact regions and cell 
buds. (b) Cytotoxicity of optCPE and empty vector control (VC) gene transfer was analyzed using MTT assay 72 h after 
transfection. All transfected Cldn3 / 4 expressing cells showed significant toxicity of optCPE expressing vector with 
toxicity rates of 40-85 %, except for AsPc-1 cells, which could be due to inaccessible Cldn expression. Also the negative 
control cell line SK MEL-5 remained unaffected, highlighting optCPE selectivity. Data are represented as means +S.D. 
(n = 6) and are expressed as mean percentage of VC treated cells. Level of significance was calculated by One way-
Anova and Turkey´s multiple comparison post-test. (c) Rescue experiment was performed to demonstrate optCPE 
specificity. Representative pancreatic cancer cell lines MIA PaCa-2 and HUP-T3 were transfected with a pool of two 
specific small interfering RNAs (siRNA; siCldn3.2/siCldn3.3 and siCldn4.1/siCldn4.2) or respective control (siCtrl), 
leading to efficient knockdown of Cldn3 / 4 on protein level, demonstrated in representative Western blot (upper panel). 
Silenced cells were transfected with optCPE and MTT assay was performed 72 h later. Significantly reduced CPE 
mediated cytotoxicity was observed in down-regulated MIA PaCa-2 and HUP-T3 cells compared to siCtrl treated cells. 
These data demonstrated again specific activity of optCPE via its receptors Cldn3 / 4. Data are represented as means + 
S.D. (n = 2) and expressed as mean percentage of siCldn3 / 4 treated cells. Level of significance was calculated by 
Student´s t-test, ns: not significant; *p < 0.05; ** p < 0.01; ***p < 0.001. 
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3.3.2 optCPE gene transfer leads to selective cytotoxicity in human PC cells 
To investigate the therapeutic potential of CPE gene transfer the human pancreatic 
cancer cell lines, Capan-1, PA-TU-8902, AsPc-1, MIA  PaCa-2, BxPC-3 and HUP-T3 
as well as the negative control cell line SK -MEL-5 and the positive control cell line HT-
29 were transfected with either optCPE or the pCpG empty vector control (VC). 
Cytotoxicity was determined 72 h after transfection by MTT assay. The experiments 
showed significant toxicity of optCPE expressing vector in all Cldn3 / 4 positive cells 
with toxicity rates of 40 - 85 %, except for AsPc-1 cells (Figure 3.4b), in moderate or low 
Cldn3 / 4 expressing HUP-T3 and BxPC-3 cells and the positive control cell line HT-29, 
optCPE exerted 75 - 85 % cytotoxicity. In Capan-1 and PA-TU-8902 significant 
cytotoxic effect (p  =  0.0073 and p  =  0.004, respectively) was measured in optCPE 
tranfected cells compared to VC. Furthermore, the optCPE gene transfer led to a 
significant (p  = 0.001) reduction of viability in MIA PaCa-2 cells. By contrast, optCPE 
transfection did not have any impact on Cldn3  /  4 expressing AsPc-1 cells, which could 
be due to altered Cldn3 /  4 distribution pattern, or insufficient transfection efficiency. 
The Cldn3 /  4-negative cell line SK-MEL-5 cells remained unaffected after gene 
transfer, indicating strict claudin-selectivity of optCPE cytotoxicity after gene transfer.  
 
To further corroborate this Cldn-selectivity of CPE toxicity, RNAi experiments were 
performed similar to knockdown experiments described in paragraph 3.1.3. Here, 
MIA  PaCa-2 and HUP-T3 cells were transfected with a pool of siCldn3 and siCldn4 or 
siCtrl, respectively (Figure 3.4 c). The downregulation of Cldn3 / 4 led to efficient 
reduction of protein expression in both cell lines 48  h after transfection (Figure 3.4c, 
upper panel). Cldn3 / 4 silenced cells were transfected with optCPE expressing vector 
and cytotoxic effect was measured 72 h after transfection. In both cell lines, optCPE 
mediated cytotoxicity was rescued in Cldn3 / 4 silenced cells as significantly (p < 0.001) 
reduced CPE mediated cytotoxicity was observed in down-regulated MIA  PaCa-2 and 
HUP-T3 cells compared to siCtrl transfected cells. These data demonstrated again 
specific activity of optCPE via its endogenous receptors Cldn3 / 4.  
 
 
3.3.3 Co-localization and complex formation of Cldn4 and optCPE  
The optCPE mediated cytotoxicity results of a multistep mechanism of action, whereby 
CPE first binds to its receptor forming a small complex. CPE localized in that small 
complex rapidly oligomerizes into a prepore complex, namely CH-1 complex, which 
consist of six CPE molecules along with one or more Cldns and assembles on 
membrane surface and inserts into membrane of targeted cells, inducing cell death. 
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To evaluate, if such pore formation is also valid for CPE gene transfer, a co-localization 
study was performed to investigate this multistep mechanism of action in pancreatic 
cancer cells [257]. For this, three representative human pancreatic cancer cell lines – 
HUP-T3, MIA  PaCa-2 and PA-TU-8902 - were transfected with the optCPE expressing 
vector and 12 h post transfection Cldn4 and optCPE co-localization and complex 
formation was evaluated by confocal microscopy. 
 
 
 
Figure 3.5: Co-localization and complex formation study. Representative human pancreatic cancer cell lines 
HUP-T3, MIA PaCa-2 and PA-TU-8902 were transfected with the optCPE expressing vector and after 12 h cells were 
stained for Cldn4 (red) and optCPE (green). Nuclei were counterstained with DAPI (blue). Co-localization and complex 
formation was evaluated by confocal microscopy. In HUP-T3 and MIA PaCa-2 cells optCPE (green) was mainly 
expressed on the membrane regions, whereas altered Cldn4 (red) was detected within the cytoplasm and membrane. 
PA-TU-8902 cells revealed ubiquitously high expressed optCPE after gene transfer. Here optCPE expression was 
detected in the nuclei, cytoplasm and cell membrane, whereas Cldn4 was expressed all over the cell membrane and 
revealed lower expression within the cytoplasm. In all tested cell lines, complex formation was found on the membrane 
of targeted cells, particularly in cell-cell contact area but was also found in the cytoplasm and perinuclear regions 
(yellow).  
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In HUP-T3 and MIA PaCa-2 cells optCPE (green) was mainly expressed on the 
membrane regions, whereas altered Cldn4 (red) was detected within the cytoplasm 
and membrane. Nevertheless, both cell lines showed co-localization and possible 
complex formation (yellow) on the cell membrane including cell-cell contact regions 
(Figure 3.5). Interestingly, co-localization was further seen within the cytoplasm, 
suggesting internalized complexes, since it is known that the CH-1 complex matured 
into larger CH-2 complex, containing occludins. The binding of CPE to claudins and 
occludins is associated with internalization of these tight junction proteins [258]. 
PA-TU-8902 cells revealed an impressive pattern of Cldn4 and optCPE expression 
after gene transfer. The toxin was ubiquitously high expressed in transfected cells; 
meaning optCPE expression (green) was detected in the nuclei, cytoplasm and cell 
membrane. On the other hand, Cldn4 (red) was expressed all over the cell membrane 
and revealed lower expression within the cytoplasm. As described for the other two cell 
lines, complex formation was found on the membrane of transfected cells, particularly 
in cell-cell contact area, highlighting the great advantage of optCPE gene transfer, as 
these tight junction-associated Cldns are inaccessible for recCPE action. Moreover, 
complex formation was found in perinuclear region and cytoplasm, suggesting that 
expressed optCPE is able to directly bind its receptor within the cytoplasm before its 
release. This could also be explained by the pore formation mediated cell damage, 
which allows optCPE access to the cytoplasm to form additional complexes. 
 
 
3.4 Detailed analysis of optCPE mechanism of action  
For the improved and more effective use of the pore-forming toxin, mode of cell death 
induced by transfected CPE was of great interest. It is known that low CPE doses 
result in formation of low numbers of pores, causing caspase-3 mediated cell death. By 
contrast, higher doses of CPE lead to formation of many pores, leading to necrosis or 
more specific oncosis. However, the timely aspect of CPE mediated cell death 
signaling was only poorly investigated. The following experiments were conducted to 
determine in more detail possible activation mechanisms of apoptotic or 
necrotic/oncotic pathways in optCPE transfected pancreatic cancer cells and their 
timely interconnection. 
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3.4.1 Cell death analyses of optCPE mediated cytotoxicity revealed activation of 
apoptosis and necrosis in PC cells 
First signs of cell death have been already seen in cells expressing optCPE (Figure 3.4 
upper panel), as Capan-1 and HUP-T3 cells revealed membrane blebbing 12 h after 
transfection. Nuclear condensation and fragmentation was further detected in optCPE 
transfected MIA PaCa-2 cells in co-localization study (Figure 3.5, MIA PaCa-2). Based 
on this data, optCPE expressing cells were analyzed in time dependent manner to 
thoroughly evaluate stages of induced cytotoxicity. Here, representatively for HUP-T3 
cells optCPE expression (green) was shown within the cytoplasm 12 h after gene 
transfer (Figure 3.6a, from left to right). Two hours later some condensed and 
fragmented nuclei were detected and cells started to swell. Then, 18 h after gene 
transfer, optCPE led to further massive cell swelling, membrane blebbing and 
formation of membrane vesicles, which reached its maximum at 24 h with enormously 
swollen nuclei that were partially fragmented. Here, optCPE led to the induction of two 
different cell death mechanisms, as characteristics for apoptosis (e.g. condensation 
and fragmentation of nucleus and formation of apoptotic bodies) and necrosis / oncosis 
(membrane blebbing, loss of membrane integrity and cell swelling) were demonstrated.  
 
Next, FACS analyses of Annexin-V and propidium iodide (PI) stained HUP-T3 (Figure 
3.6b, c) and PA-TU-8902 cells were performed to further distinguish between different 
cell death mechanisms induced by optCPE mediated cytotoxicity. Transfected cell lines 
were analyzed 12  -  48  h after optCPE or vector control (VC) gene transfer. 
Surprisingly, representative HUP-T3 cells demonstrated time dependent change of the 
entire optCPE expressing cell population compared to VC (reduced signal in Forward 
Scatter FSC), starting at 24 h and reaching its maximum at 36 h, which indicated 
massive increase of cell death as only small fragmented cell debris were detected 
(Figure 3.6b). In line with these results, majority of VC transfected cells revealed 
viability (Annexin-V- / PI) of 92.2  -  94.1 % over time, whereas optCPE transfected cells 
demonstrated decrease in viable, Annexin-V- / PI-  population and significant increase in 
cells undergoing early apoptosis (Annexin-V+ / PI-; 36 h; p = 0.0037, 48 h; p = 0.0234)  
and also late apoptosis / necrosis (Annexin-V+ / PI+; 48 h; p = 0.0017). Similar results 
were seen in the analyzed PA-TU-8902 cell line. Out of these experiments it can be 
concluded, that optCPE gene transfer triggers first apoptosis. As cells express more 
optCPE over time and apoptotic cells die, more optCPE will be available to generate 
higher numbers of pores in the cells that consequently leads to necrosis / oncosis.  
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Figure 3.6: Time dependent analysis of CPE mediated cell death. (a) Representative Immunofluorescence images 
of time dependent optCPE (green) mediated cytotoxic effect in transfected HUP-T3 cells demonstrating rapid induction 
of apoptosis and later necrosis. Cells were counterstained with Cldn4 (red) and nuclei (blue) were visualized with DAPI. 
(b) FACS analysis of representative HUP-T3 cell line transfected with vector control (VC) or optCPE, respectively 
demonstrated time dependent decrease of signal in Forward Scatter (FSC) in optCPE expressing cells compared to VC, 
starting at 24 h and reaching its maximum at 36 h, indicating massive increase of cell death as only small fragmented 
cell debris were detected. (c) Annexin-V and propidium iodide (PI) analysis of representative HUP-T3 cell line revealed 
significant increase of Annexin+ / PI- population (6.39 - 21.4 %), undergoing early apoptosis, was detected 36 h and 48 h 
after gene transfer compared to VC transfected population (2.67 - 3.90 %). Also significant gain of Annexin+ / PI+ 
population, characterizing late apoptosis/necrosis was measured 48 h after optCPE transfection (27.9 %) compared to 
VC (2.32 %). The data indicate an optCPE induction of apoptosis in a first step, which turns to necrosis at later time 
points. Data is represented as single experiment, which was confirmed in 2 independent experiments, revealing similar 
results.  
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3.4.2 Analysis of important markers and key players in optCPE mediated cell 
death  
Next, lactate dehydrogenase (LDH) assay was performed and activity of caspases-3/7, 
-8 and -9 as well as calpain-1/2 was determined to further complement previous data 
on optCPE-triggered cell death mechanisms. For these experiments the pancreatic 
cancer cell lines MIA PaCa-2 and PA-TU-8902 were thoroughly analyzed. 
 
 
3.4.2.1 Time dependent release of LDH after optCPE gene transfer 
The LDH assay is based on the fact that dead cells, whether they die by apoptosis or 
necrosis, release LDH due to loss of plasma membrane integrity. In case of apoptosis 
membrane integrity is maintained until late stages of the process, whereas strong 
release of LDH is detected early during necrosis. To analyze LDH release, supernatant 
of optCPE and VC transfected cells was collected at different time points. The 
experiment revealed no considerable increases of LDH in the supernatant of optCPE 
expressing MIA PaCa-2 cells between 8 - 16 h. However, a 1.5-fold and 3-fold LDH 
increase was measured 20 h and 48 h after transfection, respectively compared to VC 
(Figure 3.7a, left panel). On the other hand supernatant of optCPE expressing 
PA-TU-8902 cells revealed significant increase (12-fold) of released LDH 48 h after 
transfection (Figure 3.7a, right panel). Moreover, supernatant of PA-TU-8902 cells 
demonstrated 2 - 3-fold increase of LDH 14  -  20  h after optCPE gene transfer 
compared to VC (Figure 3.7a, right panel), suggesting induced necrosis at these early 
time points after optCPE gene transfer.  
 
 
3.4.2.2 optCPE induced pore formation activates caspases in PC cells 
As evidences for optCPE induced apoptosis was demonstrated, it was of interest to 
analyze the activation of caspase-3/7, -8 or -9 as key molecules of apoptosis. 
Therefore, MIA PaCa-2 and PA-TU-8902 cells, transfected either with VC or optCPE, 
were treated with respective caspase detection reagent at different time points. 
MIA  PaCa-2 cells did not show noteworthy changes of activation in any caspases 
between 24  -  72  h (Figure 3.7b, left panel). However, analysis of short-term optCPE 
action revealed significant time dependent hyperactivation of all analyzed caspases in 
optCPE expressing cells starting 12  h after transfection.  
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Figure 3.7: Study of lactate dehydrogenase (LDH) and caspase-3/7, -8 and -9 activity in optCPE-mediated cell 
death. (a) Liberated LDH was analyzed in vector control (VC) or optCPE transfected MIA PaCa-2 (left) and PA-TU-8902 
(right). The experiment revealed a 1.5-fold and 3-fold increase of LDH release in optCPE expressing MIA PaCa-2 cells 
20 h or 48 h after transfection, respectively. PA-TU-8902 cells demonstrated significant higher LDH release starting 
already 14 h after gene transfer, reaching its maximum at 48 h. Data are represented as means + S.D. (n = 3) and 
expressed as released LDH n-fold to VC. Level of significance was calculated by Two way-Anova and Turkey´s multiple 
comparison post-test. (b) Activation of respective caspases in optCPE transfected cells were investigated. Long-time 
analysis of MIA PaCa-2 cells (24 - 72 h) did not show noteworthy changes of activation in any caspases, whereas of 
short-term optCPE action (12 - 20 h) demonstrated significant time dependent hyperactivation of all analyzed caspases 
starting 12 h after transfection. The analysis of optCPE expressing PA-TU-8902 cell line demonstrated a significant 
hyperactivation of all three caspases 14 - 20 h after transfection with subsequent decrease compared to VC transfected 
cells. Data are represented as means + S.D. (n = 3) and expressed as relative caspase activity n-fold to VC. (c) Analysis 
of calpain-1/2 activation in optCPE expressing cell lines. MIA PaCa-2 cells revealed significant high calpain-1/2 
activation 14 h, 20 h and 24 h after optCPE transfer and an activity drop at 16 h (c, left). The optCPE expressing 
PA-TU-8902 cell line demonstrated significant (p < 0.0001) time dependent increase of calpain-1/2 activation, starting as 
early as 16 h after transfection, reaching its maximum at 22 h with subsequent drop of activity (c, right). Data are 
represented as means + S.D. (n = 3) and expressed as calpain-1/2 activity / µg protein. Level of significance was 
calculated by Two way-Anova and Turkey´s multiple comparison post-test, ns: not significant; *p < 0.05; ** p < 0.01; 
***p < 0.001; ****p = 0.0001. 
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Highest activation was seen over time for caspase-3/7 (4  -  6.5-fold compared to VC 
transfected cells), followed by caspase-8 activation that was 2 - 4-fold higher compared 
to VC, whereas caspase-9 was significantly activated (3.8 -fold) only 14 h post 
transfection (Figure 3.7b, left panel). The analysis of PA-TU-8902 revealed a significant 
(p < 0.0001) hyperactivation of all caspases at 14  -  20   h (Figure 3.7b, right panel), 
whereof caspase-3/7 (23 -fold) and caspase-9 (8 -fold) reached their maximum 
activation after 14 h. Caspase-8 revealed a 27-fold higher activation 16 h after optCPE 
transfection compared to VC. Nevertheless, a 1.8  -  2-fold higher activation of all 
caspases was further observed in optCPE expressing cells 24 h after transfection, 
which simultaneously decreased to 0.8  -  1.2-fold (Figure 3.7b, right panel). These 
findings further confirmed optCPE mediated timely induction of caspase-dependent 
apoptosis pathways as key features of optCPE mediated cell killing. 
 
 
3.4.2.3 Non-caspase protease calpain-1/2 activity in optCPE induced cell death 
As aforementioned, CPE dose is important for cell’s decision on a particular death 
pathway. Low CPE doses result in formation of less number of pores, causing modest 
calcium (Ca2+) influx and consequently modest calpain-1/2 activation that triggers 
apoptosis, as it is an activator of caspase-3. On the other hand higher doses of toxin 
cause formation of high numbers of pores that allow more drastic Ca2+ influx, leading to 
very strong calpain-1/2 activation, as they can cleave target proteins, which can directly 
or indirectly lead to cell rupture [225]. Thus, the next experiments were performed to 
analyze particularly time dependent activation of the non-caspase protease calpain-1/2 
in optCPE transfected cells. Similar to analyzed caspase-3/7 activities, MIA PaCa-2 
cells revealed significant (p < 0.001) high activation of calpain-1/2  14 h, 20 h and 24 h 
after optCPE transfer (Figure 3.7c, left panel) and an activity drop at 16 h. These data 
could indicate cross-talk of both proteases, since activated caspase-3 is able to cleave 
the endogenous calpain-1/2 inhibitor calpastatin, resulting in activation of calpain-1/2, 
which in turn activates more caspases causing and promoting apoptosis [259].  
 
The optCPE expressing PA-TU-8902 cell line demonstrated significant (p < 0.0001) 
time dependent increase of calpain-1/2 activation, starting as early as 16 h after 
transfection, reaching its maximum at 24 h (Figure 7c, right panel) with subsequent 
drop of activity. In optCPE transfected PA-TU-8902 cell line hyperactivation of 
caspases was measured between 16 - 20  h, demonstrating again interplay between 
both.  
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Here, Ca2+ activated calpain-1/2 might have translocated to the membrane, where 
cytoskeletal proteins are cleaved, leading to loss of membrane integrity and increased 
intracellular Ca2+ concentration, which in turn activates more calpain-1/2. This process 
can cause necrosis depending on amount of Ca2+. These results led to the conclusion 
that expressed optCPE acts similarly to bacterial CPE, produced and released during 
bacterium sporulation, as different cell death pathways were activated, depending on 
amounts of activated calpain-1/2. This also provided evidence for possible crosstalk of 
caspases and calpain-1/2 in optCPE mediated cell death.  
 
 
3.4.2.4 Live cell analysis – time course of optCPE induced cytotoxicity 
CPE mediated cytotoxic effects were further investigated by live cell imaging using the 
IncuCyte® to better analyze the timely interplay of apoptotic signaling. This system 
allowed simultaneous analyses of cell viability (measured as percent confluency), Ca2+  
 influx (visualized by Fluo-4 AM component), activation of caspase-3 (using IncuCyte® 
Caspase-3/7 Apoptosis Assay Reagents) and binding of Annexin-V to apoptotic cells 
(IncuCyte® Annexin V Red Reagent for apoptosis).  
 
In transfected optCPE PA-TU-8902 cells viability was significantly (p < 0.0001) reduced, 
suggesting that optCPE formed oligomers upon binding. This pore formation led to 
profound increase of intracellular calcium, starting already 12 h after transfection, 
reaching its maximum at 14  - 18 h (p < 0.01), followed by subsequent decreases over 
time (Figure 3.8a, blue). As Ca2+ influx decreased, caspase-3 activity significantly 
increased (p < 0.0001, Figure 3.8b, green), which corresponded also to increased 
calpain-1/2-activity shown in Figure 3.7c. This hyperactivation of proteases resulted in 
apoptosis, reflected by decrease of viability and increasing number of Annexin-V 
positive cells. Interestingly, high Annexin-V positive population appeared already 6 h 
after transfection, indicating optCPE induced necrosis due to high number of 
optCPE / Cldn pore complexes (Figure 3.8c, red). These data led to the conclusion that 
expressed optCPE is able to drive activation of different pathways (apoptosis and 
necrosis) in one cell line, which is dependent on expressed optCPE concentration and 
consequently number of formed pores. With this, the CPE triggered crosstalk of 
calpain-1/2 and caspase-3/7 was further supported.  
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Figure 3.8: Time dependent course of optCPE induced cytotoxicity in human PC cell line PA-TU-8902 and array 
analysis of apoptosis genes. (a-c) Live cell imaging using the IncuCyte®: CPE mediated cytotoxic effects were 
investigated by simultaneous analysis of calcium (Ca2+) influx (visualized by Fluo-4 AM component), activation of 
caspase-3 (using IncuCyte® Caspase-3/7 Apoptosis Assay Reagents) and binding of Annexin-V to apoptotic cells 
(IncuCyte® Annexin V Red Reagent for apoptosis). (a) The optCPE gene transfer led to profound increase of 
intracellular calcium, starting already 12 h after transfection, reaching its maximum at 14 - 18 h followed by subsequent 
decreases over time. (b) As Ca2+ influx decreased, caspase-3 activity significantly increased. (c) The activation of 
caspase-3 resulted in apoptosis, reflected increasing number of Annexin-V positive cells. Interestingly, high Annexin-V 
positive population appeared already 6 h after transfection, indicating optCPE induced necrosis due to high number of 
optCPE  /Cldn pore complexes. Data are represented as means + S.D. (n = 3) and expressed as count (1 / Image). Level 
of significance was calculated by Two way-Anova and Turkey´s multiple comparison post-test. (d, e) Human apoptosis 
array: For this experiment, transfected PA-TU-8902 cells were harvested as soon as first signs of cell death were seen 
(18 h after transfection). (d) Representative array for VC or optCPE transfected PA-TU-8902 cells already indicating 
difference in apoptosis related proteins reflected as pixel intensity difference (left). Summary of all analyzed proteins, 
detected on apoptosis array (right). (e) The pro-apoptotic proteins (green bars), Bax, pro-caspase-3, cytochrome c or 
the stress-induced apoptotic proteins second mitochondria-derived activator of caspases (SMAC/Diabolo) and high 
temperature requirement protein serine peptidase 2 (HTRA2/OMI) were significantly activated compared to vector 
control (VC) transfected cells, whereas pro-survival (red bars) proteins heat shock protein 27 (HSP 27) and survivin 
were down-regulated. Pixel density was measured using the AlphaView software, Version 3.4. Data are represented as 
means of measured pixel density + S.D. (n = 2). Level of significance was calculated by Student´s t-test, ns: not 
significant; *p < 0.05; ** p < 0.01. 
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To further investigate the potential modulation of apoptosis genes by optCPE, a 
specific human apoptosis array was performed (Figure 3.8d). For this, transfected 
PA-TU-8902 cells were harvested as soon as first signs of cell death were seen, which 
was 18 h after optCPE transfection in this cell line. Interestingly, pro-apoptotic proteins, 
such as Bax, pro-caspase 3, cytochrome c or the stress-induced apoptotic proteins 
second mitochondria-derived activator of caspases (SMAC / Diabolo) and the high 
temperature requirement protein serine peptidase 2 (HTRA2 / OMI) were significantly 
activated compared to VC transfected cells, whereas pro-survival protein survivin was 
significantly down-regulated (Figure 3.8e). In this context, these proteins can be 
associated with the intrinsic apoptotic pathway, as non-receptor-mediated stimuli 
caused cell death. Here, CPE pore formation led to Ca2+ influx, changing in the inner 
mitochondrial membrane that caused release of the pro-apoptotic proteins 
cytochrome c, SMAC / Diablo and the serine protease HTRA2 / Omi from inter-
membrane space to cytosol. Thus, caspase-dependent mitochondrial pathway is 
activated. Furthermore, it is worth mentioning that calpain-1/2, activated through Ca2+ 
influx, is not only able to cleave caspase-3, it can also cleave the pro-apoptotic 
molecule Bax, which also explains the analyzed data. With this result, more thoroughly 
the CPE triggered interplay of different pathway activations was shown.  
 
By contrast, MIA PaCa-2 cells demonstrated a slightly different pattern of cell death 
activation. Here, optCPE induced cytotoxicity was not as strong and at later time point 
as compared to PA-TU-8902. They showed early Ca2+ influx at low level that 
decreased over time (Figure 3.9a), whereas caspase-3 activity was significantly 
activated 30  h post transfection with further increase (Figure 3.9b). Noteworthy, 
Annexin-V was constantly measured over time in optCPE MIA PaCa-2, but not to the 
strong extent as seen in PA-TU-8902 (Figure 3.9c). The data for this cell line 
suggested a weaker caspase-3 dependent, but more calpain-1/2 driven apoptosis 
induction at the beginning, as optCPE expressing cells started already to die 12 h post 
transfection, a time point where no or little caspase-3 was measured but moderate 
increase of calcium was seen. This was further confirmed by the specific human 
apoptosis array, as weaker induction of apoptotic key players was seen (Figure 3.9d). 
In these array experiments optCPE expressing cells were analyzed 26 h after 
transfection, because first signs of cell death were detected at this time point. The 
array revealed significant up-regulation of cytochrome c and SMAC / Diabolo, which 
could be activated through Ca2+ induced loss of mitochondrial membrane integrity.  
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Further, significant induction of cleaved caspase-3 was observed in optCPE 
transfected MIA PaCa-2 cells that could be a result from calpain-1/2 cleavage. The 
tumor protein p53 is upregulated in response to DNA damage caused by optCPE gene 
transfer, whereby conformational change of p53 forces the protein to be activated as a 
transcriptional regulator, mediating transcription of various pro-apoptotic genes (Figure 
3.9e). The increasing knowledge of such pathway activation by optCPE gene transfer 
could be the rationale for potential combinations with conventional chemotherapeutics 
that better exploit this pathway activation by CPE gene therapy. 
 
 
 
Figure 3.9: Time dependent course of optCPE induced cytotoxicity in human PC cell line MIA PaCa-2 and array 
analysis of apoptosis genes. (a-c) Live cell imaging using the IncuCyte®. CPE mediated cytotoxic effects were 
investigated by simultaneous analyses of calcium (Ca2+ ) influx (visualized by Fluo-4 AM component), activation of 
caspase-3 (using IncuCyte® Caspase-3/7 Apoptosis Assay Reagents) and binding of Annexin-V to apoptotic cells 
(IncuCyte® Annexin V Red Reagent for apoptosis). (a) MIA PaCa-2 cells revealed early Ca2+ influx at low level that 
decreased over time. (b) Caspase-3 activity was significantly activated 30   h post-transfection with increasing course. 
(c) Annexin-V was constantly measured during live cell analysis, indicating caspase-3 independent apoptosis at the 
beginning of analysis. Data are represented as means + S.D. (n = 3) and expressed as count (1/Image). Level of 
significance was calculated by Two way-Anova and Turkey´s multiple comparison post-test. (d, e) Human apoptosis 
array: For this experiment, transfected MIA PaCa-2 cells were harvested as soon as first sign of cell death were seen 
(26   h after transfection). (d) Representative array for VC or optCPE transfected MIA PaCa-2 cells, demonstrating small 
difference in apoptosis related proteins (left). Summary of all analyzed proteins, detected on apoptosis array (right). (e) 
The pro-apoptotic proteins, cleaved caspase-3, cytochrome c or the stress-induced apoptotic proteins second 
mitochondria-derived activator of caspases (SMAC/Diabolo) and high temperature requirement protein serine peptidase 
2 (HTRA2/OMI) and the tumor protein p53 were significantly activated compared to vector control (VC) transfected cells. 
Data are represented as means + S.D. (n = 2) and expressed as pixel density. Level of significance was calculated by 
Student´s t-test, ns: not significant; *p < 0.05; ** p < 0.01; ***p < 0.001; ****p = 0.0001. 
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3.4.3 Bystander effect plays decisive role in mode of CPE action 
The transfection experiments revealed much higher optCPE toxicity than it would have 
been anticipated by transfection rates of 10  - 65  % for human pancreatic cancer cell 
lines (see Material and Methods, Table 2.3). This suggests that non-transfected cells 
are also affected due to the bystander effect by released optCPE. To prove this, 
supernatants of optCPE transfected cells were analyzed. Quantification by specific 
CPE ELISA demonstrated the presence of released optCPE within the supernatants at 
indicated time points, ranging from up to 19.5 ng ml-1 released CPE by HUP-T3 12  h 
after gene transfer to 693.3 ng ml-1 CPE liberated by Capan-1 cells 48  h post-
transfection (Figure 3.10a).  
 
Currently little is known about the intracellular transportation and liberation of 
expressed optCPE. Previous described IF analysis showed vesicle like accumulation of 
expressed optCPE within the cytoplasm, which could indicate exocytosis of the toxin. 
Here expressed proteins are packaged into transport vesicles that release its contents 
after fusion with the cell membrane. Recently exosomes came into focus. These small 
cell derived vesicles, that contain various molecular constituents, including DNA, 
mRNA, miRNA and proteins, are either released from the cell when multivesicular 
bodies fuse with the plasma membrane or directly liberated from the plasma 
membrane. Exosomes can transfer molecules from one cell to another, thereby 
influencing neighboring cells. To address, if optCPE is transported via exosomes, 
media of optCPE transfected MIA  PaCa-2 and PA-TU-8902 cells were taken to isolate 
and enrich these small vesicles. To confirm the successful isolation, determination of 
specific exosomal marker, such as heat shock protein 27 (HSP70) and the 
teatraspanin CD63, was done via Western blot analysis, whereof CD63 was higher 
expressed than HSP70 (Figure 3.10c). In both fractions – media and enriched 
exosomes – Western blot analysis further showed optCPE presence, which was 
stronger in PA-TU-8902. Additional validation was done as quantification revealed 
concentrations of 324.4 and 382.7 ng ml-1 CPE in supernatant of transfected 
MIA  PaCa-2 and  PA-TU-8902 cells and 242.6 and 344.5 ng ml-1 CPE in enriched 
exosomes, respectively (Figure 3.10b). These findings support the idea of CPE release 
from transfected cells via exocytosis or its transportation via exosomes, which 
mediates and promotes the bystander effect.  
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Figure 3.10: Bystander effect and analysis of CPE release via exosomes. Analysis of CPE release by optCPE 
transfected human pancreatic cancer cell lines. (a) Media of optCPE transfected MIA  PaCa-2 and  PA-TU-8902 cells 
were harvested at indicated time points after transfection and analyzed by specific CPE ELISA, summarized in the 
table. (b-c) Isolation and enrichment of exosomes was performed using media of optCPE transfected MIA   PaCa-2 and 
PA-TU-8902 cells. (b) Quantification of optCPE within supernatant and exosomes using CPE ELISA revealed 
concentrations of 324.4 and 382.7 ng ml-1 CPE in supernatant of transfected MIA PaCa-2 and  PA-TU-8902 cells and 
242.6 and 344.5 ng ml-1 CPE in enriched exosomes, respectively. (c) Representative Western blot of supernatant (S) 
and exosomes (E), demonstrating expression of the specific exosomal marker heat shock protein 27(HSP70) and the 
teatraspanin CD63, whereof CD63 was higher expressed than HSP70. optCPE expression was present in both, 
supernatant and expsosmes, which was stronger in PA-TU-8902. (d, e) Analysis of biological activity of released 
optCPE. Media of vector control (VC) or optCPE transfected MIA   PaCa-2 and  PA-TU-8902 cells collected at indicated 
time points was added to respective non-transfected cell lines and cytotoxicity was determined by MTT 72   h after 
application. Supernatant, collected 48   h and 72   h after transfection, led to significant reduction of viability in PA-TU-
8902 and MIA PaCa-2 cells, whereof PA-TU-8902 revealed higher toxicity rates than MIA   PaCa-2, correlating with 
amount of released optCPE (see a). Data are represented as means + S.D. (n = 3) expressed as mean percentage of 
VC. Level of significance was calculated by Oneway-Anova and Turkey´s multiple comparison post-test, ns: not 
significant; *p < 0.05; ** p < 0.01; ***p < 0.001. 
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Next, biological activity of released optCPE was tested by treating respective non-
transfected cells with supernatant, collected 24  -  72  h after transfection (Figure 3.10d, 
3.10,e). In both analyzed cell lines, MIA  PaCa-2 and PA-TU-8902, no significant 
viability reduction was seen after treatment with 24 h supernatant. After adding 
supernatant, collected 48  h and 72 h post-transfection, viability of PA-TU-8902 
drastically dropped down to only 25  % and 18 %, respectively, whereas MIA PaCa-2 
cells revealed toxicity of approximately 25  %. These results correlate with CPE 
concentrations quantified by CPE ELISA, as summarized in table of Figure 3.10a: high 
concentration of released optCPE in supernatant of optCPE expressing PA-TU-8902 
cells (24 h = 441.15 ng ml-1, 48  h  =  614.25 ng ml-1, 72 h =  661.97 ng ml-1) led to strong 
cytotoxicity and lower toxin concentration, measured in MIA  PaCa-2 
(24  h  =  277.51 ng ml-1, 48 h  =  320.43 ng ml-1, 72 h  =  272.24 ng ml-1) resulted in lower 
cytotoxicity. These data clearly emphasize the efficiency of optCPE gene therapy by 
prolonged presence of the toxin and the associated bystander effect for efficient 
pancreatic cancer cell eradication. 
 
 
3.5  Non-viral, intratumoral optCPE suicidal in vivo gene therapy 
The in vitro gene therapeutic application of optCPE led to a significant eradication of 
Cldn3 / 4 expressing pancreatic cancer cells. Thus, the toxin demonstrated its 
promising potential for the gene therapy. An indispensable step for the establishment 
of an optCPE gene therapy is the implementation of in vivo experiments. For this 
reason different cell derived xenograft (CDX) models and also PDX models were used 
to investigate the antitumoral activity of optCPE gene therapy using the non-viral jet 
injector gene transfer [255] (Material and Methods, Paragraph 2.4).  
 
 
3.5.1 Kinetic of intratumoral optCPE expression and antitumoral effects  
To analyze the time dependent expression and dispersion of optCPE after intratumoral 
gene transfer two different CDX models, derived from either PA-TU-8902 or 
MIA  PaCa-2 cells (see Material and Methods 2.4.1), were used. Each group was made 
up of eight animals, which were jet-injected with optCPE when subcutaneous tumors 
reached size of 0.3  cm3. At different time points (24   - 96  h) after gene transfer two 
animals of each group were sacrificed and tumors were shock frozen for further 
analysis. The optCPE gene expression was investigated at protein level, using 
Western blot analysis, CPE ELISA and IHC (Figure 3.11).  
 
77 
Results 
 
F  
 
Figure 3.11: Kinetics of expressed optCPE in CDX tumor tissue after non-viral in vivo gene transfer. Time 
dependent optCPE expression after in vivo gene transfer was analyzed in PA-TU-8902 or MIA PaCa-2 cell derived 
xenograft tumors. When subcutaneously transplanted s.c. tumors reached size of 0.3 cm3, CDX bearing mice were 
anesthetized and intratumoral gene transfer was performed using the jet-injector. At defined time points two animals per 
group (n = 8) were sacrificed, tumors were harvested and shock frozen. Western blot analysis and CPE quantification 
via CPE ELISA revealed successful optCPE in vivo expression in both models at all indicated time points. (a) In PA-TU-
8902 CDX tumor tissue strong toxin expression was already measured 24 h after jet-injection, reaching its maximum 
after 96 h. Time dependent increase of optCPE expression was further confirmed by CPE ELISA measuring 
concentrations from 0  ng  ml-1 at 24 h to 290 ng ml-1 optCPE after 96  h. (b) MIA PaCa-2 tumors demonstrated strong 
optCPE expression 24 h - 48 h after gene transfer (approx. 84 - 250 ng  ml-1 optCPE), which decreased over time to 
approx. 2 – 14 ng  ml-1 optCPE. ELISA data are represented as means + S.E.M Further validation of intratumorally 
expressed and accumulated optCPE in PA-TU-8902 (c) and MIA PaCa-2 (d) tumor tissue was done via immunohisto-
chemistry (brown stained areas). In addition, necrotic areas of optCPE jet-injected tumors were analyzed, as tissues 
were HE stained and vital vs. necrotic area ratio was quantified for indicated time points. Both, PA-TU-8902 (e) and 
MIA PaCa-2 (f) derived tumors showed massive necrotic areas within the tumors surrounded by residual vital tumor 
tissue.  
 
 
Both jet-injected CDX models demonstrated successful toxin expression at all indicated 
time points. Western blot analysis of PA-TU-8902 tumors showed moderate optCPE 
expression 24  h after gene transfer with increase of expression over time, which 
reached its maximum after 96 h.  
This was confirmed by quantification of expressed optCPE using CPE ELISA, detecting 
toxin concentrations ranging from 0  ng  ml-1 at 24  h to 290 ng ml-1 optCPE after 96  h 
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(Figure 3.11a). MIA  PaCa-2 tumors revealed strong toxin appearance at day one and 
two on (between 130 - 250 ng  ml-1 optCPE), which decreased over time to 2 - 14 ng ml-1 
optCPE (Figure 3.11b). The IHC validated the successful intratumoral expression and 
accumulation of optCPE (brown staining) and also revealed CPE-mediated effects in 
tumor tissues, reflected by necrotic areas (Figure 3.11c, d). Based on this, all tumors 
were further examined via HE staining (Figure 3.11e, f; lower panel) that highlighted 
massive tissue destruction within the jet-injected tumor, exemplified by ration between 
vital and necrotic tissue areas (Figure 3.11e, f; upper panel). Here it is worth 
mentioning that the peripheral tumor margins are still vital, which seem to wrap up the 
inflammatory necrotic tumor tissue, preventing release of necrotic tissue debris into 
circulation. More importantly, this kinetic study indicated a successful in vivo gene 
transfer and expression, whereby toxin mediated cytotoxicity affected tumor tissue 
already after 24  h with extended therapeutic window for tumor treatment. This strongly 
supports the great efficacy for this bacterial toxin in cancer gene therapy to treat 
Cldn3  /  4 expressing pancreatic tumors.  
 
 
3.5.2 Selective and efficient in vivo application of optCPE suicidal gene transfer 
in Cldn3 / 4 expressing PA-TU-8902/eGFP-Luc CDX tumors 
The following animal experiment was conducted to address efficiency and more 
importantly selectivity of in vivo optCPE gene transfer. Therefore, a mutated optCPE 
construct, generated by side directed mutagenesis, was introduced as additional 
control. This mutated CPE-variant (mutCPE) has almost no binding affinity to Cldn3  /  4 
and is an indicator for the selectivity of CPE action. In this experimental setup, PA-TU-
8902/eGFP-luc s.c. tumor bearing mice were randomized into three treatment groups 
(1. VC; 2. mutCPE; 3. optCPE). When tumors reached size of 0.3  cm3, non-viral 
intratumoral gene transfer using jet-injector was performed 23 days after tumor cell 
injection. In this approach significant antitumoral activity of optCPE-mediated 
cytotoxicity was observed in transfected PA-TU-8902/eGFP-Luc CDX-bearing mice. 
Tumor viability, as measured by tumor bioluminescence, was significantly reduced in 
optCPE-transfected tumors compared to mutCPE (p   =   0.0257) or VC (p   =   0.0003) 
transfected tumors (Figure 3.12a, c). This was confirmed by significant tumor growth 
inhibition in optCPE expressing tumors compared to VC (p   <   0.00001) and mutCPE 
(p   =   0.0004) transfected tumors, highlighting the strict Cldn selectivity of optCPE 
cytotoxicity also after intratumoral in vivo gene transfer (Figure 3.12b). 
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Figure 3.12: In vivo optCPE gene transfer induced selective necrotic and apoptotic cell death and led to tumor 
growth inhibition in PA-TU-8902/eGFP-Luc CDX s.c. tumors. After intratumoral optCPE gene transfer (GT; 23 days 
after tumor cell injection), significant antitumoral activity was observed in optCPE-transfected PA-TU-8902/eGFP-Luc 
CDX-bearing mice. (a) Tumor viability, measured by tumor luminescence, was significantly decreased in optCPE-
expressing tumors compared to empty vector control (VC) or the non-Cldn3 / 4 binding CPE (mutCPE) expressing 
tumors. (b) The in vivo optCPE gene transfer led to significant inhibition of PA-TU-8902/eGFP-Luc CDX tumor growth 
compared to VC or mutCPE gene transfer, respectively. (c) Representative images of tumor luminescence, reflecting 
tumor viability, revealed luminescence signal reduction in optCPE transfected CDX tumors compared to respective 
controls. (d) Ratio of vital and necrotic tumor tissue (upper panel) was determined by analyzing respective HE staining 
(lower panel) of terminal tumor sections (day 34 after PA-TU-8902/eGFP-Luc cell injection). The HE staining showed 
massive necrotic areas in optCPE transfected tumors compared to mutCPE or VC transfected tumors, which was 
further confirmed, as necrotic areas were significantly larger in optCPE expressing tissue. (e) Analysis of Ki67 reactivity 
did not show significant differences in transfected groups, respectively. (f) The TUNEL assay revealed a significantly 
increased number of TUNEL positive nuclei in optCPE transfected compared to mutCPE or VC.transfected PA-TU-
8902/eGFP-Luc CDX tumors. Data represent mean + S.E.M. (n = 8 animals / group), level of significance was 
determined using One way ANOVA based on one characteristic or factor (different treatments) or Two way-ANOVA 
based on multiple characteristics (e.g. different treatments at different time points) and Turkey´s multiple comparison 
post-test, n.s. not significant; *p < 0.05; ** p < 0.01; ***p < 0.001; ****p = 0.0001. 
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Since little is known about the mechanism of action of intratumorally expressed 
optCPE, additional analyses were performed to evaluate potential induction of 
apoptosis or necrosis in the treated tumors. First, tumor tissues were HE stained and 
evaluated under the light microscope, revealing massive areas of necrosis (26  %) 
within the optCPE transfected tumors, as was already seen in the kinetic experiment 
(Figure 3.12d). Although necrosis was also found in mutCPE (9   %) and VC (12 %) 
transfected tumors, these areas remained much smaller. This was further reflected in 
vital  vs.  necrosis ratio, as necrosis was significantly higher in optCPE expressing 
tumors compared to VC (p   =   0.0337) or mutCPE (p   =   0.0065) treated tissues. With 
this data evidence for strong optCPE induced necrosis was provided. Furthermore, 
additional experiments were conducted to investigate potentially induced cell cycle 
arrest or induced apoptosis through the optCPE mediated bystander effect within the 
adjacent tumor tissue with vital appearance.  
 
To evaluate cell cycle arrest or proliferation inhibition, Ki67 reactivity was measured by 
IHC staining of gene transfected tumor tissue, expressed as percent tumor cells 
staining positive (Figure 3.12e). By this, no significant difference in Ki67 activity was 
detected between VC, mutCPE or optCPE transfected tumor tissue. This suggests that 
optCPE has no effect on proliferation in PA-TU-8902/eGFP-Luc CDX tumors. 
Moreover, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
assay was performed to detect in situ fragmented DNA, as characteristic hallmark of 
apoptosis. Cells containing fragmented nuclear chromatin will exhibit a brown nuclear 
staining, defined as percent tumor cell nuclei staining positive. Surprisingly, a 
significantly increased number of TUNEL positive nuclei was counted in optCPE 
transfected compared to mutCPE (p   =   0.0041) or VC (p   =   0.0009) transfected PA-
TU-8902/ eGFP-Luc CDX tumors. This was particularly seen in areas close to necrosis, 
which could be explained by the optCPE mediated bystander effect (Figure 3.12 f).  
 
 
3.5.3  Tumor growth inhibition and tumor cell eradication through targeted optCPE 
gene transfer in additional Cldn3  /  4 expressing CDX tumors 
As described in previous in vitro experiments, expressed optCPE can induce different 
cell death mechanism, depending on amount of expressed and released optCPE, the 
availability of its receptors and consequently number of pores that initiate respective 
cell-death associated pathways.  
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The next animal experiments were performed to investigate if in vivo expressed 
optCPE has the same antitumoral effect in different Cldn3   /   4 expressing human 
pancreatic CDX tumors as indicated in PA-TU-8902 CDX tumors. First, the Cldn 3  /   4 
low expressing MIA   PaCa-2/ eGFP-Luc cells were subcutaneously established in 
NOD/Shi-scid/IL-2Rγnull (NOG) mice. When tumors reached size of 0.2 cm3, 
MIA   PaCa-2/ eGFP-luc CDX tumor-bearing mice were randomized into two treatment 
groups (VC group and optCPE group) and intratumoral gene transfer was performed 
34 days after tumor cell injection.  
 
 
 
 
Figure 3.13: Non-viral in vivo optCPE gene transfer led to tumor viability reduction and inhibition of tumor 
growth through optCPE induced apoptosis. After intratumoral gene transfer (GT; 34 days after tumor cell injection), 
significant inhibition of (a) tumor viability, measured as bioluminescence, and (b) tumor growth (reflected as mean tumor 
volume) was observed in optCPE transfected MIA PaCa-2/eGFP-Luc bearing mice compared to VC transfected 
animals. (c) Representative images of tumor luminescence, reflecting tumor viability, which showed decrease of 
luminescence signal in optCPE transfected CDX tumors compared to respective controls. (d) At day 39 experiment was 
terminated, tumors were removed and ex vivo tumor bioluminescence was measured, confirming significant reduction in 
tumor viability. Data represent mean + S.E.M. (n = 10 animals/ group), level of significance was determined using Two 
way-ANOVA based on multiple characteristics and Turkey´s multiple comparison post-test or the nonparametric Mann-
Whitney U-test based on comparison of two groups, *p < 0.05; ****p=0.0001. 
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Here, the non-viral optCPE gene transfer led to significant reduction of tumor viability 
(p   =   0.0336) in optCPE transfected MIA   PaCa-2/eGFP-Luc CDX-bearing mice 
compared to VC treated mice. This was also reflected in representative 
bioluminescence images (Figure 3.13a, c) and further validated as tumor growth was 
significantly inhibited (p   <   0.0001) in optCPE expressing tumors (Figure 3.13b). The 
experiment was terminated at day 39 due to ethical reason.  
 
All tumors were removed and ex vivo bioluminescence was measured, revealing 
significant reduction of tumor luminescence signal (p   =   0.0172) in optCPE transfected 
tumors compared to VC treated tumors, indicating massive decrease in vitality 
(Figure 3.13d). These results further demonstrate the highly efficient antitumoral 
activity of expressed optCPE after intratumoral gene transfer. This was further 
supported by TUNEL assay, showing a highly significant increase of TUNEL positive 
nuclei (p   =   0.0011) in optCPE transfected tumors (37  %) compared to VC transfected 
tumors (26  %). The analysis of vital vs. necrotic ratio and Ki67 activity of transfected 
tissues did not show significant differences between the two groups. In conclusion 
these results suggest that optCPE mainly induced apoptosis related mechanism of 
action particularly in the MIA  PaCa-2/ eGFP-Luc CDX tumors, which corresponds well 
to observed in vitro results described in paragraph 3.4.2.4.  
 
The next animal experiment was implemented using high Cldn3  /  4 expressing 
Capan-1/ eGFP-Luc CDX tumor bearing mice. Here, intratumoral gene transfer was 
performed 26 days post cell injection, which caused reduction of tumor viability in 
optCPE transfected tumors, whereas VC transfected tissues demonstrated increasing 
luminescence signal over time (Figure 3.14a, c). Unexpectedly, no effect on tumor 
volume was observed after gene transfer (Figure 3.14b). As experiment was 
terminated at day 36, ex vivo bioluminescence of removed tumors was measured. In 
fact this revealed highly significant and lasting reduction of tumor viability in optCPE 
transfected tumors compared to the VC transfected tumors (p   =  0.0041).  
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Figure 3.14: Significant reduction of tumor viability caused by optCPE mediated induction of necrosis after in 
vivo gene transfer in high Cldn3 / 4 expressing Capan-1/eGFP-Luc CDX tumors. (a) Reduction of tumor viability, 
measured as tumor bioluminescence (not significant), was observed after intratumoral optCPE gene transfer (GT; 26 
days after cell injection). (b) Tumor growth, measured as mean tumor volume, was not affected by intratumoral toxin 
expression. (c) Representative images of tumor bioluminescence, reflecting tumor viability, which showed decrease of 
bioluminescence signal in optCPE transfected CDX tumors compared to respective vector control (VC). (d) At end of 
experiment (36 days after cell injection) luminescence of obtained tumors was measured ex vivo, revealing significant 
reduction in viability. Data represent mean + S.E.M. (n = 7 animals / group), Two way-ANOVA based on multiple 
characteristics and Turkey´s multiple comparison post-test or the nonparametric Mann-Whitney U-test based on 
comparison of two groups, ** p < 0.01. 
 
 
Taken together, the intratumoral optCPE gene transfer demonstrated significant 
antitumoral activity through CPE mediated cytotoxicity that led to decreased tumor 
viability and tumor growth inhibition in three independent human pancreatic cancer 
CDX models. Furthermore, it can be concluded that high Cldn3 / 4 expressing tumors, 
such as PA-TU-8902 or Capan-1, mainly undergo optCPE induced apoptosis in 
combination with necrosis, mediated by the bystander effect. By contrast less 
Cldn3  /  4 expressing tumors rather undergo apoptosis.  
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3.5.4 Tumor cell elimination and tumor growth inhibition in Cldn3  /  4 
expressing PDX tumors mediated through oncoleaking suicidal optCPE 
gene therapy 
 
 
Figure 3.15: In vitro pretesting of optCPE gene transfer in human pancreatic cancer PDX derived cells. Before in 
vivo gene transfer experiments were conducted, PDX models were pretested for CPE sensitivity in vitro. Therefore, 
PDX models were used to generate single cell suspensions for Panc 9996, Panc 11344 and Panc 12536 PDX derived 
cell lines, which were transfected with either optCPE or VC plasmid DNA. (a) Representative IF images 12  h after 
optCPE gene transfer, revealing strong optCPE expression and co-localization with Cldn4. Moreover, membrane 
blebbing and budding was observed in these cells. (b) Cytotoxicity of optCPE in transfected human pancreatic cancer 
PDX derived cell lines. MTT was performed 72 h after gene transfer, which demonstrated significant reduction of cell 
viability with toxicity rates of 35  -  65 % in optCPE transfected cells compared to VC.  Data represent mean + S.E.M. 
(n  =  3), level of significance was determined using the nonparametric Mann-Whitney U-test, **p < 0.01; ***p < 0.001. 
 
 
3.5.4.1 optCPE gene transfer in PDX derived cell lines led to expression and 
binding of optCPE, causing significant elimination of tumor cells 
Before non-viral intratumoral optCPE gene therapy was performed in human 
pancreatic cancer PDX tumors in vivo, pretests were conducted using respective PDX 
derived cells in vitro (see Material and Methods, Paragraph 2.1.4). Therefore, 
established Panc  9996, Panc  11344 and Panc  12536 PDX derived cell lines were 
transfected with either optCPE or VC plasmid DNA and optCPE expression and 
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cytotoxicity was analyzed. To evaluate successful optCPE expression IF was 
performed 12 h after transfection (Figure 3.15a).  
Here, strong optCPE expression (green) was observed in cytoplasm and membrane of 
transfected cells, which co-localized with Cldn4 protein (red) leading to CPE  / Cldn 
complex formation (yellow). This was particularly seen in Panc9996 and Panc12536 
derived cells. Moreover, these cells demonstrated signs of optCPE mediated cell 
death, as massive membrane blebbing and budding was observed (Figure 3.15a). 
Further, cytotoxicity was determined 72  h after transfection by MTT assay. The 
experiment showed significant (p   <   0.001) toxicity in all three optCPE expressing PDX 
derived cell lines, with toxicity rates of 35   -   65   %. This is highlighting the antitumoral 
potential of expressed toxin also in human pancreatic PDX derived cell lines. 
 
 
3.5.4.2 Oncoleaking suicidal optCPE gene therapy in human pancreatic cancer 
PDX revealed significant antitumoral activity  
Since strong antitumoral activity of expressed optCPE was demonstrated in PDX 
derived cell lines, in vivo experiments were performed using the PDX derived cell line 
Panc  12536, which was stably transduced with luciferase expressing vector eGFP-Luc. 
The first experiment was implemented using subcutaneously Panc12536/eGFP-Luc 
PDX tumor bearing mice. As tumors reached size of 0.2 cm3, non-viral intratumoral 
gene transfer was performed using jet-injector (GT; 21 days after cell injection). 
Significant antitumoral activity of optCPE mediated cytotoxicity was observed in 
transfected Panc12536/eGFP-Luc bearing mice, as tumor viability, measured by tumor 
bioluminescence, was significantly reduced in optCPE transfected tumors compared to 
VC (p = 0.0007, Figure 3.16a, c). This was confirmed by significant tumor growth 
inhibition (p = 0.0142), expressed as reduced tumor volume in optCPE expressing 
tumors compared to VC transfected tumors (Figure 3.16b,d). As demonstrated in 
previous animal experiments, ex vivo bioluminescence signal of tumors that were 
removed at end of experiment (27 days after cell injection) showed significantly 
decreased intensity (p = 0.014) in optCPE expressing tumors compared to VC treated 
tumors. This was further confirmed by increase in necrotic areas in optCPE transfected 
tumors (32 %) compared to VC transfected tissues (17 %). Moreover, the intratumoral 
optCPE gene transfer led to significant reduction of Ki67 reactivity within the tissue 
(p = 0.0015), particularly in regions close to necrotic areas (Figure 3.16e). Further, 
induction of apoptosis was observed in these optCPE transfected tissue areas, 
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reflected by significant increase in TUNEL positive nuclei (p = 0.0002) in optCPE 
transfected tumors compared to VC treated tissues (Figure 3.16f). 
 
 
 
 
 
Figure 3.16: Oncoleaking of optCPE suicidal in vivo gene therapy in heterotopic human pancreatic cancer PDX 
model. Subcutaneously (s.c.) grown Panc12536/eGFP-Luc tumors were established and intratumoral optCPE gene 
transfer was performed via non-viral jet-injection (GT; 21 days after PDX derived cell injection). Significant antitumoral 
activity was observed in optCPE-transfected Panc12536/ eGFP-Luc-bearing mice. (a) Tumor viability, measured as 
tumor bioluminescence, was significantly decreased in optCPE-expressing tumors compared to empty vector control 
(VC). (b) The in vivo optCPE gene transfer led to significant inhibition of Panc12536/ eGFP-Luc PDX tumor growth 
compared to VC treated tumors. (c) Representative images of tumor bioluminescence (reflecting tumor viability) 
revealed luminescence signal reduction in optCPE transfected tumors compared to respective vector controls (VC).        
(d) The quantification of ex vivo bioluminescence of removed tumors (upper panel) and representative bioluminescence 
images thereof (lower panel), confirmed significant reduction of viability in optCPE transfected tumor tissues.                  
(e) Analysis of Ki67 reactivity. The intratumoral optCPE gene transfer led to significant reduction of Ki67 reactivity within 
tumor tissue compared to VC treated tissue. (f) The TUNEL assay revealed a significantly increased number of terminal 
deoxynucleotidyl transferase dUTP nick end labeling TUNEL positive nuclei in optCPE-transfected compared to VC 
transfected Panc12536/eGFP-Luc PDX tumors. Level of significance was determined using Two way-ANOVA based on 
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multiple characteristics and Turkey´s multiple comparison post-test or the nonparametric Mann-Whitney U-test based on 
comparison of two groups, *p<0.05; ***p<0.001. 
 
 
The second experiment was performed in orthotopically grown Panc12536/ eGFP-Luc 
tumors, whereof tumor volume and viability was only monitored by bioluminescence 
measurement. When tumors reached sufficiently strong bioluminescence signal, non-
viral gene transfer was performed by intratumoral needle injection of optCPE plasmid 
DNA or VC plasmid DNA. One week after gene transfer, the experiment was 
terminated and bioluminescence was measured in vivo and ex vivo (Figure 3.17). The 
intratumoral expression of optCPE showed antitumoral effects as luminescence signals 
were significantly (p  =  0.0290) reduced after treatment with optCPE. By contrast, no 
antitumoral effect was measured in VC transfected tumors (Figure 3.17a). The ex vivo 
imaging confirmed this result by demonstrating significant decrease in tumor viability 
(p   =   0.0499) in optCPE expressing tumors compared to VC transfected tumors 
(Figure 3.17 b). This is illustrated by representative bioluminescence images in Figure 
3.17c, d.  
 
 
 
 
Figure 3.17: Oncoleaking in vivo effect of optCPE suicidal gene therapy in orthotopic human pancreatic cancer 
PDX model Orthotopically grown Panc12536/eGFP-Luc tumors were generated to analyze antitumoral effect of optCPE 
at orthotopic tumor site. The non-viral gene transfer was achieved by intratumoral needle injection. (a) Antitumoral 
effects mediated through optCPE were observed, as luminescence signals were significantly reduced after treatment. 
The VC transfected tumors remained unaffected. (b) The ex vivo bioluminescence quantification of removed tumors 
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(end of experiment 1 week after GT) further revealed significant reduction of vitality of optCPE expressing tumors 
compared to VC expressing tumors. (c, d) Representative images of tumor luminescence in vivo and ex vivo. Data 
represent mean + S.E.M. (n = 8 animals / group). Level of significance was determined using the nonparametric Mann-
Whitney test, ns: not significant; n.s. not significant; *p < 0.05. 
 
 
With these experiments, first successful oncoleaking in vivo use of optCPE suicidal 
gene therapy was demonstrated in heterotopically and more importantly orthotopically 
grown human pancreatic cancer PDX. These results emphasize the high potential of 
expressed optCPE, as it is safe and selective with a prolonged cytotoxic effect leading 
to efficient reduction of tumor volume in association with tumor necrosis.  
 
 
Taken all results together, we have been able to evaluate the feasibility and potential of 
the oncoleaking gene therapy using the translation optimized CPE vector (optCPE) as 
a new suicide approach for the treatment of Cldn3  /  4 overexpressing PC in vitro and 
in vivo. We demonstrated the successful use of optCPE gene transfer in a panel of 
human PC cells and more importantly patient derived PDX derived cells. Further, we 
showed significant reduction of cell viability in all Cldn3 / 4 overexpressing PC cells 
after optCPE transfection and demonstrated a positive correlation between CPE 
cytotoxicity and level of claudin expression. Moreover accessibility of CPE receptors for 
toxin binding was shown to be determining for optCPE mediated cytotoxicity. Here the 
investigation of optCPE induced cell death mechanism was of particular interest, 
therefore detailed analyses of apoptotic and necrotic key players were performed. By 
this, caspase dependent- and independent apoptosis and oncosis / necrosis activation 
after gene transfer was demonstrated, which was dependent on amount of expressed 
optCPE and accessibility of Cldn. But more importantly, this present study 
demonstrated the applicability and antitumoral efficacy of optCPE gene therapy by the 
non-viral intratumoral jet-injection gene transfer in vivo in different luciferase-
expressing CDX and PDX pancreatic cancer models. Our animal experiments 
demonstrated the selective CPE mediated tumor growth inhibition, associated with 
reduced tumor viability and effective induction of tumor necrosis. These data further 
corroborated the advantages of this novel oncoleaking strategy. 
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4. Discussion 
The intensive research of the past two decades emphasized bacterial toxins as 
powerful therapeutic option to effectively combat cancer [180, 183]. Meanwhile a 
continuously growing number of promising experimental in vitro and in vivo studies, 
using bacterial toxins, e.g. diphtheria toxin, streptolysion O or clostridium perfringens 
enterotoxin and their encoding genes for cancer treatment, has been conducted, 
revealing their capability of efficient cell killing [174, 179, 181]. The establishment of 
this “toxin-based therapy” introduced novel features, such as pore-formation to the 
suicide gene therapy, recently defined as oncoleaking therapy.  
 
The Clostridium perfringens enterotoxin (CPE), produced by the anaerobic Clostridium 
perfringes bacteria, is a pore-forming toxin, which binds to claudin-3 and -4 (Cldn3 / 4) 
and exerts a selective, receptor-dependent cytotoxicity [260]. The transmembrane tight 
junction proteins Cldn   3    /   4 are known CPE receptors and are highly upregulated in 
several human epithelial cancers such as breast, colon, ovarian and pancreatic cancer 
[241, 246, 249, 252, 256, 261–268]. Particularly recombinant CPE has demonstrated 
remarkable and specific cytotoxicity for Cldn3 / 4 overexpressing epithelial tumors [246, 
269–271]. Until now little is known about the gene therapeutic approach and induction 
of cell death mechanism after CPE gene transfer [12, 25]. Hence, more profound 
knowledge about the regulation of CPE mediated cell death signaling could be crucial 
for the improvement of the oncoleaking effect and could further allow possible 
combination therapies with conventional therapies, such as chemotherapy.  
 
In this regard, this study aimed at the evaluation of feasibility and potential of the 
oncoleaking gene therapy using CPE as a new suicide approach for the treatment of 
Cldn3 / 4 overexpressing pancreatic cancer. 
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4.1 Cldn3 / 4 expression analysis and CPE sensitivity of pancreas carcinoma 
4.1.1  Human pancreatic cancer (PC) cells endogenously overexpress Cldn3 / 4  
In order to achieve the aims of this study it was of particular importance to select 
suitable tumor cell models. Prerequisite was the determination of the endogenous 
expression of the CPE receptors Cldn3 and Cldn4 in human PC cells, as the toxin-
mediated cytotoxicity is linked to their presence. The transmembrane proteins Cldn3 / 4 
belong to the Cldn family, which has been shown to provide the main constituent 
membrane protein of tight junctions (TJs) [261, 272–275]. These are involved in 
various physiological processes, such as regulation of paracellular permeability and 
conductance and are expressed within the gastrointestinal tract of mammalians 
[276, 277]. Interestingly, the expression profile of Cldns is altered in various cancers 
compared to normal tissues and occurs in a tissue-specific manner [278]. The 
association between altered Cldn expression and cancer has been widely reported and 
increasing evidences indicate that comprised TJs are responsible for tumor pathology 
in carcinogenesis [273, 275]. The altered expression of Cldns is regulated by multiple 
molecular mechanism and occur at transcriptional and post-transcriptional level 
[242, 261, 273, 274]. The promoter activity and expression of Cldn3 / 4 for example is 
regulated by the transcription factor specificity protein 1 (Sp1) in ovarian cancer cells 
[279]. Also other transcription factors, such as hepatocyte nuclear factor-1 alpha (HNF-
1A), Snail or the GATA Binding Protein 4 (GATA-4) have been shown to bind to 
promoter regions of several CLDN genes, affecting their expression [273, 275]. 
Moreover, the downregulation of certain Cldns, such as Cldn1 and Cldn7 in cancer, 
which has been seen in many studies, is suggested to play a key role in 
carcinogenesis by disrupting TJs and suppression thereof with subsequent increased 
cell proliferation, motility and invasiveness of cancer cells [280–286]. However, 
elevated expression level of Cldns, particularly Cldn3 / 4, has also been reported in 
various types of cancer, such as ovarian, breast, prostate, colon, nasopharyngeal and 
pancreatic cancer (PC) [241, 256, 262, 264, 287–290]. 
 
In this present study we demonstrated a diverse expression pattern of Cldn3 / 4 within 
a representative panel of the six different human PC cell lines, as overexpression of at 
least one but mainly both specific CPE receptors was shown, which is in line with 
several other expression analyses [251, 252, 267, 291–293]. Generally, PC 
demonstrates a morphological diversity and exhibit different expression pattern of 
Cldn3 / 4 depending on tissue of origin.  
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Endocrine islet cell tumors revealed Cldn3 expression, whereas adenocarcinomas and 
cystic mucinous tumors of exocrine origin denoted strong Cldn4 positivity [245, 251, 
268]. Using expression profiling, Michl and colleagues found Cldn4 to be 
overexpressed in most PC tissues and cell lines [251], which was further confirmed by 
various methods for identifying expression profiles [289, 291, 292]. Moreover, Cldn4 
mRNA expression analysis was performed in a panel of nine PC cell lines and 
increased expression was confirmed in all PC cell lines tested compared to normal 
ductal epithelial cells and fibroblasts. This study further documented a significant 
association between low expression of Cldn4 and shorter survival in PC patients [266]. 
Controversially, Alikanoglu et al. did not find any significant relation between Cldn4 
expression level and survival [292]. However, the upregulation of different Cldns has 
highlighted their impact on tumorigenesis in several types of cancer. Recent research 
demonstrated that, at least in the case of ovarian and breast cancer cells, the 
expression of Cldn3   /   4 may lead to increased cell invasion, motility, and survival, 
which are characteristics for metastasis [294, 295]. Consistent with these in vitro and in 
vivo findings, Tsutsumi and colleagues reported an association of Cldn4 expression in 
pancreatic intraductal papillary mucinous neoplasms with a more invasive phenotype 
[266, 296].  
 
All these findings open up new prospects in the targeted therapy of high Cldn3 / 4 
expressing tumors and highlight the great potential of a CPE based gene therapy for 
PC. This might be of particular importance as PC is one of the most lethal solid 
malignancies worldwide [297]. Even though recent therapeutic advances have 
extended the overall survival of PC patients at advanced stage, their prognosis 
remains dismal [298]. Given these facts, novel treatment concepts, such as an 
oncoleaking toxin based gene therapy, might raise hope for a more effective therapy.  
 
 
4.1.2 Altered patterns of Cldn3 / 4 distribution in PC cells 
The distribution and assembly of Cldns is decisive for the access and binding of CPE. 
In normal tissue Cldns are found in tight junctions (TJs) that are known to be the most 
apical cell-cell contacts between neighboring cells in epithelial monolayers [299]. Cldns 
consist of a short cytoplasmic N-terminal domain, four transmembrane domains, two 
extracellular loops (ECL-1 and -2) and a cytoplasmatic C-terminal tail [227]. Studies 
using chimeric Cldns revealed that the ECL-2 region is crucial for Cldn to bind CPE 
[230].  
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Further studies demonstrated that both, the ECL-1 and ECL-2 regions of Cldn 
receptors interact with CPE, meaning the interaction of ECL-1 and the toxin is also 
necessary for binding [228]. However, only Cldns with a suitable ECL-2 region are able 
to bind CPE [229]. All Cldns harbor a C-terminal domain present in PSD-95, Dlg and 
ZO-1/2 (PDZ)-binding motif that enables direct interaction with other TJ proteins, such 
as the cytoplasmic scaffolding proteins zonula occludnes (ZO) -1, -2, -3, multi-PDZ 
domain protein (MUPP)-1 and PALS associated TJ protein (PATJ). Particularly the 
interaction with ZO-1 and ZO-2 indirectly connect Cldns to the actin cytoskeleton, 
stabilizing the tight junction and is required to maintain permeability and signal 
transduction [300]. Our IHC for Cldn3 / 4 demonstrated first evidence for altered cellular 
distribution pattern of both receptors within the panel of PC cell lines. Capan-1 for 
example showed strong membranous Cldn3 presence also within cell-cell contact 
regions, whereas Cldn4 was present within the cytoplasm and the nuclei. PA-TU-8902 
cells on the other hand revealed strong Cldn3 / 4 localization within the cytoplasm, 
which accumulated in a vesicle like pattern. It is of importance to know that the network 
of tight junction proteins is constantly remodeled through endocytosis followed by 
either recycling and incorporation back into the membrane or degradation and de novo 
synthesis [301, 302].  
 
The internalization and redistribution of TJ proteins is an important function for 
epithelial and endothelial cells. It has been described that the internalization of TJ 
proteins depends on an extracellular stimulus (e.g. extracellular Ca2+ increase, 
cytokines or bacterial toxins), but also on the cell line and the particular TJ protein 
[300, 303, 304]. This was further supported by the study of Zwanziger et al., as their 
results indicated that Cldn1 was internalized by the clathrin-mediated endocytosis and 
macropinocytosis as well as to a lower amount by the caveolae-mediated pathway. By 
contrast Cldn5 was taken up by caveolae-mediated endocytosis and in a lesser 
amount by macropinocitosis. [305]. Unfortunately, nothing is known about the dynamic 
process of Cldn3 / 4, but we conclude that the vesicle like patterns, observed in our 
study, might indicate such process of endocytosis mediated uptake, recycling or 
degradation. 
 
In this study more insights into the distribution were gained by cell fractioning Western 
blot analysis and immunofluorescence experiments of representative Capan-1, 
HUP-T3, MIA PaCa-2 and PA-TU-8902 cells. In line with previous investigation, diverse 
distribution of Cldn3 / 4 reassembly was confirmed as their expression was detected in 
various cell compartments (membrane, cytoplasm and nucleus).  
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These distribution and assembly patterns could facilitate strong CPE binding, as toxin 
receptors are more accessible compared to normal junction-Cldns.  
 
However, the deregulation of Cldn from their membrane localization can modulate 
cellular homeostasis in different tissue-specific manner. Singh et al. demonstrated an 
increased mislocalized distribution of Cldn1 within the cytoplasm and nucleus in 
colorectal cancer. This delocalization of Cldns from the membrane, which was also 
observed in all cell lines analyzed in this study, appeared to be common among 
transformed cells [306–309]. The mislocation might conduct to a better selectivity of 
CPE action as Cldns are more accessible compared to TJ associated Cldns in normal 
epithelial tissue. This is supporting the concept of a selective tumor gene therapy. 
Nevertheless, a better understanding of the specific functions of Cldns and their 
regulation in cancer is needed to better explore Cldns as a specific target for cancer 
therapy. 
 
 
4.1.3 Targeted dose-dependent cytotoxicity of recCPE in Cldn3 / 4 expressing 
pancreas cancer cells 
Interestingly, Cldn3 / 4 were first described as CPE receptors and have been 
reclassified as members of the Cldn family that consists of 27 reported members with a 
typical size of 20-27 kDa [46-48]. Among those, additional receptors of the pore-
forming toxin CPE have been reported, as Cldn 6, 8 and 14 are also able to bind the 
toxin [230, 232, 233, 310]. By contrast, Cldn 1, 2, 5 and 10 do not bind CPE at 
pathophysiologically relevant toxin concentrations [225, 312]. A variety of studies 
demonstrated the application of recombinant CPE in vitro and in vivo, as well as a 
cytotoxic effect on Cldn3 / 4 overexpressing pancreatic, breast and ovarian carcinoma 
cells, which was associated with tumor reduction or elimination [239, 248–250, 270, 
271, 313]. These results were extended to PC cells by this present study, as a dose-
dependent cytotoxic effect was measured in all PC cell lines, revealing toxicity rates of 
up to 90   %. Furthermore a positive correlation between recCPE cytotoxicity and level 
of Cldn expression was observed. In addition, selectivity and dependency on receptor 
availability of recCPE mediated cytotoxicity was supported by our RNAi experiments. 
Since the binding of CPE to its receptors is highly specific, CPE demonstrated its great 
potential for the targeted treatment of Cldn3     /     4 overexpressing tumors, such as PC.  
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4.2 Pancreatic cancer patient derived xenograft overexpress Cldn3 / 4 
In the last decade, patient derived xenograft (PDX) models have emerged as important 
tool for translational research [314]. In contrast to conventional cancer cell line derived 
xenografts (CDX), which lack complex tissue interactions, structural properties of the 
donor tissue, PDX better mimic the features of human malignancies. These PDX 
models are biologically stable and better represent the original individual tumor by 
retaining the cellular and histological structure of the original primary tumor, including 
stromal elements that provide sustenance under periods of extensive growth [253]. 
Furthermore, cytogenetic analysis of PDX tumors revealed strong preservation of the 
overall genomic and gene expression profile of corresponding primary tumor [315]. 
These models have been shown to be predictive of clinical outcomes and are being 
used for preclinical drug evaluation, biomarker identification, biologic studies and 
personalized medicine strategies [71–75]. Thus, PDXs represent relevant preclinical 
models, which closely resemble the heterogeneous human tumor tissue.  
 
To extent our approach beyond models of established human cell lines and for a more 
translational approach we analyzed a heterogeneous panel of 18 human PC PDX 
regarding their histopathological features and their appearance of the CPE receptors 
Cldn3 / 4. Both, primary and xenograft tissue, were found to exhibit similar histologic 
phenotype, characteristic for PC. Well-defined morphologic criteria have been 
described to differentiate between neoplastic and reactive glands; PC infiltrates in a 
haphazard pattern and neoplastic glands can be found adjacent to muscular arteries 
without intervening pancreatic parenchyma. Moreover, perineural and vascular 
invasion are features of an invasive adenocarcinoma. Nuclear pleomorphism, 
incomplete glands and intraluminal necrosis complete the distinct list of PC 
characteristics [7, 41, 44, 321].  
 
In our Cldn3 / 4 expression analysis, five models revealed a strong overexpression of 
both receptors, whereas only one tumor appeared to have low Cldn3 / 4 expression. 
The remaining thirteen PDXs showed moderate to high expression of one or the other 
Cldn. This underlined the utility of these PDX models for our novel oncoleaking 
approach of CPE gene therapy as they reveal similar expression profiles found in 
tissue samples of patients with primary and metastatic PC and pancreatic 
intraepithelial neoplasia (PanIN) [289, 292]. 
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4.3 in vitro CPE gene transfer  
As gene therapy comes of age, it has shown its potential for the treatment of cancer 
disease, reflected by application of this strategy in multiple clinical trials [95, 114, 322]. 
In fact, more than 7   % of all gene therapeutic clinical trials worldwide are employing 
suicide approaches either as monotherapy or in combination with conventional 
therapies such as chemo-and radiotherapy [120, 323–327].  
 
Numerous suicidal systems have been established and successfully employed [93, 
124, 164, 166, 167, 328–332]. Among them bacterial toxins might experience some 
thorough re-evaluation as potential tool for more effective and to some extend more 
targeted gene therapies. Apart from strategies of intervention in protein translation by 
toxins like diphtheria toxin (DT), the approach of cell lysis by pore-forming toxins, such 
as streptolysin O (SLO) and CPE, is of attractiveness to eradicate tumor cells [174, 
192, 199, 210, 214, 249, 269, 271, 333–336].  
 
The bacterial toxins DT and SLO have already been analyzed regarding their gene 
therapeutic efficacy and antitumoral effects. After transfection of SLO and DT 
expressing vectors, both toxins exerted toxic effects in vitro and in vivo, but also led to 
side effects, as these toxins also act on non-tumor targets [183, 199, 200, 214, 336, 
337]. By contrast, CPE has the advantage of specific binding to Cldn3 / 4, which is 
accessible at the cell surface and potentially also in the cytoplasm of a variety of 
cancer cells. Our group established the eukaryotic translation optimized CPE vector 
(optCPE) that combines both, target specificity and efficient cytotoxicity. The reported 
intracellular CPE expression and accumulation after gene transfer led to effective 
eradication of Cldn3 / 4 high expressing cells [252]. Our very recent study 
demonstrated the first successful tumor - targeted, oncoleaking CPE gene therapy for 
colon carcinoma in vitro and in vivo and underlined the promising and efficient option to 
treat cancer. Furthermore, it provided evidence that such approach might be of value 
for the local control of the disease [256]. Regarding these facts, this oncoleaking 
strategy could be of particular value for treatment of therapy-refractory tumors or 
metastases thereof, such as pancreatic cancer.  
 
 
4.3.1 Targeted optCPE gene transfer in Cldn3 / 4 overexpressing PC cells 
Using the optCPE vector construct in this present study, significant cell killing was 
achieved after gene transfer in selected PC cells and more insights of mechanism of 
CPE mediated action were given.  
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Here, toxicity rates of 40    -    85     % were achieved in Cldn3 / 4 overexpressing cells, 
whereas the negative human melanoma cell line SK-MEL-5 remained unaffected. The 
high expressing Clnd3     /     4 expressing cell line PA-TU-8902 revealed a 60     % 
reduction of cell viability 72     h after gene transfer, whereas 30     % were measured 
after external recCPE application. By contrast AsPc-1 cells remained unaffected after 
transfection, although high sensibility with a toxicity rate of 80     % was measured after 
recCPE treatment.  
These results could be explained by the different distribution and assembly of the 
receptors at the time of CPE expression, as availability and accessibility is crucial for 
the optCPE mediated cytotoxic effect. This is consistent with the pathobiology of C. 
perfringens, as enterocyte damage and heavy cellular blebbing were found 
predominantly at accessible villus tips, which exhibit an abundant presence of Cldn4 of 
CPE treated human small intestinal tissue ex vivo [225, 338–340]. Furthermore, we 
elucidated the Cldn specificity of CPE, as Cldn3 / 4 silenced PC cells abrogated the 
binding of the toxin that consequently led to reduced cytotoxicity. Due to the 
aforementioned CPE resistance of transfected AsPc-1 cells, it could also be assumed 
that a stress-induced accumulation of the unfolded or misfolded protein led to a general 
translational attenuation and protein degradation [341]. This could be an explanation 
but needs further investigation to improve therapeutic efficacy of CPE. 
 
 
4.3.2 Co-localization and complex formation of optCPE and junctional and non-
junctional Cldns  
The in vitro optCPE gene transfer demonstrated a correlation between level of 
Cldn3 / 4 expression and optCPE mediated cytotoxic effect. As receptor availability and 
accessibility is of high importance for the CPE mediated mechanism of action, a 
fundamental point of this study was to investigate the distribution and localization of 
optCPE after gene transfer. Therefore co-localization studies with three representative 
PC cell lines were performed 12     h after optCPE gene transfer. The analyzed cell lines 
HUP-T3, MIA    PaCa-2 and PA-TU-8902, which exhibited different levels of Cldn3 / 4 
expression, revealed membranous binding of optCPE to its receptor and consequently 
complex formation, particularly in cell-cell contact regions. This highlights the great 
advantage of the gene transfer, as junctional-Cldns that have been inaccessible for the 
externally applied recCPE are now targetable. Moreover, complex formation was found 
in perinuclear regions and within the cytoplasm.  
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Here two possible mechanism could be involved: first, internalization of the Cldn:CPE 
complexes and second, Cldn:CPE interaction in intracellular organelles. Regarding the 
first proposed mechanism, it has been shown that toxins such as E.coli cytotoxic 
necrotizing factor-1, H. Pylori associated factors and also CPE induced claudin 
internalization, leading to deleterious increase in paracellular permeability [230, 342, 
343]. Fujita and colleagues described that the effect of CPE is due to a direct 
interaction with the second extracellular loop domain of Cldn3 / 4, which also inhibits TJ 
reformation in addition to enhanced endocytosis [230]. 
Evidences were given that Cldns can oligomerize in different ways. The early pathway 
corresponds to the classical ER quality control pathway for transmembrane protein 
oligomerization [300, 344–346]. However, Cldn3 / 4 form heteromeric oligomers and 
tight junctions, indication a later oligomerization beyond the ER, which is likely to 
happen in late secretory pathway of the trans-Golgi network (TGN) [347–349]. It is 
conceivable that expressed CPE is able to bind to its receptors within vesicular cargos. 
This hypothesis indeed needs further investigation, as it is only speculative. 
 
Taken together, these data identified intracellular and extracellular accessibility of CPE 
receptors as determinants for optCPE mediated cytotoxicity and corroborated the 
advantages of this oncoleaking gene therapeutic strategy.  
 
 
4.3.3 Cellular mechanism of action of CPE mediated cytotoxicity after in vitro 
gene transfer 
In addition to the cytotoxic evaluation of expressed optCPE, this study focused at the 
improved understanding of the cellular mechanism of action. Many studies have 
described the highly specific interaction of CPE and Cldn3 / 4 [91, 243, 252, 256, 258, 
270, 350, 351].  
 
CPE mediated cytotoxicity results of a multistep mechanism of action, whereby the C-
terminal domain of CPE (cCPE) binds to the ECL-2 region of its receptor. Under 
physiologic conditions, the enterotoxin rapidly forms a small complex, containing both, 
receptor and non-receptor Cldns [223]. This complex is insufficient to trigger 
cytotoxicity, thus several small complexes interact to promote CPE oligomerization that 
leads to prepore formation on the plasma membrane [237]. This process results in a 
large CH-1 complex and β-hairpin loops from CPE.  
 
98 
Discussion 
 
They assemble into a β-barrel that inserts into membrane to form a pore, causing 
changes in plasma membrane permeability [205, 352]. This pore is cation permeating 
and allows rapid calcium (Ca2+) influx, resulting in CPE mediated cell death [238, 239, 
353].  
 
From a therapeutic point of view, however, it is important to determine the exact 
mechanism particularly of optCPE mediated toxicity for the improved and more 
effective use of the pore forming toxin. Here, it is of particular interest to distinguish 
between different induced cell death pathways, such as apoptosis and necrosis . 
Matsuda as well as Chakrabarti and colleagues documented that low doses of CPE 
result in formation of low numbers of pores, causing modest Ca2+ influx [238, 240].  
The limited Ca2+ influx triggers caspase-3 mediated cell death via activation of calpain 
protease, resulting in classical apoptosis. On the other hand, higher concentration of 
the toxin cause formation of many pores, producing massive Ca2+ influx, which 
consequently hyper-activates calpain and results in a form of necrotic cell death, 
known as oncosis [353]. As morphological damage develops in CPE treated cells, 
basolateral cell surface gets exposed, whereby additional binding of CPE forms an 
even lager complex that also includes another component of epithelial TJs, occludin 
[223, 239].  
 
Based on this knowledge, we established a time course dependent analysis of optCPE 
treated cells to characterize and determine different parameters and key players of 
apoptosis and necrosis, such as Annexin-V  /  PI labeling, caspase activation, LDH 
release and Ca2+ influx, after optCPE transfection. The novel live cell analysis 
demonstrated the over-time mechanism of toxin action and documented a timely 
interplay of the aforementioned parameters in dependence on the amount of 
expressed optCPE and number of pores formed. Our findings further revealed a 
detailed insight of the optCPE triggered death signaling events, as novel gene 
expression profiling of apoptosis-related genes using human specific apoptosis arrays 
identified potential modulations of pro- and anti-apoptotic genes by optCPE gene 
expression. With the obtained new data the complexity of optCPE induced mechanism 
was exemplified, as the expressed toxin is able to trigger different pathways within one 
cell line, which varies in different cell lines. Notwithstanding, these findings could allow 
targeted combination with cytostatic therapeutics that activate similar death pathways.  
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4.3.3.1 Activation of apoptosis and necrosis in optCPE treated PC cells 
First signs of cell death have already been seen in cells expressing optCPE 12           h 
after transfection. Capan-1 and HUP-T3 cells revealed rapid membrane blebbing and 
nuclear condensation, whereas cell fragmentation was observed in optCPE transfected 
MIA      PaCa-2 cells. These observations gave first evidence for optCPE induced 
apoptosis, since morphological features that describe apoptosis include (i) rounding-up 
of the cell; (ii) retraction of pseudopodes, (iii) reduction of cellular volume; (iv) 
chromatin codensation, followed by nuclear shrinkage and breakdown; (v) plasma 
membrane blebbing but maintanance of membrane integrity; (vi) shedding of apoptotic 
bodies [354–357]. Similar to apoptotic counterparts, necrotic cells exhibit distinctive 
morphological characteristics, including (i) increasingly translucent cytoplasm; (ii) 
swollen organelles; (iii) modifications of the nucleus, such as dilation of nuclear 
membrane and chromatin condensation into circumscribed, asymmetrical patches; (iv) 
membrane blebbing and loss of cellular integrity; (v) increased cell volume (oncosis), 
causing breakdown of plasma membrane [356, 358, 359].  
 
The time course analysis in HUP-T3 cells unveiled the optCPE induced cytotoxic 
effect, as 14           h post transfection condensed and fragmented nuclei were 
demonstrated. We documented massive cell swelling, membrane blebbing and 
formation of membrane vesicles 18            h after transfection that reached its maximum 
at 24           h with enormously swollen nuclei. With this data we concluded that 
expressed optCPE is able to induce different cell death mechanisms over time in one 
particular cell line in dependency of ability to form complexes. This was strengthened 
by FACS analysis of Annexin-V  /  PI, as optCPE triggered first apoptosis and necrosis 
at later time points. Although considered as different cell death mechanisms, there is 
an overlap between apoptosis and necrosis, reported as “apoptosis-necrosis 
continuum” [360]. The phenomenon of coexistent apoptotic and necrotic 
characteristics, as seen in time course and FACS analysis of optCPE expressing HUP-
T3 cells, results from the same stimulus. Two defined factors have been identified that 
convert an ongoing apoptotic process to a necrotic process: the availability of 
intracellular ATP and of caspases [360–362]. As mitochondrial membrane potential is 
abrogated and cytochrome c is released, the resulting decrease of ATP production 
contributes to cell death in absence of caspases. The apoptosome, which plays a 
major role in intrinsic apoptosis pathways, is dependent on ATP for its pro-apoptotic 
activity, thus progressive ATP depletion would rather cause necrosis [363–365].  
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Dead cells, whether they die by apoptosis or necrosis release lactate dehydrogenase 
(LDH). In case of apoptosis membrane integrity is maintained until late stages of this 
process, whereas strong release of LDH is early detected in necrosis [133, 135]. This 
was further tested in supernatant of optCPE transfected cells. Here PA-TU-8902 and 
MIA      PaCa-2 cells revealed significant increase of LDH release after 14      h    and 
20          h respectively, underlining the optCPE induced activation of necrosis. Moreover, 
massive amounts of released LDH were detected 48    h in the PA-TU-8902 cell line 
(12-fold) and in a lesser intensity in MIA     PaCa-2 cells (3-fold) compared to control, 
that would usually characterize apoptosis and holds true for MIA     PaCa-2 cells. By 
contrast, the high concentrations, measured in PA-TU-8902 cells, are rather associated 
with necrosis. Similar observations were made for streptolysin O gene transfer, where 
intracellular toxin expression leads to perforation of cell membranes verified by LDH 
release [214]. 
 
 
4.3.3.2  optCPE induced activation of caspases and calpains  
At more detailed analysis of optCPE expressing PA-TU-8902 cells, we elucidated a 
crosstalk of caspase dependent and independent apoptosis. Here, rapid increase of 
intracellular Ca2+ led to activation of calpain-1/2 and caspase-3/7, causing apoptosis 
indicated by decrease of cell viability and increase of Annexin-V positive population. 
The Ca2+ activated, non-lysosomal cysteine proteases calpain-1/2 are known to be 
able to cleave numerous cellular proteins, including caspases and play crucial roles at 
all stages of cellular existence – from proliferation to cell death [366, 367]. In fact, both 
types of enzymes – caspases and calpains – are each other´s substrates, which adds 
to the complexity of their possible interaction [368]. The accumulated data of recent 
years indicate a positive feedback of both proteases, as caspase-3 is able to cleave 
calpastatin, the endogenous calpain inhibitors, which in turn facilitates calpain 
activation and further proteolysis [259, 367, 369]. Controversially, calpain-2 is also 
associated with the direct proteolysis of caspase-7, -8 and -9 into inactive fragments, 
as our observations revealed hyperactivation of all caspases [370]. Their influence on 
caspases might be different in various cell types or under varying stimuli [367, 371]. 
 
The optCPE induced apoptotic mechanism of transfected PA-TU-8902 cells was 
further evaluated as the human specific apoptosis array revealed upregulation of the 
pro-apoptotic proteins Bax, cytochrome c and the stress-induced apoptotic proteins 
SMAC/Diabolo and HTRA2      /      Omi. These proteins are connected to the intrinsic 
death signaling pathway.  
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As CPE binds and pore formation starts, intracellular Ca2+ concentrations increase, 
causing changes in the inner mitochondrial membrane that results loss of mitochondrial 
transmembrane potential and release of two groups of pro-apoptotic proteins. The first 
and most interesting group in this manner comprises cytochrome c, 
SMAC      /      Diabolo and the serine protease HTRA2      /      Omi; all activated in optCPE 
transfected cells [372]. These proteins promote the caspase-dependent mitochondrial 
pathway. Hence cytochrome c activates Apaf-1 and procaspase-9, which form an 
apoptosome. SMAC      /      Diablo and HTRA2      /      Omi are reported to promote 
apoptosis by inhibiting inhibitors of apoptosis proteins (IAPs) [373–375]. It is also worth 
mentioning that calpain-1/2 is not only able to cleave procaspase-3, it can also cleave 
the Bcl-2 family member Bax, which is translocated during apoptosis into mitochondria, 
activating the aforementioned pathway [376]. Besides apoptosis induction, the toxin led 
to early necrosis, since significantly increased amount of Annexin-V positive cells was 
measured already 6            h after optCPE transfection, where no other key player of 
apoptosis was activated.  
 
By contrast, analyzed MIA PaCa-2 cells revealed a slightly different picture, since here 
optCPE transfection led to a weak caspase-3 but more calpain-driven apoptosis 
induction at the beginning, which turned around at later time points. Here, calpain 
facilitated caspase activation as described previously. This was further confirmed by 
the induction of cleaved caspase-3 and pro-apoptotic proteins cytochrome c and p53.  
 
Taken these data together, we can conclude that optCPE is able to drive activation of 
different pathways within one cell line, which varies in different cell lines, depending on 
amount of expressed toxin, availability and accessibility of its receptors and number of 
formed pores. This is on one hand in line with the postulated knowledge of dose 
dependent mechanism of action after external CPE application [225, 240]. On the other 
hand these findings will allow a well-targeted combination with cytostatic therapeutics 
that induce similar death pathways. Numerous clinically used anticancer agents trigger 
apoptosis, ranging from DNA damaging agents, such as cisplatin, antimetabolites 
including gemcitabine to tyrosine kinase inhibitors e.g. erlotinib. A successful 
combination might overcome resistance to apoptosis as apoptotic effects could be 
enhanced.  
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4.3.3.3 Release of optCPE bystander effect  
Currently little is known about the intracellular transportation and release of expressed 
optCPE. CPE is naturally produced by the clostridium bacteria and only liberated by 
lyses during bacterial sporulation [225, 377]. By contrast, our immunofluorescence 
analysis of optCPE transfected cells revealed vesicle like accumulations, which could 
be an indicator for exocytosis. Additionally, membrane budding away from cytosol was 
observed, which represents a key step in vesicular transport, multivesicular body and 
exosome formation. This particular pathway reveals unusual topology and involves 
novel mechanisms, which could be a possible transport mechanism for optCPE but 
need further investigation [378]. As we have described previously and observed in this 
study, liberated CPE is present in the media of transfected cells. This is independent of 
CPE-mediated cytotoxicity or Cldn3     /     4 expression, as it was also released by the 
Cldn-negative SK-MEL-5 cells [252, 256].  
 
High transfection efficiency allows sufficient expression of the therapeutic gene, which 
is decisive for a successful suicide gene therapy. A supportive element in using these 
suicidal systems is the bystander effect. Here neighboring or by-standing cancer cells 
that were not transduced or transfected with the suicide gene are eliminated along with 
transduced or transfected cells, leading to an improvement of therapeutic efficiency 
[92, 379–381].  
 
The very recent study of Shrestha and colleagues also confirmed the bystander killing 
mechanism of CPE [382]. Moreover they demonstrated evidences that supernatant 
collected from a CPE treated sensitive cell is able to kill other cells that are insensitive 
(e.g. fibroblasts) towards the toxin. This was explained by the release and delivery of 
cytotoxic factors, such as caspase-3 or LDH after treatment with the toxin in CPE 
sensitive cells. Neither in this present study nor in any of our previously published 
studies we have seen this phenomenon in vitro as our negative control remained 
unaffected. However, this could be of particular importance after in vivo gene transfer. 
Their study further demonstrated appearance of membrane blebs and release of small 
and large membrane vesicles into supernatants, which has been also documented by 
us. These membrane vesicles contained CPE and also the CH-1 pore complex. It is 
known that vesicles released from bacteria serve as mechanism for delivery of toxins 
into the host, thus it would be conceivable that CPE-containing vesicle might deliver 
bound CPE monomer or CH-1 complex [382–384].   
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As exosomes came into focus for protein transport, the question arose if optCPE might 
be also transported via those small cell derived vesicles that contain various molecular 
constituents, including DNA, RNA, mRNA and proteins. With the isolation and 
enrichment of exosomes from media of transfected cells, we demonstrated strong toxin 
presence with concentrations of 324.4- 382.7 ng  ml-1 optCPE in PA-TU-8902 cells and 
242.6-344.5 ng ml-1 optCPE in MIA PaCa-2 cells, respectively. Furthermore, exosomes 
have been shown to act as shuttles between cells by transmitting signals, thus referred 
as “communicasomes”. They transfer information to the targeted cell through three 
main ways; (i) receptor-ligand interaction; (ii) direct fusion with plasma membrane or 
(iii) endocytosis [385, 386]. This might be of importance for the transportation and 
uptake of released, biological active optCPE, which was shown to significantly reduce 
viability of non-transfected cells in this present study. Another evidence for the decisive 
role of the bystander effect was given by the live cell analysis, where optCPE, released 
by cells dying from necrosis, seemed to drive neighboring cells into apoptosis. This 
would be in line with our results described in paragraph 4.3.3.2. 
 
Here we describe a novel transport mechanism of the expressed toxin via exsosomes 
that supports the bystander effect, which can be crucial for the improved therapeutic 
efficiency, particularly for in vivo application.  
 
 
4.4 The in vivo use of suicidal optCPE gene therapy  
The selective and efficient cytotoxic effect of CPE gene transfer was proven for human 
PC cell lines in vitro. Our study extended the promising anticancer potential of CPE 
gene therapy to locally applied in vivo optCPE gene transfer scrutinization in different 
luciferase-expressing cell derived xenograft (CDX) and patient derived xenograft (PDX) 
models. The effectiveness of a locally applied toxin-based gene therapy has been 
successfully tested for diphtheria toxin in PSA positive human prostate xenograft 
tumors [387]. In our very recent study we demonstrated the selective and efficient 
antitumoral action of CPE gene therapy in the Cldn3      /      4 overexpressing colon 
cancer PDX Co7515, where gross tumor necrosis of the treated tumors was observed 
[256].  
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4.4.1 Selective and efficient optCPE gene transfer in subcutaneously grown 
CDX tumors 
To corroborate the effectiveness of a locally applied gene therapy, we performed 
kinetic studies in two different Cldn3           /           4 PC CDX models. Here, successful 
expression of the toxin was documented already 24          h after intratumoral application 
with an extended therapeutic window up to 96  h. These results corresponded to our 
previous published data, documented in breast cancer and colorectal cancer CDX 
[252]. Besides an inhomogeneous optCPE distribution and accumulation within the 
tumor tissue, our findings further revealed optCPE mediated effects reflected by 
necrotic areas, which strongly supports the great efficiency for this CPE based gene 
therapeutic approach to treat PC. 
 
In this present study we further addressed in vivo specificity of optCPE gene transfer, 
thus we included a binding-deficient mutated optCPE (mutCPE) construct (CPE-
Y306A / L315A; kindly provided by J. Piontek, unpublished data) as negative control. 
Local application of the non-viral intratumoral optCPE gene transfer was performed in 
s.c. PA-TU-8902/eGFP-Luc CDX bearing mice using the jet-injector. Tumor viability, 
measured as tumor bioluminescence, was significantly reduced in optCPE tumors 
compared to mutCPE, which was also reflected in tumor growth inhibition.  
 
We further demonstrated massive areas of necrosis in optCPE expressing tumor 
tissues compared to mutCPE, morphologically indicated by discontinuities in plasma 
and organelle membranes, amorphous osmiophilic debris and aggregates of “fluffy 
material” probably representing denatured protein [359]. However, this is in line with 
results of others, as necrosis was seen after local in vivo application of recCPE 
[232, 235, 388]. Michl and colleagues for example performed four injections of recCPE 
directly into Cldn4 expressing Panc-1 tumors over the course of 5 days and 
documented large necrotic areas in CPE treated tumor tissue compared to no or 
minimal necrosis in control tissue [251]. As our time course analysis documented 
different activation of cell death mechanism in vitro, we also investigated apoptosis 
induction by TUNEL assay and cell cycle arrest via Ki67 staining. Interestingly, 
apoptosis induction was observed in areas close to necrosis, supporting the optCPE 
mediated bystander effect. 
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For a more translational and time-dependent in vivo evaluation of CPE toxicity, we 
performed the intratumoral suicidal optCPE gene transfer in two additional luciferase-
expressing CDX tumors: the low       /       moderate Cldn3            /            4 expressing cell 
line MIA            PaCa-2 and the high expressing Capan-1 cells. By this approach we 
demonstrated significant decrease in tumor viability in both CDX tumors, but only 
MIA            PaCa-2 CDX bearing mice revealed reduced tumor viability. This data 
highlighted the novel aspect that the rapid toxin mediated cytotoxic effect is more 
apparent by tumor viability decrease than by reduction of tumor volume, as peripheral 
tumor margins are still vital. Moreover, MIA            PaCa-2 tumors demonstrated less 
amounts of necrosis and strong apoptosis induction compared to Capan-1 CDX tissue.  
 
Our in vivo findings highly support the well-described CPE dose dependent mechanism 
of action, which is determined by accessibility of CPE receptors for toxin [225, 240].  
 
 
4.4.2 Oncoleaking suicidal optCPE gene therapy in Cldn3 / 4 overexpressing 
subcutaneously and orthotopically grown PDX tumors  
As earlier described, PDX models better mimic attributes of human malignancies and 
are therefore of translational relevance [389]. To perform the optCPE gene therapy in 
those models, this present study also aimed at the establishment of PDX models stably 
expressing the reporter genes green-fluorescence protein (GFP) and luciferase (Luc).  
 
PDX are hard to transfect or transduce and require a time intensive procedure; starting 
with the dissociation of fresh tumor tissue to transfection/transduction of PDX derived 
cell line and eventually to selecting or sorting of high GFP expressing cells, which will 
be transplanted subcutaneously or orthotopically into the pancreas of immunodificent 
mice. With the successful engraftment an in vivo tracking of particularly tumor growth at 
primary site as well as reduction in tumor viability after treatment can be achieved. In 
this study we have been able to establish four stable GFP-Luc expressing PDX derived 
cell lines, of which two have been successfully engrafted. In fact, this is to our 
knowledge the first study using GFP-Luc expressing pancreatic cancer PDX for in vivo 
imaging.   
 
Our novel strategy of oncoleaking suicidal gene therapy efficiently eradicates tumor 
cells and provides an attractive therapeutic option for potential local treatment of 
unresectable residual cancer tissue or refractory liver metastasis of PC.  
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To further evaluate this potential, we used the GFP-Luc expressing Panc12536 PDX 
model, which highly expressed Cldn3 / 4 and was derived from liver metastasis of PC. 
In both experimental setups, the subcutaneously and orthotopically grown tumors, 
significant reduction of tumor viability was observed in optCPE transfected tumors 
compared to respective vector control. Moreover s.c. grown tumors revealed 
morphological changes in optCPE expressing tumors, as massive necrosis was 
detected, followed by apoptosis induction and additional proliferation inhibition in areas 
close to necrosis. This might be a result of the bystander effect, which is also of 
importance for the in vivo efficacy of optCPE gene therapy in PC.  
 
In summary we were able to establish the first successful oncoleaking use of optCPE 
suicidal gene therapy in heterotopically and more importantly orthotopically grown 
human pancreatic cancer PDX. These data highly emphasize the great potential of this 
novel strategy, as it is safe since throughout the course of optCPE gene transfer no 
systemic toxicities, such as loss of body weight or diarrhea were observed and 
selective with prolonged cytotoxic effect, leading to efficient inhibition of tumor growth. 
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5. Outlook 
The present study reported the first successful CPE based oncoleaking gene therapy 
for high Cldn3 / 4 expressing pancreatic cancer in vitro and in vivo. Our approach 
focused on the local application of the optCPE expressing vector, which demonstrated 
high specificity and safety as no unwanted side effects were seen in vivo. The CPE 
gene therapy has demonstrated its efficacy for PC cell eradication supported by 
effective treatments of CDX and PDX PC tumors. Apart from this, this therapy concept 
also featured some limitations. Up to this point only a local application was shown to be 
effective and safe, whereas systemic administration might require proper targeting and 
could lead to adverse side effects. For the potential clinical translation of our approach, 
local gene therapy might represent the primary option. For patients who possess a 
resectable tumor, the intratumoral CPE gene transfer could be conducted during 
surgery, which might be valuable to prevent recurrence as unresectable residual tumor 
tissue could be eliminated by toxin mediated cytotoxic effect. Beyond that, the toxin-
based strategy could be of great value for an improved local control of the disease, 
particularly for unresectable tumors or metastases thereof. This could contribute to 
improved quality of life for patients suffering from this dismal disease. Besides the 
intratumoral application of toxin expressing vector DNA, it could be also conceivable to 
use engineered CPE producer cells, which could be implemented into the tumor, where 
they would permanently liberate expressed CPE over time into the tumor resulting in 
more efficient cancer cell eradication. Such delivery system could be equipped with 
inducible features for proper expression control to optimize such therapy. 
 
For a more diverse implementation, a systemic administration of CPE-expressing 
vectors would be of great clinical benefit, which remains still challenging as Cldn3 / 4 is 
also expressed in normal tissue. To achieve this, active targeting by e.g. surface 
modification of nanoparticles is an option to decrease uptake in normal tissue and 
increased accumulation within the tumor tissue. Also nanobodies, the smallest 
fragments of naturally occurring heavy chain antibodies, have been employed as 
delivery systems in cancer. Due to the ease of nanobody engineering they represent a 
great alternative as targeting carrier that transport effector domains, such as toxic 
peptides, drugs or maybe even genes coding for toxins, such as CPE. The important 
findings of this study regarding cell death signaling revealed that CPE is able to trigger 
activation of different death pathways, depending on amount of expressed toxin, 
availability and accessibility of its receptors.  
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This knowledge allows the design of novel combinations with cytostatic drugs that 
induce similar death pathways to synergize with the toxin action. Such effective 
combination might overcome resistance as apoptotic effects could be better exploited 
for tumor eradication by affecting residual tumor cells. 
 
  
Figure 3.18: Novel combination of conventional chemotherapies and optCPE gene transfer .(a) Drug treatment 
led to induced Cldn3 / 4 expression in PC PDX. In earlier studies, tumor bearing mice were treated with gemcitabine, 
oxaliplatin/ 5-FU+Oxaliplatin or their respective vehicle control. The quantitative real time PCR (qRT-PCR) 
demonstrated induced Cldn3 and Cldn4 expression in treated tumor tissue of four analyzed PC PDX. Panc9699 and 
Panc12535 revealed significantly high upregulation of both Cldns after gemcitabine treatment, whereas treatment with 
oxaliplatin/ oxaliplatin+5-FU led to increased   level in Panc10991 and Panc12532. Data are represented as means  +  
S.D. (n = 2) (b) Synergistic effect of combination of gemcitabine and optCPE gene therapy in Panc12535 bearing mice. 
Subcutaneously grown Panc12535 tumors were established. When tumors reached size of 0.25 cm3 (day 27) 
gemcitabine was applied intraperitoneally and four days later optCPE gene transfer was performed (GT; 31 days after 
transplantation). The in vivo optCPE gene transfer itself (green) led to significant inhibition of tumor growth, which was 
further enhanced by the combination with gemcitabine (yellow) compared to gemcitabine alone (red) or respective 
vehicle control (black). Level of significance was determined using Two -way-ANOVA and Dunnett´s multiple 
comparison post-test; ns: not significant; *p<0.05; ***p<0.001. 
109 
Outlook 
 
In fact we addressed such combinatorial approach in our very recent experiments. By 
this we have been able to document the novel aspect of using the CPE based gene 
therapy in combination with gemcitabine. In earlier studies PC PDX bearing mice were 
treated with the conventional used chemotherapeutics, gemcitabine and oxaliplatin and 
tumors (kindly provided by D. Behrens, EPO GmbH) have been analyzed regarding 
their Cldn3 / 4 expression. We were able to show for the first time a significant induction 
of both Cldns in four treated PDX models, whereof Panc12535 demonstrated the 
highest effect (Figure 3.18 a, lower right panel). This preliminary data gave first 
evidences for a drug treatment induced upregulation of the CPE receptors. Due to this 
unexpected result, we performed an animal experiment with ether single gemcitabine 
treatment, optCPE gene transfer or the combination of both (Figure 18b). The in vivo 
data of the treated Panc12535 demonstrated a synergistic effect of combination of 
gemcitabine and optCPE based gene transfer, as tumor volume was significantly 
reduced in tumors treated with the combination compared to the respective control. 
This implicated that gemcitabine is able to induce Cldn expression by altering their 
signaling pathways, which in turn leads to a better target availability for CPE gene 
therapy. These findings indeed demand further validation and they open new clinical 
perspectives, as gemcitabine resistant tumors could be better eradicated by 
combination with the oncoleaking strategy. 
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Abbreviations 
ADP    Adenosine Diphosphate 
AS    antisense 
ATCC     American Type Culture Collection  
ATM     ataxia-telangiectasia mutated serine/threonine kinase  
ATP    Adenosine Tri-Phosphate 
BAX    BCL2 associated x  
BCL2    Apoptosis Regulator, B-Cell CLL/Lymphoma 2 
BRCA1/2   Breast Cancer 1/2 
BSA    bovines serum albumin 
CA19-9   Carbohydrate Antigen 19-9 
Ca2+    calcium  
cCPE    C-terminal fragment of CPE 
CD     cytosine deaminase  
CDH1    cadherin1  
CDKN2A    cyclin-dependent kinase inhibitor 2A 
CDX     cell line derived xenograft 
CEA     carcinoembyronic antigen 
CLDN    claudin 
CPE    Clostridium perfringens enterotoxin 
Ctrl    control 
Da    Dalton 
DAB    diamino-benzidine 
DMEM    Dulbecco´s Modified Eagle Medium 
DMSO    dimethylsulfoxid 
DNA    deoxyribonucleic acid 
DSMZ    German Collection of Microorganisms and Cell culture 
DT     diphtheria toxin  
DTT    dithiothreitol 
ECL    enhanced chemiluminescence 
ECL     extracellular loops  
EDTA    ethylenediaminetetraacetit acid 
EF2    Elongation Factor 2  
EP300    histone actetyltransferase p300  
EPHA3   EPH receptor A3  
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ER    endoplasmic reticulum 
FACS    Fluorescence-Activated Cell Sorting 
FASL    Fas ligand  
FBS    fetal bovine serum  
FBXW7   F-box and WD repeat domain containing 7  
FITC    fluorescein isothiocyanate 
GATA-4   GATA Binding Protein 4  
GCV     Ganciclovir  
GDEPT    gene-directed enzyme-producing therapy  
GFP    green fluorescent protein 
H19    imprinted maternally expressed transcript  
HB-EGF   heparin-binding epidermal growth factor precursor  
HE    hematoxylin and eosin  
Her2/neu    human epidermal growth factor receptor 2  
hMLH1   human mutL homolog1  
HNF-1A    hepatocyte nuclear factor-1 alpha  
HRP    horseradish peroxidase 
HSP70   heat shock protein 70 
HSV-tk    herpes simplex virus thymidine kinase  
HTRA2  /  OMI    high temperature requirement protein serine 
peptidase 2  
IAPs     inhibitors of apoptosis proteins  
IF    immunofluorescence 
IgG    immunoglobulin G 
IHC    immunohistochemistry 
IPMN     intraductal papillary mucinous neoplasm 
KRAS     V-KI-ras2 Kirsten rat sarcoma viral oncogene homolog  
LDH    lactate dehydrogenase 
Luc    luciferase 
MART1   melanoma antigen recognized by T cells 1 
MCN     mucinous cystic neoplasm  
miRNA   micro RNA 
MLH1    MutL homolog 1  
MSH2     MutS protein homolog2 
MSH6    MutS homolog 6  
MSI     microsatellite instability  
MSLN     mesothelin  
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MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide 
MUC1    mucin 1  
MUPP-1    multi-PDZ domain protein 1 
mutCPE   mutated Cldn3 / 4 binding deficient CPE 
ODN    oligonucleotides 
optCPE   translation optimized CPE 
OS     overall survival  
PALB2    partner and localizer of BRCA2  
PanIN     pancreatic intraepithelial neoplasia  
PATJ     PALS associated TJ protein 
PBS     Phosphate buffered saline 
PC     Pancreatic cancer 
PCR     polymerase chain reaction 
PDAC     Pancreatic ductal adenocarcinoma  
PDX     patient derived xenograft  
PDZ     PSD-95, Dlg and ZO-1/2  
PE    Phycoerythrin 
PEI    polyethylenimine 
PFA    paraformaldehyde 
PI    propidium iodide  
PRSS1/PRSS2  protease, serine 1/2  
PS    phoshatidylserine 
PSA     prostate specific antigen  
qrtPCR   quantitative real time PCR 
recCPE   recombinant CPE protein 
RLU    relative light unite 
RNA    Ribonucleic acid 
RNAi    RNA interference 
ROBO2   roundabout guidance receptor 2  
RR    relative risk 
RT    room temperature  
s.c.    subcutaneously  
siRNA    short interfering RNA 
SLO    Streptolysin O 
SMAC  /  Diabolo   second mitochondria-derived activator of caspases  
SMAD4   SMAD family member 4 
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SMARCA4 SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin  
SNAIL    snail homolog (Drosophila) 
SNPs     single nucleotide polymorphisms  
Sp1    specificity protein 1  
SPINK1   serine protease inhibitor Kazal-type 1  
STAT3    signal transducer and activator of transcription 3 
STK11    Serine/threonine kinase 11  
TAAs     tumor-associated antigens  
TGN     trans-Golgi network  
TJ    tight junction 
TNM     tumor, nodes and metastasis classification 
TP53    tumor antigen p53 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end 
labeling 
TUSC2    tumor suppressor candidate 2  
TV    tumor volume 
VC    vector control 
WHO    world health organization 
wt    wild type 
ZO    zonula occludens 
5-FU     5-fluorouracil 
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